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Foot-and-mouth disease virus (FMDV) is one of the most contagious viruses of 
animals and is recognised as the most important constraint to international trade in 
animals and animal products. Two fundamental problems remain to be understood 
before more effective control measures can be put in place. These problems are the 
FMDV „carrier state‟ and the short duration of immunity after vaccination which 
contrasts with prolonged immunity after natural infection. The aim of this thesis was 
to study the interaction between FDMV and cells in lymphoid tissue in the natural 
bovine host, in order to improve our understanding of the protective immune 
response. 
 
Using laser capture microdissection in combination with quantitative real-time 
reverse transcription polymerase chain reaction, immunohistochemical analysis and 
corroborated by in situ hybridization, it is shown that FMDV locates rapidly to, and 
is maintained in, the light zone of germinal centres following primary infection of 
naïve cattle. Maintenance of non-replicating FMDV in these sites may represent a 
source of persisting infectious virus and also contribute to the generation of long-
lasting antibody responses against neutralising epitopes of the virus. 
 
The role of T-lymphocyte subsets in recovery from FMDV infection in calves was 
investigated by administering subset-specific mouse monoclonal antibodies. 




 γδ T cells was achieved for a period 
extending from before challenge to after resolution of viraemia and peak clinical 
signs, whereas CD8
+
 cell depletion was only partial. Depletion of CD4
+
 cells was 
 5 
also confirmed by analysis of lymph node biopsies 5 days post-challenge. Depletion 
with anti-WC1 and anti-CD8 antibodies had no effect on the kinetics of infection, 
clinical signs and immune responses following FMDV infection. Three of the four 
CD4
+
 T-cell-depleted calves failed to generate an antibody response to the non-
structural polyprotein 3ABC, but generated a neutralising antibody response similar 
to that in the controls, including rapid isotype switching to IgG antibody. These data 
suggest that antibody responses to sites on the surface of the virus capsid are T cell-
independent whereas those directed against the non-structural proteins are T cell-
dependent. CD4 depletion was found to substantially inhibit antibody responses to 
the G-H peptide loop VP1135-156 on the viral capsid, indicating that responses to this 
particular site, which has a more mobile structure than other neutralising sites on the 
virus capsid, are T cell-dependent. Depletion of CD4
+
 T cells had no adverse effect 
on the magnitude or duration of clinical signs or clearance of virus from the 
circulation. In conclusion, CD4
+
 T-cell-independent antibody responses play a major 
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1. General introduction 
The livestock sector plays a vital role in the economies of many developing countries 
by providing food, income, a means of transport, draught power and employment 
(Otte et al., 2004). An estimated 600 million people worldwide rely directly on 
livestock production for their livelihoods. In addition, the population of developing 
countries grows by an estimated 72 million each year and the average meat 
consumption in the developed world is increasing, adding to the demand for meat 
products (Caspari, 2007). Livestock diseases constitute a major barrier to agricultural 
and economic development. Transboundary animal diseases pose the biggest threat 
to the livestock industry. Transboundary animal diseases are defined as “those that 
are of significant economic, trade and/or food security importance for a considerable 
number of countries; which can easily spread to other countries and reach epidemic 
proportions; and where control/management, including exclusion, requires 
cooperation between several countries” (Otte et al., 2004). Significant transboundary 
animal diseases identified by the Food and Agriculture Organisation include 
rinderpest, contagious bovine pleuropneumonia, bovine spongiform encephalopathy, 
rift valley fever, peste des petits ruminants, classical swine fever, African swine 
fever, Newcastle disease and of particular importance; avian influenza and foot-and-
mouth disease (FMD) (Caspari, 2007). 
 
Although FMD is not important from a public health perspective, it significantly 
constrains smallholder livestock producers and has a significant socio-economic 
impact in the developing and the developed world (Perry and Rich, 2007). 
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Subsequently, the prevention, control and eradication of FMD attracts a significant 
amount of effort and resources. 
  
1.1. Foot-and-mouth disease  
FMD is a highly contagious, acute vesicular disease, caused by FMD virus (FMDV), 
which affects wild and domestic cloven-hoofed animals (Alexandersen et al., 2003b). 
It is endemic in many areas of Asia, Africa, South America and eastern Europe 
where it plays an important role in the limitation of international trade of livestock 
and livestock products and impacts the livelihood of the poor (Perry and Rich, 2007). 
The ability of the virus to infect in small doses, multiple modes of infection and wide 
host range make FMD a difficult and expensive disease to control and the cost of 
eradication can be enormous (Scudamore, 2002). The achievement and maintenance 
of FMD-free status has major benefits for international trade and countries free of 
disease take great precautions to maintain their disease-free status. Cost-benefit 
analyses have indicated that the potential economic benefits of FMD control in many 
endemic situations outweighs the financial investment associated with eradication 
(Caspari, 2007).      
 
FMD can be established in susceptible animals by direct or indirect contact with 
infected animals, inhalation of airborne virus or contact with contaminated animal 
products, materials and people (Alexandersen et al., 2003b). The length of the 
incubation period is highly variable under field conditions and dependent on the 
infecting strain, the dose and route of infection, the animal species, individual 
susceptibility and the husbandry and environmental conditions (Quan et al., 2004). 
 20 
The reported incubation period for farm-to-farm and within-farm spread is between 1 
to 14 days (Garland and Donaldson, 1990, Sellers and Forman, 1973). The length of 
the incubation period under experimental conditions is also variable and influenced 
by the same factors for field conditions. The reported mean incubation periods under 
experimental conditions are 3.5 days, 2 days and 1 to 3 days for cattle, sheep and 
pigs respectively (Alexandersen et al., 2003a).   
 
The literature provides evidence that transmission of FMDV in domestic animals by 
the nasal or oral route results in primary infection and replication in the dorsal soft 
palate and the roof of the pharynx. The stratified squamous respiratory epithelium 
and tonsils in these areas are thought to be important for primary replication of the 
virus (Alexandersen et al., 2003b, Prato Murphy et al., 1999). Following aerosol 
inoculation of FMDV in cattle, virus can also be detected in the lung (Pacheco et al., 
2008). However, it is still unclear what part lung tissue plays in primary infection as 
a site of entry or secondary viral amplification (Alexandersen et al., 2003b). Authors 
of in situ hybridization studies suggested that early replication takes place in lung 
tissue and alveolar macrophages after aerosol exposure with subsequent 
dissemination to distal sites (Brown et al., 1992, Brown et al., 1996). 
 
Following primary replication, the virus disseminates rapidly through the host.  
Dissemination of the virus from the primary sites of infection to the rest of the body 
is thought to occur via the lymphatic and circulatory system, however, the mode of 
dissemination still remains inconclusive. There is no significant evidence for 
replication or transport of FMDV in bovine peripheral blood mononuclear cells 
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(PBMC) (Zhang and Alexandersen, 2004). However, a transient lymphopenia has 
been noted during the early stages of infection in swine (Bautista et al., 2003). The 
susceptibility of porcine PBMC to active infection during the acute stages of FMD 
may depend on the serotype of virus. PBMC isolated from serotype C infected swine 
were shown to be actively infected with viral titres corresponding to the period of 
peak viraemia as determined by infectious centre assays (Bautista et al., 2003). In 
contrast, PBMC isolated from serotype O infected swine during the acute stages of 
FMD were not infected (Diaz-San Segundo et al., 2006). Macrophages and 
Langerhans cells are considered to take part in virus dissemination (Brown et al., 
1992, Brown et al., 1995, David et al., 1995, di Girolamo et al., 1985, Summerfield 
et al., 2008), however, more data is required to determine the ability of bovine 
immune cells to support virus replication and transport. The greater part of viral 
amplification is considered to occur within the cornified stratified squamous 
epithelium of the skin, particularly in and around the mouth, feet and mammary 
glands, distinguishing these tissues as the sites of secondary replication 
(Alexandersen et al., 2003b). Interestingly, in calves exposed to aerosol virus, 
FMDV RNA was detected in coronary band and interdigital epithelium as early as 
six hours post-infection, before the onset of viraemia and clinical signs (Brown et al., 
1992). 
 
FMD in livestock is characterised by high morbidity and low mortality in adult 
animals. The earliest clinical signs in cattle include pyrexia, depression, a fall in milk 
yield and cessation of rumination. These signs are superseded within a few hours by 
vesicles at the sites of secondary replication, which are characteristic of FMD. FMD 
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vesicles generally rupture within 1 to 2 days resulting in the formation of erosions. 
Erosions on the feet cause lameness and are often complicated by secondary bacterial 
infections which delay the healing process. Although mortality is rare in adults, 
infection can cause abortion and the virus can replicate in the myocardium of lambs 
which can be fatal (Gulbahar et al., 2007).      
   
The viraemic phase in cattle lasts approximately for 3 to 5 days and FMDV is 
normally cleared from peripheral sites within 2 weeks (Salt, 2004, Zhang and 
Alexandersen, 2004). However, FMDV can cause a prolonged, asymptomatic 
infection in ruminants leading to the „carrier‟ state. „Carriers‟ are defined as animals 
from which live-virus can be recovered from scrapings of the oropharynx, using a 
probang sampling cup, after 28 days following infection (Sutmoller and Gaggero, 
1965). The oropharynx and dorsal soft palate have been implicated as the sites of 
viral persistence (Burrows, 1966), yet the cell type maintaining FMDV during 
persistence in vivo has not been conclusively identified and no confirmed mechanism 
of persistence has been reported. 
 
1.2. Foot-and-mouth disease virus  
1.2.1. Classification and structure 
FMDV is a member of the family Picornaviridae which consists of 8 genera, 
Enterovirus, Cardiovirus, Aphthovirus, Hepatovirus, Parechovirus, Erbovirus, 
Kobuvirus and Teschovirus. The genus Aphthovirus consists of two species, FMDV 
and Equine rhinitis A. Equine rhinitis A virus, which is closely related to FMDV, 
causes a respiratory infection in horses characterised by coughing, anorexia, 
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pharyngitis and persistent virus shedding from the pharyngeal region and in the urine 
and faeces (Kriegshäuser et al., 2005). Recent nucleotide sequence data has shown 
that bovine rhinoviruses, which are associated with respiratory disease in cattle, 
should be re-classified in the genus Aphthovirus (Hollister et al., 2008). 
 
The first reference to FMD is that by Hieronymus Fracastorius, who described the 
disease in cattle in Italy in 1514 (Fracastorius, 1546). During the latter half of the 
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 century, FMDV was identified as the first animal agent to cause disease that was 
small enough to pass through Berkfeld filters, and only the second virus to be 
discovered (Loeffler and Frosch, 1898). It was soon observed that cattle which had 
recovered from FMD were resistant to re-infection, however this was not always the 
case and serotypes were assigned on the basis of lack of cross protection. The 
serotype prevalent at this time in France was designated type O as it originated from 
the Oise valley. The virus that re-infected type O recovered animals was called type 
A, for “Allemagne”, as it originated from Germany (Vallée and Carré, 1922). A third 
serotype was discovered soon afterwards, designated C as the authors wanted to 
rename the serotypes A, B and C (Waldmann and Trautwein, 1926). The Southern 
African Territories (SAT) 1, 2 and 3 serotypes were described by the Pirbright 
laboratory in 1948 (Brooksby, 1958) and the final serotype, Asia 1 was typed from a 
sample from Pakistan in 1954 (Brooksby and Rogers, 1957). Based on genome 
analysis (Figure 1), types O, A, C and Asia 1 constitute a clear evolutionary lineage 
distinguishable from the SAT serotypes (Knowles and Samuel, 2003). Most human 
and animal RNA viruses display extensive genetic and antigenic heterogeneity 
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within infected hosts and populations, FMDV is no exception and within a serotype 












    
Figure 1. Unrooted Neighbour-joining tree showing the relationships between the outer-capsid 
polypeptides of FMDV. 
Unrooted Neighbour-joining tree shows the relationship between the outer-capsid 
polypeptides (VP1, VP2 and VP3) of the seven FMDV serotypes (O, A, C, Asia 1, 
SAT1 to 3). The seven FMDV serotypes cluster into type-specific lineages when 









The FMDV particle consists of a non-enveloped icosahedral protein shell (capsid) 
contained a single stranded positive sense RNA genome approximately 8500 
nucleotides in length (Forss et al., 1984). The capsid is comprised of 60 copies each 
of the four structural proteins VP1 (1D), VP2 (1B), VP3 (1C), and VP4 (1A). These 
four proteins assemble to form a protomer and five protomers join to form a 
pentamer. Twelve pentamers join to enclose the genomic RNA creating the virus 
particle (Acharya et al., 1989). VP1 to 3 are surface orientated, while VP4 is internal 
and in contact with the RNA (Figure 2). The surface structural proteins VP1 to 3 of 
FMDV are smaller than their counterparts in other picornaviruses. In addition, 
FMDV lacks distinctive surface features such as canyons and pits which have been 
described for other picornaviruses (Acharya et al., 1989, Hogle et al., 1985, Parry et 
al., 1990). It has been suggested that the canyons and pits protect the site of cell 
receptor attachment from the humoral immune response, in addition, receptor-
binding into the canyon destabilises the virus to initiate the uncoating process 
(Rossmann et al., 2002). In contrast, a long protein loop containing elements of the 
cell attachment site and the major viral antigenic site of FMDV forms a highly 
accessible protrusion which distinguishes FMDV from other picornaviruses 
(Acharya et al., 1989). Crystallographic studies of the three-dimensional structure of 
several FMDV isolates and antigenic variants have been reported, these studies have 
shown that VP1 to 3 have the same eight-stranded β-barrel folding motif (Figure 2) 
seen in other picornaviruses (Acharya et al., 1989, Curry et al., 1996, Logan et al., 
1993, Parry et al., 1990). Protein loops, joining the β-strands and C-termini of the 
surface structural proteins are exposed on the surface of the capsid (Figure 2). The 
highly exposed and flexible G-H loop, also called the “FMDV loop”, of VP1 
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contains an antigenic site and the conserved sequence arginine-glycine-aspartate 
(RGD) which constitutes the main cellular attachment site for integrin recognition 
(Logan et al., 1993). 
 
Antibodies are considered as the major effector for protection against FMD, 
therefore a number of studies have focused on the structural and functional aspects of 
their interaction with FMDV. Crystallographic studies of serotypes O, A and C have 
shown that major conformational differences and sequence variability between the 
capsid proteins of these serotypes exists in their loop structures and C-terminal 
segments, and these regions define their antigenic character (Acharya et al., 1989, 
Curry et al., 1996, Lea et al., 1995, Lea et al., 1994). Multiple antigenic sites have 
been described for FMDV. A site is defined as a discrete area on the antigen surface 
where a B-cell epitope or several overlapping epitopes have been mapped by 
monoclonal antibodies (MAbs) (Mateu and Verdaguer, 2004). The B-cell epitope 
denotes the part of the antigen recognised by a specific antibody. These epitopes are 
defined as „continuous‟ or „linear‟ when they are contained within a short peptide 
sequence, for example, a single loop of a folded protein, or as „discontinuous‟ or 
„conformational‟ when they are formed by residues that are located apart in the 
primary structure, but are brought together in the folded protein conformation 
(Mateu, 1995).           
 
Cross neutralisation assays and sequencing of different FMDV serotype O MAb 
resistant mutants has identified 5 antigenic sites (Figure 2) on the virus particle 
involved in virus neutralisation, these sites are often referred to in the literature as the 
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“major antigenic sites” (McCullough et al., 1987a). Site 1 involves both the trypsin-
sensitive residues in the G-H loop (site 1a) and the VP1 C-terminus (site 1b), because 
mutations that allow escape from the same MAb were described in either region 
(Kitson et al., 1990, Strohmaier et al., 1982). Site 2 involves residues within the two 
surface loops B-C and E-F of VP2 (Kitson et al., 1990, Mateu and Verdaguer, 2004). 
Sites 3 and 4 involve residues within the B-C loop of VP1 and B-B knob of VP3 
respectively (Kitson et al., 1990) . A fifth functionally independent site is located 
within the G-H loop of VP1(Crowther et al., 1993).    
 
FMDV is insensitive to organic solvents, as the virus lacks a lipid envelope, however 
the virus particles are unstable at pH below 6.8. In common with other 
picornaviruses, heat or acid degradation causes the capsid to dissociate into its 
pentameric subunits and VP4 forms an insoluble aggregate, releasing the RNA 
(Brown and Cartwright, 1961). The FMDV RNA genome can be divided into three 
main functional regions, the 5‟ untranslated region (UTR), the protein coding region 
consisting of a single open reading frame (ORF) and the 3‟ UTR (Figure 3). The 
FMDV genome is infectious and no viral proteins are required to initiate replication, 
a feature consistent with other picornavirus RNA (Belsham and Bostock, 1988). 
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Figure 2. Structure of foot-and-mouth disease virus particles. 
(a) Arrangement of the three surface proteins VP1 (blue), VP2 (red) and VP3 (green) 
in a protomer. (b) Structure of the capsid. A pentamer, consisting of 5 protomers 
arrayed in five-fold rotational symmetry about the pentagonal centre, is outlined in 
the capsid and a protomer is indicated inside the pentamer. Each protein presents an 
approximately trapezoidal shape on the surface. Adapted from Sobrino et al., 2001. 
(c) Topology of the wedge-shaped eight-stranded β-barrel fold found in icosahedral, 
positive-strand RNA viruses (Harrison, 1989). Eight β chains (arrows) labelled B to I 
and two α chains (cylinders). The loops connecting the β chains tend to be exposed 
on the protein surface (G-H loop of VP1 highlighted in blue), sometimes protruding 
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from the protein core. The two-letter codes for the loops name the connected β 
chains. The carboxyl (COOH) and amino (NH2) termini may also occur at the 
surface. Adapted from Frank, 2002. (d) A pentamer viewed from above. Lines 
labelled on one protomer represent the location of 5 antigenic sites on the virus 
particle involved in virus neutralisation. The sites were identified by cross 
neutralisation assays and sequencing of different FMDV serotype O MAb resistant 
mutants. These sites are often referred to in the literature as the “major antigenic 
sites” (McCullough et al., 1987a). Site 1 involves both the trypsin-sensitive residues 
in the G-H loop (GH, site 1a) and the VP1 C-terminus (COOH, site 1b), because 
mutations that allow escape from the same MAb were described in either region 
(Kitson et al., 1990, Strohmaier et al., 1982). Site 2 involves residues within the two 
surface loops B-C (BC) and E-F (EF) of VP2 (Kitson et al., 1990, Mateu and 
Verdaguer, 2004). Sites 3 and 4 involve residues within the B-C (BC) loop of VP1 
and B-B (BB) knob of VP3 respectively (Kitson et al., 1990) . A fifth functionally 
independent site is located within the G-H (GH) loop of VP1 (Crowther et al., 1993). 
Adapted from Frank, 2002. (e) Ribbon representation of VP1 (blue), VP2 (red) and 
VP3 (green). Locations of the 5 antigenic sites are shown in yellow. Adapted from 

















1.2.1.1. The FMDV 5‟ UTR 
The 5‟ UTR of FMDV is larger than the UTR of most other picornaviruses and can 
be considered to be composed of various regions including the S-fragment, a 
polyribocytidylate [poly (C)] tract, the cis-acting replication element (cre) and the 
internal ribosomal entry site (IRES) (Biswas et al., 2005). The function of the S-
fragment, which is approximately 360 nucleotides in length, has not been 
characterised, however it may serve to circularise the RNA and may facilitate 
replication and/or translation (Herold and Andino, 2001). The S-fragment is followed 
by the poly(C) tract, which varies in length amongst different strains of FMDV but 
the significance of the size of this sequence is not clear (Mellor et al., 1985). 
Upstream from the cre are multiple pseudoknots that may be involved in a joint 
function with the poly(C) tract (Belsham and Martinez-Salas, 2004). The cre is a 
stable stem loop structure upstream of the IRES in FMDV that is essential for 
replication of the picornavirus RNA (Mason et al., 2002, Tiley et al., 2003). The 
FMDV IRES is a highly structured region of approximately 450 nucleotides that 
serves for the internal initiation of viral protein synthesis in a cap-independent 
fashion (Roberts et al., 1998). In contrast, eukaryotic mRNA translation depends on 
the recognition of the 7-methyl-G cap structure at the 5‟ end of the mRNA and the 
heterotrimeric initiation factor eIF4F composed of eIF4E, eIF3 and eIF4G which 
interacts with the small ribosomal subunit (Gingras et al., 1999).  
 
1.2.1.2.  The ORF 
The ORF, a region of approximately 7000 nucleotides, encodes a polyprotein, the 
full length polyprotein is never detected in infected cells or during in vitro translation 
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reactions since primary processing of the nascent polypeptide begins co-
translationally (Belsham and Martinez-Salas, 2004). The viral proteins are generated 
from the polyprotein through the cleavage activities of two-trans acting virus 
encoded proteases, namely the L protease (L
pro
) and 3C protease, and by 2A protein 
(Belsham et al., 2008). The L
pro
 cleaves itself from the viral polyprotein at the L/P1 
junction (Figure 3), releasing the P1-2A precursor at its N-terminus (Belsham, 2005). 
The P1-2A capsid precursor is released at the junction between the C-terminus of the 
short 2A peptide and the N-terminus of the 2B region, a process mediated by the 2A 
sequence together with the first amino acid of 2B (Ryan et al., 1991). It has been 
proposed that this event is not in fact a proteolytic cleavage of an existing peptide 
bond, but instead results from a modification of translation such that the bond is 
never formed but translation of the downstream sequence still continues (Donnelly et 
al., 2001). The properties of the 2A oligopeptide together with the first residue of 2B 
(a proline) can also mediate cleavage in artificial polyprotein systems (Donnelly et 
al., 1997). The P1-2A capsid precursor is processed further by 3C protease to yield 
VP0 (1AB, which is the precursor for VP4 and VP2), VP3 (1C) and VP1 (1D) 
(Belsham, 2005). The P2 precursor is processed into 2B and 2C by 3C protease. 
Although the function of these proteins and precursors is not entirely clear, they have 
been shown to enhance membrane permeability and may assist in evasion of the host 
immune response by blocking protein secretory pathways (Belsham, 2005, Moffat et 
al., 2005). The L
pro
 mediates cleavage of eIF4G, FMDV 3C protease also takes part 
in shutting off host cap-dependent mRNA translation by cleaving eIF4A and eIF4G, 




The FMDV P3 precursor is processed by the 3C protease into 3A, three copies of the 
3B peptide (VPg), 3C protease and 3D polymerase, in addition, a variety of 
intermediates are produced during processing (Figure 3) (Vakharia et al., 1987). The 
3A protein serves to localise the FMDV RNA to membrane vesicles (Rosas et al., 
2008) and is thought to deliver 3B peptides, which act as primers for RNA synthesis, 
to the sites of RNA replication (Nayak et al., 2005, O'Donnell et al., 2001). The 3D 
polymerase is thought to recognise both positive and negative sense viral RNA.  
 
1.2.1.3.  The FMDV 3‟ UTR 
The 3‟UTR is composed of a heterogeneous sequence and the poly(A) tail. 
Information about the role of these different regions is limited. The heterogeneous 
sequence has been shown to stimulate IRES activity (Lopez de Quinto et al., 2002) 
and is crucial for virus infectivity (Saiz et al., 2001). The poly(A) tract, which unlike 
cellular mRNA, is encoded by the genome, may be important for RNA stability and 
for a possible interaction between the 3‟ and 5‟ UTR.  
      
1.2.1.4. Synthesis of viral RNA 
The FMDV genomic RNA functions both as mRNA to produce virus-encoded 
proteins and as a template for the production of new RNA transcripts (Nayak et al., 
2005). Translation of the viral RNA must precede RNA replication so that viral 
proteins required for replication are generated within the infected cell. At some point 
there has to be a switch in the function of the input genomic RNA so that translation 
is blocked and RNA synthesis can commence. This is required because the process 
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of translation in which the ribosomes move along the RNA in a 5‟ to 3‟ direction is 
not compatible with the movement of the 3D polymerase in the 3‟ to 5‟ direction 
(Belsham and Martinez-Salas, 2004, Gamarnik and Andino, 1998). The genomic 
RNA is uncapped but is linked at its 5‟ end to the virus encoded peptide VPg (Nayak 
et al., 2006). The primer for initiating RNA synthesis is the peptide VPg or its 
precursor, 3AB (Belsham et al., 2008). FMDV makes three alternative forms of VPg 
which are incorporated at the 5‟ end of new RNA strands at equal frequencies 
(Belsham et al., 2008). The uridylylation of the VPg peptide primer is the first stage 
in the replication of picornavirus RNA (Nayak et al., 2006). The VPg is modified by 
the addition of uridyl residues to produce VPgpUpU in a reaction involving 3D 
polymerase, its precursor 3CD and the cre (Belsham et al., 2008). Attachment of this 
peptide to the RNA occurs via a Tyr residue and is performed by the 3D polymerase. 
RNA synthesis by the virus encoded RNA-dependent 3D polymerase takes place 
within membrane-bound replication complexes in a two-stage process, the genomic 
RNA is used to make an antisense copy, the antisense copy is then used as a template 
for the production of new genomic RNA. The genomic RNA can then be translated 
to make more viral protein, it can also be packaged into new virus particles or it can 
be used as a template for making more antisense template. Considerably more 
genomic RNA molecules are made than the antisense template (Belsham et al., 
2008). It is not clear how the genomic RNA molecules are packaged into virions, 
empty capsid formation can occur in the absence of virion RNA however it is not 
clear if this is a dead-end product or to what extent the capsid proteins assemble prior 




Figure 3. Genome organisation of FMDV. 
Genome organisation and polyprotein processing of FMDV (reproduced from 
Belsham and Martinez-Salas, 2004). The FMDV genome can be divided into three 
main functional regions, the 5‟ UTR, a single ORF that encodes a polyprotein which 
is cleaved by viral proteases into the products indicated and a 3‟ UTR with a poly(A) 
tail (AAA(n)). The 5‟ UTR is composed of various regions including the S-fragment, 
a poly(C) tract (CC(n)) , the cis-acting replication element (cre) and the internal 
ribosomal entry site (IRES). Upstream from the cre are multiple pseudoknots  
(PK(2-4)) that may be involved in a joint function with the poly(C) tract. At the 3‟ end 
of the IRES element a polypyrimidine tract is followed by both AUG codons 
approximately 84nt apart. Both AUG codons are used as initiation sites for protein 
synthesis and thus 2 distinct forms of the Leader (L) protein are generated termed the 
Lab and Lb which differ in their N-termini. The sites of primary cleavage and the 
virus proteins responsible are indicated by the curved arrows. The FMDV 
polyprotein undergoes primary cleavage at the L/1A junction and the C-terminus of 
protein 2A. Secondary processing of the primary cleavage products gives rise to a 
series of alternative products as described under section 1.2.1.2. The viral RNA is 
synthesised by the virus encoded RNA-dependent RNA polymerase (3Dpol), the 










1.2.2. Cell entry and replication 
FMDV initiates infection of cells by attaching to the host cell membrane by surface 
receptors. Two classes of receptors have been recognised for FMDV, integrins and 
heparin sulphate proteoglycans (Jackson et al., 1996). Four RGD-dependent 
integrins, αvβ6, αvβ3, αvβ8 and αvβ1 have been reported as receptors for initiating 
wild-type FMDV infection in cell culture (Berinstein et al., 1995, Jackson et al., 
2000, Jackson et al., 2002, Jackson et al., 2004). In cattle, αvβ6 has been 
demonstrated as the major cellular receptor that determines viral tissue tropism in 
vivo (Monaghan et al., 2005). Propagation of FMDV in cell culture results in the 
selection of variants with high affinity for heparin sulphate proteoglycans, a 
ubiquitous protein located at the external surface of cells (Jackson et al., 1996). 
These tissue culture adapted viruses were previously thought to be less virulent in 
cattle compared to integrin binding isolates, however, this was shown not to be the 
case during the UK 2007 outbreak (Cottam et al., 2008). Following multiple cell 
passages, viruses which do not bind heparin sulphate proteoglycans and lack the 
RGD integrin-binding motif still replicate efficiently in baby hamster kidney (BHK)-
21 cells, suggesting that FMDV can adapt to an alternative unidentified surface 
receptor (Baranowski et al., 2000). Following receptor binding, virus is taken up 
through clathrin-dependent endocytosis into the early and recycling endosomes 
(Berryman et al., 2005). After uptake, the acidic environment in the endosome 
triggers the capsid to dissociate, the viral RNA is released and moves across the 
endosomal membrane into the cytoplasm by an unknown mechanism (Belsham, 
2005, Berryman et al., 2005).  
  
 37 
1.2.3. Prevention and control of FMD 
The control policies adopted by a particular country or region vary according to the 
FMD-status. The introduction of FMDV into a country previously classified as 
FMD-free usually results in attempts to eradicate the disease by slaughter so that the 
country can re-establish its FMD-free status for trade purposes. This was the policy 
adopted during the 2001 outbreak in the United Kingdom, although effective, the 
policy resulted in a massive overkill of healthy animals primarily due to delays in 
implementing movement restrictions. Public perception was that vaccination should 
be used in future outbreaks, however, during the 2007 outbreak in the United 
Kingdom, rapid and extensive movement restrictions and rapid diagnosis and 
slaughter effectively controlled the disease. If vaccinates are not slaughtered, a 12 
month period was required before a country could re-apply for FMD-free status, the 
OIE reduced this period to 6 months in 2002, however, culling of infected and 
susceptible in-contact animals is still thought to be economically more viable in 
many situations. Control of the disease is further complicated when wildlife are 
involved and control policies in countries where the disease is endemic require a 
balance to support livestock-based initiatives and preserve the wildlife heritage in 
their natural ecosystems (Thomson et al., 2003).  
 
The current commercially available FMD vaccines commonly contain chemically 
inactivated FMDV as the antigen. The virus may be inactivated by, for example, 
treatment with aziridines which disrupt the RNA (Burrage et al., 2000). Once 
inactivated the seed virus is blended with suitable adjuvant and excipients. Two 
categories of chemically inactivated vaccines are available, water based vaccines 
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adjuvanted with aluminium hydroxide and saponin, which are used for cattle, sheep 
and goats, and oil based vaccines which can also be used in pigs (Doel, 1999). The 
commercial vaccines are highly immunogenic and perform very well for regular 
vaccination programs and for control of outbreaks, however, the vaccines do not 
induce sterile immunity and protection is relatively short lived requiring a booster 
every 6 months to maintain immunity (Doel, 2003). Other limitation include thermal 
instability, lack of cross-protection between serotypes, risk of virus escape from 
production plants, absence of a defined chemical content which has been linked to 
anaphylactic shock and the difficulties distinguishing between infected and 
vaccinated animals (Barteling and Vreeswijk, 1991, Sobrino et al., 2001). Therefore 
different approaches are being adopted to develop a safer and more effective vaccine. 
 
1.3. The immune system and response to FMDV 
The immune system can be broadly divided into the innate and adaptive immune 
systems. Interaction between the innate immune system, which responds quickly and 
non-specifically to a pathogen with recognition reliant on a limited number of 
germline-encoded receptors, and the adaptive immune response, which acts in an 
antigen-specific manner, is essential for the induction of an effective immune 
response to pathogens like FMDV (Palm and Medzhitov, 2009). 
 
1.3.1. The innate immune system 
During the early stages of infection, FMDV interacts with the innate immune system, 
a component of the host response to FMDV which has not yet received a significant 
amount of research. Consequently, in contrast to adaptive immunity, very little is 
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known about the contribution of innate immune defence during FMD. An effective, 
non-specific and rapid innate immune response is essential for the control of rapidly 
replicating, highly cytopathic and antigenically diverse viruses (Bachmann and 
Zinkernagel, 1997). 
 
1.3.1.1. The complement system 
As a first line of defence against pathogens, the complement system forms an 
important part of the innate immune response, able to activate cells involved both in 
the innate and adaptive immune response (Ricklin and Lambris, 2007). The 
complement cascade can be activated by three distinct pathways (Walport, 2001). 
The first pathway involves binding of C1q to antibody complexes on the surface of 
pathogens, activating the classical pathway. The related lectin pathway is activated 
when mannose-binding lectin interacts with mannose-containing carbohydrates on 
bacteria or viruses (Gadjeva et al., 2001). The alternative pathway is initiated when 
the spontaneously activated complement component C3 binds directly to the surface 
of a pathogen (Favoreel et al., 2003). Each pathway generates C3 convertase which 
results in the formation of the highly reactive C3b component which binds to the 
pathogens surface. This process, called opsonisation is critical for all subsequent 
steps in the complement cascade for elimination of pathogens (Favoreel et al., 2003).   
Given the importance of complement as a central component of innate immunity, it 
is not surprising that mice deficient of important complement components like C3 
are inefficient at controlling certain viral infections, for example influenza virus 
(Kopf et al., 2002). Complement in early immune complexes can bind to 
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complement receptors and contribute substantially to antigen recruitment and 
facilitate B-cell activation (van Noesel et al., 1993). 
 
1.3.1.2. Type 1 interferons 
The type 1 family of interferons (IFNs) are cytokines produced at the early stages of 
an immune response which are able to exert a vast array of biological functions 
including development and regulation of the innate and adaptive immune systems 
(Theofilopoulos et al., 2005). Although virtually all cells can produce type 1 IFNs in 
response to pathogens and endogenous stimuli, plasmacytoid dendritic cells are the 
most potent and are referred to as “natural IFN-producing cells” (Colonna et al., 
2002). Current knowledge of the interactions of FMDV with plasmacytoid dendritic 
cells is discussed under section 1.3.1.5. 
 
It has been demonstrated that mRNA encoding for type 1 IFN is induced within 
FMDV-infected cells in vitro and in vivo, however it is unclear if this message is 
translated into protein (Brown et al., 2000, Chinsangaram et al., 1999, Zhang et al., 
2009, Zhang et al., 2006). FMDV can shut down protein synthesis through the 
activity of the viral L
pro
 which cleaves the translation initiation factor eIF4G, a factor 
essential for CAP-dependent mRNA translation (Devaney et al., 1988, Medina et al., 
1993). The viral L
pro
 is a feature unique to the aphthovirus genus of the 
Picornaviridae family (Hinton et al., 2002) and L
pro
 interference with host protein 
synthesis has been proposed as an important evolutionary immune evasion technique, 
counteracting the innate immune response (de Los Santos et al., 2008). L
pro
 plays a 
critical role in FMD pathogenesis and viruses lacking this coding region are 
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attenuated in vitro and in vivo (Brown et al., 1996). Blocking host translation is 
particularly relevant for IFN expression since FMDV is highly sensitive to the 
actions of type 1 IFNs in vitro, with IFN induced dsRNA protein kinase and 
ribonuclease L shown to inhibit replication (Chinsangaram et al., 2001, de Los 
Santos et al., 2006). In addition, type 1 IFNs can protect pigs against challenge 
infection highlighting the importance of IFN during the innate immune response to 
FMDV (Chinsangaram et al., 2001, Chinsangaram et al., 2003, Grubman, 2005). 
Studies in our laboratory have recently identified significant titres of biologically 
active type 1 IFN in the circulation of FMDV contact-infected cattle (unpublished 
data) demonstrating that translation of type 1 IFN is not completely blocked in all 
cell types that are infected in vivo (see section 1.3.1.5).  
 
1.3.1.3. Natural antibodies 
Natural antibodies are low-affinity, polyreactive antibodies in the sera of normal, 
non-immunised individuals, detected even under germ-free conditions (Haury et al., 
1997, Ochsenbein and Zinkernagel, 2000). The B1 B-cells in mice produce natural 
antibodies (see section 1.3.2.1). Natural antibodies are considered as a link between 
the innate and adaptive immune responses, able to limit pathogen dissemination and 
forming immune complexes to activate adaptive immunity, recruit antigen to 
follicular dendritic cells in organised lymphoid tissue (see section 1.4) and activate 
complement (Dörner and Radbruch, 2007). Virus neutralising titres of natural 
antibodies have been identified, for example, natural antibodies have been detected 
in mice that can directly neutralise the highly cytopathic vesicular stomatitis virus 
(VSV), (Hangartner et al., 2006). The importance of natural antibodies for an 
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effective immune response, specifically for responses against cytopathic viruses, is 
highlighted by impaired immune protection in mice lacking natural antibodies and 
challenged with influenza virus (Baumgarth et al., 2000). There are no reports of 
natural antibodies in cattle or of natural antibodies directed against FMDV. However, 
anecdotal evidence of nonspecific background in non-immunised cattle detected by 
immunological assays in the FMDV World Reference Laboratory, Pirbright, supports 
a case for further investigation.  
 
1.3.1.4. Macrophages and neutrophils 
Macrophages and neutrophils are important, not only for phagocytosis and killing of 
pathogens but also for antigen presentation, therefore forming an important 
connection between the innate and adaptive immune systems (Sandilands et al., 
2005). Recognition and uptake of pathogens by macrophages is restricted by a 
number of phagocytic receptors including fragment crystallisable (Fc) receptors and 
complement receptors. Ligand interaction with these receptors also induces the 
production of cytokines and chemokines that stimulate other cells, for example, 
dendritic cells to migrate to the site of infection (Aderem and Underhill, 1999). 
Phagocytosis induced by Fc receptors results in the production and secretion of 
reactive oxygen intermediates and arachidonic acid metabolites, in contrast, 
complement receptor mediated phagocytosis does not (Aderem et al., 1985, Wright 
and Silverstein, 1983). It has been reported that porcine macrophages take up FMDV 
in vitro, a process enhanced in the presence of antibody-virus complexes 
(McCullough et al., 1988, Rigden et al., 2002). During the first 10 hours post-
infection these cells contain non-structural viral proteins and release small quantities 
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of virus, although it is not clear if this represents progeny virus released before the 
productive virus replication cycle is aborted or exocytosed uptake virus (Rigden et 
al., 2002).  
 
1.3.1.5. Dendritic cells 
Dendritic cells (DCs) can be broadly divided into 2 major subsets, conventional DCs 
and plasmacytoid dendritic cells (pDCs). DCs are an important member of the 
antigen presenting cell family, unique in their ability to stimulate naïve T cells 
(Kapsenberg, 2003). Like macrophages they are highly endocytic and constantly 
sample their environment through both receptor-mediated and non-specific routes of 
endocytosis. DCs are distributed in the body in both lymphoid and non-lymphoid 
tissues forming a vast sentinel system able to respond to foreign antigen by 
expressing pattern recognition receptors both on the surface and within endocytic 
compartments (Lee and Kim, 2007). DCs are also able to react to conditions of injury 
or infection by responding to a number of inflammatory mediators including pro-
inflammatory cytokines, called “danger signals” which promote DC maturation and 
migration (Gallucci and Matzinger, 2001). The process of maturation is essential for 
effective antigen presentation to lymphocytes in lymphoid tissue (Banchereau and 
Steinman, 1998). As DCs mature they efficiently capture antigen and express major 
histocompatibility complex (MHC) class I and II-peptide complexes and high-levels 
of co-stimulatory molecules on their surface (van Vliet et al., 2007). Maturation also 
results in migration to the lymph tissue and a change of morphology to the 
characteristic form with highly dendritic processes, increasing the cell surface area 
and allowing intimate contact with T cells (Banchereau and Steinman, 1998). DCs 
 44 
can also take up and maintain intracellular pools of undegraded antigen (Wykes et 
al., 1998). The undegraded antigen can be transported to draining lymph nodes and 
recycled to the cell surface for engagement with B cells that recognise the intact 
protein (Qi et al., 2006). The location of DCs within lymph nodes of mice varies 
according to their origin. Resident DCs are sessile, they are localised throughout the 
lymph node but are concentrated in the cortical ridge where they actively probe 
passing motile T cells (Cavanagh and Weninger, 2008). Freshly migrated DCs carry 
antigen from the periphery and traverse through the cortex of the draining lymph 
nodes scanning for T cells (Mempel et al., 2004). Migratory Langerhans-derived 
DCs populate the deeper cortex, whereas dermal DCs localise to the cortical ridge at 
the T-B cell border where they continually scan T cells or near the high endothelial 
venules (HEV) where they encounter newly homed T cells (Cahalan and Parker, 
2008, Cavanagh and Weninger, 2008).  
 
DCs have a dual role, they are capable of inducing an effector immune response or 
they can maintain tolerance by either inducing cells with immune-suppressive 
functions or by deleting and suppressing certain T-cell clones (Steinman and 
Banchereau, 2007). DCs therefore comprise a diverse and complex subset of cells 
that differ from one another in terms of location, antigen presentation, state of 
maturation and interaction with different lymphocyte populations, making them an 
extremely difficult population of cells to study (Banchereau and Steinman, 1998). 
Consequently, there are conflicting results of DC interaction with FMDV in the 
literature, in addition all the studies reported so far have been performed with either 
murine or porcine derived cells and not bovine cells (Summerfield et al., 2008). It is 
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clear from these studies that DCs do take up FMDV, a process which can be 
enhanced in the presence of FMDV-specific antibody. Uptake is also enhanced for 
cell culture adapted viruses, which can bind and infect cells via surface expressed 
heparin sulphate structures (Jackson et al., 1996). However, it is not clear how 
susceptible the different subsets of DCs are to infection and what affect this has on 
the way DCs interact with other cells (Bautista et al., 2005, Gregg et al., 1995). 
Following FMDV infection of DCs, non-structural viral proteins and double-stranded 
RNA can be detected for up to 24 hours post-infection. In addition, small quantities 
of virus are released between 2 and 8 hours post-infection. However, as is the case 
for macrophages, it is not clear if this represents progeny virus released before the 
productive virus replication cycle is aborted or exocytosed uptake virus (Harwood et 
al., 2008). Studies in our laboratory (Robinson et al. manuscript in preparation) have 
recently described the interactions of FMDV with bovine cells generated from cluster 
of differentiation (CD) 14
+
 PBMC. FMDV was able to infect bovine monocyte-
derived macrophages and DCs and infection was enhanced in the presence of 
specific antibody and cell culture adapted virus, similar to the results reported above 
for DCs isolated from other species. However, it is still unclear if the infection is 
productive and further studies are required for clarity. FMDV infection of bovine 
monocyte-derived DCs results in cell death and as a consequence, the amount of 
antigen processed and presented by DCs to T cells is reduced, as determined by 
proliferation assays, highlighting the importance of understanding the interaction of 
FMDV with DCs (Robinson, 2008). 
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pDCs were first described in humans as a subset of cells specialised in the secretion 
of type 1 IFNs in response to certain viruses (Fitzgerald-Bocarsly, 1993, Lennert and 
Remmele, 1958). These lymphoid derived cells were identified on the basis of their 
plasma-cell-like morphology and expression of CD4, their ability to stimulate helper 
T cells and their location in the T-cell areas of lymph nodes (Colonna et al., 2002). 
pDC have also been described in human skin (Zaba et al., 2007) and in the lung, liver 
and blood of mice (Abe et al., 2004, de Heer et al., 2004, Diacovo et al., 2005). 
pDCs respond to microbial nucleic acids during infection, in addition, when there is a 
breakdown of innate tolerance they can respond to self nucleic acid which can trigger 
autoimmune diseases, for example, systemic lupus erythematosus (Gilliet et al., 
2008). In order to discriminate between pathogen derived and self nucleic acids, 
pDCs do not express receptors for nucleic acids on their surface but rely on the 
subcellular localisation of Toll-like receptors (TLR) to response to pathogens that 
invade by endocytosis. Endosomal TLR7 is required to respond to single-stranded 
RNA viruses like influenza virus or VSV (Lund et al., 2004) and endosomal TLR9 
expression is required to respond to single-stranded DNA molecules. In addition, 
TLR9 is only activated by single-stranded DNA molecules that contain unmethylated 
CpG-containing motifs, which are commonly found in the genomes of DNA viruses 
such as herpesviruses and in bacteria (Gilliet et al., 2008, Krug et al., 2004). Unlike 
DCs, pDCs do not express TLR2, TLR4, TLR5 or TLR3, which explains why they 
do not respond to bacterial products such as peptidoglycans, lipopolysaccharide and 
flagellin, or viral double-stranded RNA (Colonna et al., 2004).  
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pDC homologs have been described in pigs (Domeika et al., 2004, Summerfield et 
al., 2003, Riffault et al., 2001) and in sheep (Pascale et al., 2008). They have been 
identified in the skin and at mucosal surfaces of these two species where they are 
able to interact with invading pathogens, for example, transmissible gastroenteritis 
virus infection in piglets (Riffault et al., 2001). In addition, pDCs are able to migrate 
in afferent lymph to the draining lymph node, enabling presentation of antigen 
captured at peripheral sites (Pascale et al., 2008). Interactions with FMDV have been 
investigated with porcine blood derived pDCs (Guzylack-Piriou et al., 2006). FMDV 
was shown to undergo a similar abortive replication cycle in porcine pDCs as it does 
in DCs. However, infection was only initiated in the presence of specific antibody 
and associated with CD32 expression (Guzylack-Piriou et al., 2006). Type 1 IFN 
induction was dependent on FMDV replication and the authors concluded that the 
response was mediated by receptors associated with the endocytic process, for 
example, TLR7 (Guzylack-Piriou et al., 2006). Cells have been identified in bovine 
lymph nodes that are capable of producing type 1 IFN in response to noncytopathic 
bovine viral diarrhoea virus (Brackenbury et al., 2005). However, these cells 
expressed myeloid markers and did not express CD4 or CD45RB suggesting that 
they were not the bovine homolog of pDCs. Researchers have not yet identified 
pDCs in cattle, other cell types, including monocytes and B cells are also capable of 
producing type 1 IFN in response to viral infections (Fitzgerald-Bocarsly, 2002) and 
the cellular source of the biologically active type 1 IFN detected in FMDV infected 
cattle is yet to be determined.   
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1.3.1.6. Natural killer cells  
Natural killer (NK) cells are bone marrow derived lymphoid cells that are capable of 
lysing tumour cells and virus-infected cells without prior sensitisation (Yokoyama et 
al., 2004). NK cells are activated either by cytokine stimulation, for example, by  
Interleukin (IL) -12 produced by activated macrophages and DCs (Gerosa et al., 
2002, Yokoyama et al., 2004) or by target cell recognition. NK cells are able to 
discriminate between healthy cells and target cells, recognising and killing infected 
cells or tumour cells by a complicated process mediated by the concomitant action of 
activating and inhibitory receptors (Lanier, 2005). Some of the inhibitory receptors 
recognise MHC class I, which is present on most healthy cells thereby dampening 
NK-cell activity and preventing attack (Lanier, 2005). Activated NK cells lyse virus 
infected or tumour cells in the same way as CD8
+
 cytotoxic T cells, a process 
mediated by perforin pores and granzyme (Biron and Brossay, 2001). In addition, 
NK cells produce a number of cytokines, for example TNF-α and IFN-γ, both of 
which are important modulators of the immune response, capable of inducing DCs 
and macrophages (Walzer et al., 2005).  
 
The interaction of FMDV with NK cells is a neglected field of research, primarily 
because NK cells have only recently been identified and characterised in ruminant 
(Storset et al., 2004). The only evidence to support a putative role for NK cells in 
FMDV pathogenesis in bovines stems from studies of cells with an NK-cell like 
phenotype, derived from FMDV restimulated PBMC of vaccinated cattle (Amadori 
et al., 1992). These IL-2 stimulated CD45
+
 cells were able to lyse FMDV-infected 
target cells in a non-MHC restricted manner (Amadori et al., 1992). It has also been 
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suggested that NK cell activity could play an important role in FMD during viral 
down-regulation of MHC class I on infected epithelium (Sanz-Parra et al., 1998). 
However, it has also been suggested that down-regulating MHC class I may be part 
of the viral immune evasion strategy to prevent cytolysis by MHC class I-restricted T 
lymphocytes (Grubman et al., 2008, Summerfield et al., 2008). Recently, it was 
shown that a population of non-adherent porcine PBMC enriched for NK cells by 
negative selection, were able to lyse FMDV infected porcine kidney fibroblasts in 
vitro after stimulation with proinflamatory cytokines (Toka et al., 2009). The 
fibroblasts were infected with an attenuated, heparin sulphate binding strain of FMD, 
LL-KGE which lacks the L
pro
. The greatest lytic capacity was seen after incubation 
with IL-2 or IL-15. Lower activation was induced by IL-12, IL-18 or IFN-α, however 
combining IL-12 and IL-18 increased the lytic capacity of these cells. These data 
suggest that the porcine innate immune response against FMDV can be enhanced by 
proinflamatory cytokines (Toka et al., 2009). The recent characterisation of an 
antibody directed against bovine NK cells, NKp46, should lead to more detailed 
studies of NK cell function and the role of these cells in FMD pathogenesis (Storset 
et al., 2004).  
 
1.3.1.7. Gamma delta T cells 
The γδ T cells account for a relatively large proportion of the lymphocyte population 
in ruminants, with even greater numbers (50% of the lymphocytes in circulation) 
reported in juvenile animals (Clevers et al., 1990, Pollock and Welsh, 2002). Like αβ 
T cells the γδ T cells express a T-cell receptor (TCR) on their surface which 
recognises antigen. The bovine TCR, as is the case for other animals, is associated 
 50 
with up to 5 non-covalently linked invariant components termed the CD3 γ, δ, and ε 
and TCR δ and ε chains and together they form the TCR complex (Pescovitz et al., 
1998). However, the majority of γδ T cells lack the co-receptor molecules CD4 and 
CD8, which play an important role in MHC restricted activation of αβ T cells (Cron 
et al., 1989). Similar to the αβ TCR, each chain of the heterodimeric γδ TCR 
comprises of an immunoglobulin like extracellular domain with a variable and 
constant region, a transmembrane segment and a cytoplasmic domain. However, 
sequence analysis in humans has revealed that the γδ TCR is more closely related to 
surface expressed immunoglobulin‟s on B cells and structural analysis has revealed 
fundamental differences in the extracellular domain when compared to the αβ TCR 
(Allison et al., 2001). The main differences exist in the third complementary-
determining region (CDR3) loop of the TCR, a region which interacts directly with 
antigenic peptides (Nishio et al., 2004). This region of the γδ TCR has been shown to 
be longer and more variable than the αβ TCR in humans and in mice (Rock et al., 
1994). These differences allow antigens and damaged tissue to interact directly with 
the γδ TCR without the requirement for MHC molecules and protein processing 
pathways (Schild et al., 1994, Rock et al., 1994). However, this is not the case for all 
γδ T cells because the small percentages of γδ T cells which express CD4 or CD8 in 
humans and mice depend on antigen processing pathways and presentation by MHC 





 thymocytes (Haas et al., 1993, Nishio et al., 2004). Although a 
defined role for the γδ T cells remains unclear, these cells have been attributed as a 
first line of defence with other innate immune responses and seem to be biased 
towards the recognition of certain types of microbial antigens (Hayday, 2000). It is 
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unclear if these cells are able to display immunological memory and participate in 
recall responses (Blumerman et al., 2007). There is evidence in humans and mice 
that γδ T cells can undergo antigen priming, altering the cellular responsiveness on 
secondary encounter with the antigen (Hoft et al., 1998, Spaner et al., 1993). 
Similarly in cattle, in vivo priming with killed Leptospira vaccine has been shown to 
alter the cellular response of a subset of γδ T cells on re-encounter with the antigen in 
vitro. Priming was associated with a larger percentage of γδ T cells undergoing 
blastogenesis in vitro compared to cells from naïve animals, suggestive of a memory-
like phenotype (Blumerman et al., 2007).  
 
Two distinct populations of γδ T cells have been characterised in cattle based on their 
cell-surface phenotype and tissue distribution. Workshop cluster (WC) 1 is a 






 γδ T cells 
(Carr et al., 1994, Clevers et al., 1990). In cattle, WC1
+
 γδ T cells represent less than 
10% of the mononuclear cell population in the lymph node, thymus and spleen and 
represent between 10 to 15% of the PBMC, with higher percentages reported in 
juvenile animals (MacHugh et al., 1997). The WC1
−
 subset expresses CD2 and CD8. 
The majority of bovine WC1
−
 γδ T cells reside in the red pulp of the spleen where 
they are reported to represent approximately 30% on the mononuclear cell population 
(MacHugh et al., 1997). 
 
Three isoforms of WC1, a protein associated with γδ T cells growth arrest, have been 
identified in ruminants, WC1.1, WC1.2 and WC1.3 (Hanby-Flarida et al., 1996, 






subpopulations have been shown to act as regulatory cells ex vivo and express IL-10, 
potentially playing an important role for maintenance of both innate and antigen 
specific adaptive immune responses (Ferrick et al., 1995, Hoek et al., 2009). WC1
+
 
γδ T cells have been found to play a role in the immune response against bacterial, 
parasitic and viral infections in cattle.  The majority of evidence for the role of WC1
+
 
γδ T cells in cattle is based on studies of the immune response to bacterial infections, 
for example Mycobacterium bovis, Leptospira species and staphylococci (Fikri et al., 
2001, Kennedy et al., 2002, Naiman et al., 2002) where they have been shown to 
proliferate and produce the cytokines IL-12, IFN-γ and TNF-α. Proliferation and 
transcription of cytokines has also been reported in response to parasitic infections 
including Theileria annulata, Theileria parva, in addition, NK-like cytotoxicity has 
been reported following in vitro exposure to Babesia bovis (Brown et al., 1994, 
Collins et al., 1996, Daubenberger et al., 1999). The response of WC1
+
 γδ T cells in 
ruminants to viral infections has not been extensively investigated and little is known 
about the involvement of these cells in viral pathogenesis. There are reports of a 
regulatory role during immune responses to viral infections with enhanced antibody 
responses detected following respiratory syncytial virus challenge in WC1
+
 depleted 
calves (Taylor et al., 1995). These cells have also been shown to increase in 
circulation following challenge with bovine leukaemia virus, however the 
significance of this response is unclear (Ungar-Waron et al., 1996). Purified, naïve 
porcine WC1
+
 γδ T cells are able to respond directly to FMDV antigen, a response 
characterised by proliferation and increased expression of pro-inflammatory 
cytokines and chemokines (Takamatsu et al., 2006). There are no reports in the 
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literature on the response of bovine γδ T cells to FMDV and a role for these cells in 
FMD pathogenesis has not been investigated. 
 
1.3.2. The adaptive immune system 
1.3.2.1. Humoral immunity 
Humoral immunity is the component of the adaptive immune response mediated by 
antibody produced by B cells. B cells are generated in the bone marrow and 
recognise antigen through the antigen specific B-cell receptor which is formed by 
somatic recombination of germline encoded genes (Murre, 2007). Bovine B cells can 
be divided into two subsets, B1 and B2 B-cells. Bovine B1 B-cells are considered a 
more primitive cell type and express the antigens CD5, a molecule implicated in the 
negative regulation of B-cell-receptor signalling (Lenz, 2009) and CD11b, a receptor 
for the proteolytically inactive product of the complement cleavage fragment C3b 
(Michishita et al., 1993). The majority of these cells are L-selectin
−
 and subsequently 
do not recirculate through the lymph nodes and can be found predominantly in the 
pleural and peritoneal cavities (Howard and Morrison, 1994, Naessens and Williams, 
1992). In contrast, the L-selectin
+
 B2 B-cells, considered to be conventional B cells, 
recirculate through lymph nodes and do not express CD5 or CD11b (Howard and 
Morrison, 1994, Naessens and Williams, 1992). The B1 B-cells in mice are 
responsible for producing natural antibodies (see section 1.3.1.3) and together with 
mouse splenic marginal zone B cells are classified as “innate B lymphocytes”, acting 
as a first line of defence against invading pathogens (Carey et al., 2008, Kearney, 
2005). These cells express mostly immunoglobulin (Ig) M and are involved in T-
independent (T-I) antibody responses (Howard and Morrison, 1994, Ostrowski et al., 
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2007). Antigens that are able to stimulate naïve B cells in the absence of T cell help 
are known as T-I antigens (Obukhanych and Nussenzweig, 2006). The T-I antigens 
can be further subdivided into type I and type II T-I antigens. Type I T-I antigens are 
mitogenic agents, for example, lipopolysaccharides, unmethylated CpG and 
polyriboinosinic: polyribocytidylic acid (poly IC), that activate TLRs to elicit 
polyclonal B cell activation. Type I T-I antigens are generally considered to be  more 
potent B cell stimulators than type II T-I antigens and are able to activate immature B 
cells (Cambier et al., 1994, Obukhanych and Nussenzweig, 2006, Scher, 1982). Type 
II T-I antigens are typically complex, rigid structures that engage and cross-link the 
immunoglobulin receptors on the surface of B cells generating strong activation 
signals to produce antibody, in the absence of specific T cell help (Obukhanych and 
Nussenzweig, 2006). The repetitiveness and degree of antigen organisation 
determines whether the antigen can generate a strong enough signal to induce 
antibody production or if there is a requirement for accessory signals from antigen 
presenting cells or T cells (Cambier et al., 1994). Interaction of the B-cell surface 
immunoglobulin receptor with T-dependent (T-D) antigens leads to activation of a 
cascade of protein kinases and antigen internalisation (Cambier et al., 1994). The 
antigen is processed and presented on MHC class II molecules, however, antibody is 
not produced and the B cell does not undergo proliferation. This mechanism of 
uptake by a B cell is highly efficient and B cells constitutively express high levels of 
MHC class II molecules. A successful B-cell response to a T-D antigen is dependent 
on encounter with a primed CD4
+
 T cell since B cells will tolerise naïve T cells 
(Cambier et al., 1994, Eynon and Parker, 1992). The costimulatory molecules B7.1 
(CD80) and B7.2 (CD86) are upregulated on encounter with a specific, primed 
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helper T cell (June et al., 1994). These molecules interact with CD28 on T cells, 
leading to CD40 ligand (CD154) expression. The CD40-CD154 interaction induces 
B-cell proliferation, antibody production and isotype class switching (Armitage et 
al., 1992). The B cell co-receptor complex CD19:CD21:CD81 is also an important 
component of B-cell activation, coupling the innate complement system with B-cell 
activation (Fearon and Carroll, 2000). CD21 is a receptor for the complement 
fragment C3d, an interaction which increases B-cell responsiveness (Carter et al., 
1988). However, it is not clear if the increased responsiveness is a result of increased 
B-cell signalling, the induction of co-stimulatory molecules on the B cell or 
increased receptor mediated uptake of antigen (Fearon and Carroll, 2000). 
 
A number of cytopathic viruses, for example VSV (Battegay et al., 1996), influenza 
virus (Lee et al., 2005) and rotavirus (Franco and Greenberg, 1997) have been 
described to act as T-I antigens in mice. The rapid induction of a protective immune 
response directed against these acute cytopathic viruses is essential to ensure host 
survival by controlling virus spread through systemic circulation (Bachmann and 
Zinkernagel, 1997). The capacity of these viruses to induce a T-I antibody response, 
characterised by a rapid and potent IgM response, is associated with the high 
organisation of viral surface antigens (Bachmann and Zinkernagel, 1996). FMDV is 
able to induce a rapid and specific T-I neutralising antibody response in mice (Borca 
et al., 1986, Lopez et al., 1990), a response mediated, at least in part, by splenic 
innate B cells (Ostrowski et al., 2007). However, it is unknown whether this response 
exists in any natural host of FMDV. The importance of humoral immunity in FMD is 
well documented, over a hundred years ago it was demonstrated that antibodies form 
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the major mechanism of protection against FMDV using passive transfer 
experiments in cattle (Loeffler and Frosch, 1897). Because of the importance of 
antibody, a number of studies have examined the classes and subclasses of virus 
neutralising antibody in serum and probang samples of cattle. Specific IgM is 
detected in the serum between 3 to 7 days after challenge, reaching a peak between 5 
and 14 days then slowly declining to an undetectable level at the latest 56 days post-
infection. Isotype switching occurs rapidly with specific IgG1 and IgG2 detected 
from 4 days post-challenge and reach maximal levels between 14 and 20 days 
(Collen, 1994, Doel, 2005, Salt et al., 1996a). Virus neutralising antibody has been 
detected up to 4.5 years after experimental infection in bovines (Cunliffe, 1964). IgA 
is initially detected in serum and probang samples from 7 days after challenge with a 
peak titre detected at 7 to 14 days in serum and an initial peak titre at 14 days in 
probang samples. The IgA titre in serum slowly declines from 14 days except in 
„carriers‟ where a significant second late response beginning at 28 days is detected. 
A second late response is detected from day 28 in probang samples of all infected 
cattle independent of their „carrier‟ state. The IgA titre in probang samples either 
decline to undetectable levels or persist in animals classified as „carriers‟ (Salt et al., 
1996a). The titre of secretory IgA has been considered as a tool for identifying 
„carrier‟ animals and for detecting sub-clinical infection in vaccinated cattle (Parida 
et al., 2006).  
 
An effective immune response against FMDV is characterised by the induction of 
high titres of antibody. Although there is a close correlation between FMDV serum 
neutralising antibody titres (SNTs) and protection from infection, this correlation is 
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not precise (McCullough et al., 1992). This imprecise correlation is highlighted in 
certain vaccine potency testing studies during which animals with low or no 
detectable neutralising antibody titre were resistant to challenge while others with 
acceptable titres were susceptible (Barnett and Carabin, 2002). This disparity could 
be explained by different neutralisation mechanisms in vivo in the presence of other 
immune system components compared to the in vivo FMDV neutralising antibody 
test used to determine the antibody titres. The ability of antibody to neutralise virus 
in vivo is far more complex, involving the interaction of antibody with cells and 
molecules of the innate immune system and under these conditions non-neutralising 
antibody can contribute to protection (Reading and Dimmock, 2007). The described 
mechanisms of FMDV neutralisation in vitro, as determined by the virus neutralising 
antibody test, includes inhibition of cell attachment leading to loss of infectivity due 
to steric hindrance with integrin interactions or destabilisation of the virus capsid, 
which leads to premature uncoating and particle destruction (McCullough et al., 
1992, McCullough et al., 1987b). It is noteworthy that the 4C9 destabilising MAb 
described by McCullough et al. could disrupt the virion capsid at 37
o
C under normal 
ionic conditions, in contrast to MAbs described for poliovirus which could only 
irreversibly inactivate poliovirus at temperatures above 39
o
C or in a low-ionic-
strength environment (Delaet and Boeye, 1993, McCullough et al., 1987b). 
  
A number of antibody-mediated mechanisms that inhibit virus attachment or virus 
cell entry events have been described. Antibodies can block the cell attachment site 
on the virus particle or induce aggregation (Brioen et al., 1983). In addition, it has 
been hypothesised that a single antibody molecule can induce conformational 
 58 
changes in crucial capsid molecules which can block virus attachment or block post-
entry events, for example, preventing virus uncoating by cross-linking the capsid as 
demonstrated for a MAb directed against human adenovirus (Reading and Dimmock, 
2007, Wohlfart et al., 1985). However, the role of antibody in blocking late steps in 
entry is largely unknown. Recently, a new mechanism by which antibodies block 
virus infection has been described for human adenovirus (Smith et al., 2008). Human 
adenovirus is a nonenveloped DNA virus that interacts with cellular integrins 
through a conserved RGD motif in addition to the adenovirus receptor CD46 and is 
taken up through clathrin-dependent endocytosis (Wickham et al., 1993). A 
neutralising antibody has been described that blocks infection in vitro by inhibiting 
virus microtubule-dependent translocation from the site of endosome penetration 
through the cytoplasm to the nuclear envelope (Smith et al., 2008).    
 
An antibody occupancy model to block virus entry has also been proposed (Burnet et 
al., 1937). According to this model, virus attachment or entry into the host cell is 
inhibited when a large proportion of the epitopes on the virion are occupied by 
antibody which increases the size of the virus particle (Burton, 2002). This model 
highlights the importance of high affinity antibody directed against epitopes on the 
virion surface at sites not involved with cell-receptor recognition (Burton, 2002). 
Binding of a single IgM molecule or two closely spaced IgG antibodies to a virus can 
also activate the classical pathway of the complement system by binding of C1q to 
the immune complex (Spear et al., 2001). As complement activation proceeds at the 
virus surface, there is a build-up of complement components which coat the virus, 
interfering with virus binding, as shown in vitro with avian infectious bronchitis 
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virus (Berry and Almeida, 1968). In addition, as the membrane attack complex of 
complement is activated, pores are formed in the membrane of enveloped viruses, for 
example human immunodeficiency virus (HIV) type-1, leading to virolysis (Sullivan 
et al., 1996). Fc and complement receptors can also bind the immune complexed 
virus which leads to phagocytosis and virus inactivation. This process has been 
described in vitro for FMDV and the protective immune response against FMDV in 
vivo is thought to be dependent on the interaction between antibody-virus complexes 
and the phagocytic cells of the reticuloendothelial system (McCullough et al., 1986, 
McCullough et al., 1992, McCullough et al., 1988). Antibody-complexing of virus 
can also enhance infection of Fc receptor bearing cells, for example, enhancement of 
Dengue virus infection in vitro is mediated by Fc receptors (Boonnak et al., 2008, 
Halstead, 1982), a process that may also enhance infection in vivo (Goncalvez et al., 
2007).   
 
Antibody can also interact with infected cells by binding viral proteins that are 
expressed on the cell surface. Binding of antibody to infected cells can lead to cell 
lysis or clearance by Fc-mediated antibody-dependent cellular cytotoxicity or 
complement dependent cytotoxicity (Burton, 2002). Binding of antibody to viral 
molecules on the cell surface has also been shown to inhibit viral replication within 
the cell, for example, clearance of alphavirus infection from rat neurons in vitro 
(Levine et al., 1991). In addition, virus release from the infected cell and cell-to-cell 
transmission can be inhibited, for example, antibodies directed against influenza 
virus transmembrane protein can reduce virus yield (Gerhard, 2001, Reading and 
Dimmock, 2007). Generally, antibody functions against extracellular and cell surface 
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antigen whereas cell-mediated immunity forms a surveillance system for intracellular 
pathogens. However, polymeric IgA and IgM are the exception and can mediate 
intracellular neutralisation of viruses, for example, HIV transcytosis can be blocked 
in vitro by IgA and IgM specific for envelope proteins leading to intracellular virus 
neutralisation (Bomsel et al., 1998). In addition, non-neutralising IgA can protect 
against rotavirus infection in mice in vivo by a similar mechanism (Burns et al., 
1996).      
 
1.3.2.2. Cell mediated immunity 
Cell mediated immunity describes the effector function of T lymphocytes that serve 
as a defence against intracellular pathogens. Classical antigen recognition by αβ T 
cells is mediated by the αβ TCR complex which recognises processed antigenic-
peptide presented on the surface of antigen presenting cells or infected cells by MHC 
molecules (Roitt and Delvis, 2001). The αβ TCR, like the immunoglobulin receptor 
of B cells, undergoes somatic recombination of germline encoded genes resulting in 
numerous antigen specific TCRs. Antigen can be presented to T cells by four types 
of antigen-presenting cell, monocytes, macrophages, DCs which are able to present 
antigen and stimulate naïve T cells and B cells which present antigen fragments 
recognised by their surface immunoglobulin (Trombetta and Mellman, 2005). 
Classically, it is considered that proteins synthesised intracellularly such as viral 
proteins are degraded and presented by MHC class I molecules to cytotoxic CD8
+
 T 
cells whereas extracellular proteins are presented by MHC class II molecules to 
CD4
+
 T cells (Germain, 1994), however, it is now recognised that additional, 
alternative routes exist for proteins to be presented, including cross-presentation and 
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autophagy (Cresswell, 2005). Once the TCR is engaged with an antigen of the 
correct specificity it receives the first TCR complex activation signal. The T cell will 
only be activated if it receives the second activation signal involving the interaction 
of CD28 on the T cell and B7.1 and B7.2 on the antigen presenting cell. If the T cell 
does not receive this second signal it becomes anergic. Activation results in the 
production of  IL-2 which induces clonal expansion in an autocrine manner 
(Colombetti et al., 2006). The T cells then differentiate into effector cells and 
memory cells (see section 1.6.1).   
 
The CD4 molecule consists of a single polypeptide belonging to the immunoglobulin 
gene superfamily, with CD4
+
 T cells representing approximately 24 to 35% of 
PBMC in cattle (Howard and Morrison, 1994). As for other species, CD4
+
 T cells in 
ruminants are MHC class II restricted (Baldwin et al., 1986). Depletion experiments 
in cattle, targeting CD4
+
 cells with specific mouse MAbs, have demonstrated that 
these cells are essential for producing antibody to T-D antigens (Howard et al., 
1989). The progeny of antigen stimulated CD4
+
 T cells differentiate into effector 
cells that can activate macrophages, cytotoxic CD8
+
 T cells and B cells. 
  
A role for CD4
+
 T cells during the immune response against FMDV has not yet been 
defined. FMDV is able to induce a rapid and specific T-I neutralising antibody 
response in mice (Borca et al., 1986, Lopez et al., 1990). However, it is not clear if T 
cells are required to induce a protective neutralising antibody response in cattle. 
FMDV-specific CD4
+
 T-cell-proliferative responses are detectable following 
infection or vaccination with virus or peptide (Blanco et al., 2001, Collen and Doel, 
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1990, Gerner et al., 2007) and several haplotype-restricted and “promiscuous” CD4
+
 
T cell epitopes have been identified on both the structural and non-structural proteins 
suggesting that cell-mediated immunity may be involved in the immune response 
(Blanco et al., 2000, Collen and Doel, 1990, Gerner et al., 2007, van Lierop et al., 
1995). Current work in our group (Windsor et al, manuscript in preparation) has 
detected CD4
+
 T-cell-proliferative responses to vaccine antigen following primary 
FMDV O UKG infection in cattle. However, these responses are usually variable and 
of low magnitude. These reduced responses are not a consequence of generalised 
immunosuppression during infection because recall responses to unrelated antigens 
are unaffected, therefore bringing into question the contribution by CD4
+
 T cells to 
the immune response and memory response after primary FMDV infection. 
  
The CD8 molecule, which also belongs to the immunoglobulin gene superfamily, is 
usually expressed as a noncovalently linked heterodimer consisting of α and β 
chains. However, homodimers of only the α chain can exist, which is the chain 
involved in binding to MHC class I molecules through its immunoglobulin like 
extracellular domain (Howard and Morrison, 1994). CD8
+
 T cells represent 
approximately 15 to 25% of PBMC in cattle (Howard and Morrison, 1994). The 
CD8
+
 T cells differentiate into effector cytotoxic T lymphocytes and mediate MHC 
class I restricted cytotoxicity against infected cells with help from CD4
+
 T cells. 
Depletion experiments in cattle have demonstrated the importance of these cells in 
viral infections like respiratory syncytial virus and rotavirus where they play a major 
role in resolution of the primary infection (Oldham et al., 1993, Taylor et al., 1995). 
The role of CD8
+
 T cells in FMDV infection is also unclear.  Recently, FMDV-
 63 
specific MHC class 1 restricted CD8
+
 T cells were detected in cattle, following both 
infection and vaccination, using an IFN-γ restimulation ELISpot assay (Guzman et 
al., 2008). As discussed under section 1.3.1.6, FMDV down regulates MHC class I 
on infected epithelial cells (Sanz-Parra et al., 1998). MHC class I expression is 
reduced by approximately 50% just 6 hours post-infection, potentially effecting the 
ability of CD8
+ 
T cells to recognise and eliminate infected cells (Grubman et al., 
2008).    
 
1.4. Follicular dendritic cells 
Follicular dendritic cells (FDCs) (Chen et al., 1978) are specialised, non-endocytic, 
immune accessory cells found in the follicles of organised lymphoid tissue (Allen 
and Cyster, 2008, Sukumar et al., 2008). Although morphologically heterogeneous, a 
factor attributed to differences in maturity (El Shikh et al., 2006, Szakal et al., 1989), 
FDCs characteristically possess long, delicate cytoplasmic extensions which form a 
reticular network in close contact with adjacent lymphocytes. They are also 
characterised by electron-lucent vesicles in the cytoplasm and deeply indented or 
bilobed euchromic nuclei (Sukumar et al., 2008). A particular striking feature of 
FDCs is their ability to trap and retain antigen in the form of immune complexes on 
the surface of their dendrites for long periods of time, which serves as a repository of 
unprocessed antigen (Tew and Mandel, 1979, Tew et al., 1982). FDCs are localised 
in the central region of primary follicles, in contrast, FDCs in secondary follicles 
show a polarised distribution. FDCs in the germinal centre light zone display 
abundant dendrites with a higher level of membrane-bound immune complexes 
compared to dark zone FDCs, which display fewer dendrites (Allen and Cyster, 
 64 
2008). Light zone FDCs have been extensively described (Allen and Cyster, 2008) 
and are associated with upregulated expression of three low affinity Fc receptors, 
CD23 for IgE and CD16 and CD32 for IgG (Hazenbos et al., 1998, Maeda et al., 
1992, Qin et al., 2000) and the integrin ligands inter-cellular adhesion molecule 1 
(ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and mucosal vascular 
addressin cell adhesion molecule 1 [MAdCAM-1] (Balogh et al., 2002). In contrast, 
the properties of dark zone FDCs have not been extensively described, although 
recently fibrinogen has been shown in association with dark zone FDCs (Lefevre et 
al., 2007). 
    
The cellular origin of FDCs and the conditions of their development are poorly 
understood, with early FDC development studies complicated by their resistance to 
radiation (Kinet-Denoel et al., 1982). Recent studies support the model that FDCs are 
stromal cells of mesenchymal origin, although it is not certain if the cells originate 
from within the follicle or migrate from another site (Cyster et al., 2000). 
Transplantation experiments in severe combined immunodeficiency (SCID) mice, 
which lack B cells, T cells and FDCs, have elucidated some of the requirements for 
FDC development. After reconstitution of SCID mice with donor B cells, FDCs of 
host origin were observed, suggesting that FDCs developed under the influence of B 
cells (Yoshida et al., 1995, Yoshida et al., 1994). Similar results were reported for 
SCID mice reconstituted with bone marrow and fetal liver, however FDCs of host 
and of donor origin were detected, indicating that progenitor cells were present in the 
transferred primary lymphoid tissues (Kapasi et al., 1998). Tumour necrosis factor 
(TNF) and a subset of the TNF-family proteins known as lymphotoxin (LT) are 
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required for normal FDC development (Cyster et al., 2000). LT can exist either as a 
secreted protein called LTα3 which binds the receptors TNFR1 and TNFR2, or as a 
membrane-bound protein called LTα1β2 which binds the LTβR (Tumanov et al., 
2003). LTβR-deficient mice lack FDCs (Allen and Cyster, 2008) and mouse spleens 
can be depleted of FDCs and retained antigen by administering a LTβR-Ig fusion 
molecule consisting of the extracellular domain of LTβR and the constant region of 
human IgG1 (Gatto et al., 2007). In addition, it has been demonstrated that 
membrane-bound LT on B cells is required for FDC development (Fu and Chaplin, 
1999), this would explain the ability of B cells, as described above, to restore FDCs 
when transferred to lymphocyte deficient mice. It is also important to note that 
germinal centre B cells have elevated amounts of surface LTα1β2 compared to naïve 
B cells (Ansel et al., 2000).  
 
Evidence in the literature supporting the stromal derivation of human FDCs is based 
on studies of cells isolated from tonsils. These cells were CD45 negative, suggesting 
that they were not bone marrow derived cells. In addition, these cells expressed the 
α-smooth muscle actin, suggesting that FDCs are a specialised form of 
myofibroblasts, similar to bone marrow stromal cell progenitors (Munoz-Fernandez 
et al., 2006, Schriever et al., 1989). It must be remembered that the low proportion of 
FDCs in lymphoid follicles, together with technical difficulties in their isolation, 
make these cells very difficult to study. More support for stromal derivation of 
human FDCs is provided in the literature by evidence of ectopic FDCs associated 
with conditions of chronic inflammation and rare primary FDC-tumours. These cells 
have been identified by their expression of the long human isoform of CD21, thought 
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to be a human FDC-specific molecule (Liu et al., 1997, van Nierop and de Groot, 
2002).  
 
1.4.1. Function of follicular dendritic cells 
FDCs form an important component of the germinal centre reaction, playing a role in 
antigen trapping, lymphoid follicle organisation and promoting B cell proliferation, 
survival and differentiation. 
 
1.4.1.1. Antigen trapping 
The ability of FDCs to trap and retain antigen in the form of immune complexes 
(composed of antibody, complement or antibody and complement) is linked to their 
variable expression of complement and Fc receptors (CD16, CD23 and CD32) 
(Hazenbos et al., 1998, Maeda et al., 1992, Qin et al., 2000). The complement 
receptors CD21 (for complement component 3d) and CD35 (for complement 
component 3b/4b) are expressed in both primary and secondary follicles (Imal and 
Yamakawa, 1996) and may play an important role to trap complement containing 
immune complexes formed rapidly after exposure to a pathogen (Carroll, 1998). 
Recently, FDCs were identified as the predominant cell type expressing the human 
Fc receptor for IgA and IgM (Fcα/µR) (Kikuno et al., 2007). IgM is the first 
antibody to be produced during a humoral immune response and natural antibodies 
are mainly IgM (Ochsenbein et al., 1999a), therefore this receptor may play an 
important role in membrane-bound antigen presentation to B cells during the initial 
stages of an immune response to a pathogen (Ochsenbein and Zinkernagel, 2000). A 
number of studies have examined how antigen is presented to B cells in lymph node 
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follicles using real-time imaging approaches, B cells can encounter soluble antigen 
that has diffused into the follicle or antigen can be presented by macrophages, DCs 
or FDCs (Batista and Harwood, 2009, Cinamon et al., 2008, Kraal, 2008, Pape et al., 
2007). However, the mechanism of immune complex transport and deposition on 
FDCs is unknown, future work using high-resolution imaging approaches may 
provide a better understanding of this important process. Marginal zone B cells in the 
spleen are able to take up blood-borne antigens, these cells constantly shuttle 
between the marginal zone and the follicle, carrying antigen to the FDCs (Cinamon 
et al., 2008, Kraal, 2008). 
 
1.4.1.2. Interaction between B cells and follicular dendritic cells 
Antigen, in the form of immune complexes, on FDCs is markedly more effective at 
stimulating B cell differentiation, proliferation, somatic hypermutation and class 
switch recombination (Aydar et al., 2005) than soluble antigen or soluble immune 
complexes (Kosco et al., 1988). The enhanced stimulation is proposed to result from 
the interaction of B cells with repetitive, membrane-bound antigen on the surface of 
the FDCs causing clustering of the B-cell receptor and co-receptor complex (Kosco-
Vilbois, 2003).  However, the importance of the interaction of FDC-bound immune 
complexes with B cells has been brought into question. In a study of transgenic mice 
deficient of secreted immunoglobulin, therefore lacking antigen-antibody complexes, 
there was no effect on germinal centre development or B-cell memory (Anderson et 
al., 2006). This observation could be explained by FDC-bound complement 
components interacting with the B-cell co-receptor complex through CD21, 
providing activation and proliferation signals (Allen and Cyster, 2008). In addition, 
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the presence of immunoglobulin Fc in antigen-antibody complexes in vitro causes 
inhibition by engagement of the inhibitory FcγRIIB on B cells (Tew et al., 1997). 
However, it has been proposed that this mechanism could form part of the B-cell 
selection process (affinity maturation) in germinal centres in vivo. B cells with low 
affinity B-cell receptors may undergo apoptosis as a result of the relatively stronger 
inhibitory signal received by engagement with FcγRIIB (Ravetch and Nussenzweig, 
2007). Furthermore, the high concentration of FcγRIIB on FDCs is thought to bind 
excess immunoglobulin Fc regions on the immune complexes. This reduces the 
number of Fc regions available that would otherwise bind FcγRIIB on the B cells, 
therefore reducing down regulation (Fakher et al., 2001). Another important 
interaction between membrane-bound antigen and B cells occurs as the germinal 
centre reaction progresses. As the FDC mature the dendrites form beaded structures 
coated with immune complexed antigen, these beads are called immune-complex 
coated bodies or iccosomes (Szakal et al., 1988). These iccosomes are dispersed to B 
cells (or other antigen presenting cells) where they are endocytosed and processed 
for MHC class II presentation to T cells (Tew et al., 2001). FDCs can retain antigen 
for long periods of time and immune complex deposition on FDCs may be involved 
in maintaining neutralising antibody titres, memory cells and recall responses (Gatto 
et al., 2007). FDC also provide a number of B-cell trophic factors and cytokines 
including B-cell activating factor (BAFF), which is able to rescue germinal centre B 
cells from apoptosis in vitro, and membrane bound IL-15 which augments B-cell 
proliferation (Park and Choi, 2005).  
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1.4.1.3. Organisational functions 
When FDC receive the proper developmental and maturation signals they cluster and 
express the B-lymphocyte chemokine CXCL13 (which is strongly dependent on 
LTα1β2 and TNF) for which B cells constitutively express the receptor CXCR5. B 
cells migrate and home into follicles under the influence of CXCL13 to form the 
germinal centre (Chaplin and Zindl, 2006). CXCL13 induces LTα1β2 production by 
B cells providing a positive feedback loop (Ansel et al., 2000). FDCs appear to have 
higher ICAM-1 expression than any other cell type in the lymph node. The adhesion 
molecules play a major role in FDC and B-cell interaction mainly via ICAM-1 and 
VCAM-1 pathways (Koopman et al., 1991, Tew et al., 1997).  
 
1.5. The germinal centre reaction 
The HEVs within lymph nodes secrete the chemoattractant cytokine CCL21 (C-C 
motif chemokine ligand 21) (Hedrick and Zlotnik, 1997). DCs (these cells also 
express CCL21) and T cells expressing the CCL21 receptor CCR7 (C-C motif 
chemokine receptor 7) (Yoshida et al., 1997) migrate out of the HEV into the T-cell 
zone of the lymph node. Recirculating B cells, which also express CCR7, enter the 
lymph node via the HEV and migrate to the primary follicle under the influence of 
CXCL13 and CXCL12 (Allen et al., 2004, Chaplin and Zindl, 2006). Entry of cells 
into the spleen is from the splenic artery, cells migrate to the white pulp in the 
periarteriolar lymphocyte sheath. Recirculating T and B cells move to the red pulp 
and exit the spleen in the venous blood (Welsh et al., 2004). Specific B cells are 
trapped at the border between the follicle and the T-cell zone where they proliferate 
forming a primary focus after interaction of antigen with the B-cell antigen receptor 
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(BCR) and after receiving the appropriate costimulatory signals. These proliferating 
cells will either migrate to extrafollicular areas and differentiate into short lived 
antibody-producing plasma cells (with an approximate half-life of 3 to 5 days in 
vivo) (Ho et al., 1986) or migrate to the nearby follicle to participate in the germinal 
centre reaction (MacLennan, 1994).  
 
B cells undergo a number of modifications during the germinal centre reaction. 
Within the germinal centre dark zone, B cells proliferate and undergo somatic 
hypermutation, altering the variable regions of their immunoglobulin gene (Kim et 
al., 1981). During this process the large rapidly proliferating B cells, termed 
centroblasts, reduce their surface immunoglobulin expression. The process of 
somatic hypermutation introduces point mutations into the variable regions of the 
heavy and light chain immunoglobulin genes at a very high rate, giving rise to a large 
number of mutant BCRs with variable affinity for the antigen (McHeyzer-Williams 
and McHeyzer-Williams, 2005). As development progresses the B cells move into 
the FDC-populated light zone of the germinal centre. These small, non-proliferating 
B cells, termed centrocytes, compete for binding antigen on FDCs and are subjected 
to the process of positive and negative selection, isotype switching and 
differentiation (Tarlinton and Smith, 2000). Cells with improved affinity for the 
antigen are selected and expanded either by the prevention of cell death and/or the 
enhancement of cell division resulting in isotype switching and differentiation 
(McHeyzer-Williams and McHeyzer-Williams, 2005). Isotype switching via 
irreversible DNA recombination enables the assembled high affinity variable gene 
region, selected after somatic hypermutation, to be expressed on different constant 
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immunoglobulin chain regions. Switching to other isotypes only occurs after the B 
cell has been stimulated by antigen. Isotype switching in T-D immune responses 
requires the interaction between helper T cells and B cells. The CD40L/CD40 
interaction between these cells is considered the most important interaction for a 
sustained and isotype switched immune response to a T-D antigen. Isotype switching 
can also occur during a T-I immune response with the development of a thymus-
independent germinal centre (Gaspal et al., 2006, Zubler, 2001).  Recent advances 
using real-time imaging has shown that the germinal centre reaction is a much more 
dynamic process, challenging the classical germinal centre model described above 
(Allen et al., 2007b, Hauser et al., 2007, Schwickert et al., 2007). Germinal centre B 
cells are actually highly motile and transit in both directions between the germinal 
centre light and dark zones, a process regulated by the level of CXCR4 receptor 
expression for CXCL12 expressed on B cells (Allen et al., 2004, Allen et al., 2007a). 
In addition, dark zone and light zone B-cell morphology has been shown to be 
similar, with proliferation and cell death occurring in both zones and competition not 
only for antigen, but also for T-cell help (Allen et al., 2007a, Allen et al., 2007b, 
Hauser et al., 2007, Schwickert et al., 2007). The T helper cells may also undergo a 
degree of antigen-driven selection during the germinal centre reaction (Zheng et al., 
1996). However, not all T helper cells enter the germinal centre reaction and the 
germinal centre phase is not thought to be necessary for memory T cell development 
(Mikszta et al., 1999).   
 
The B cells that survive the germinal centre reaction differentiate into plasmablasts 
and finally into plasma cells or memory B cells (Tarlinton and Smith, 2000). The 
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plasma cells migrate to bone marrow niches and potentially live for a long period, 
obtaining signals from bone marrow stromal cells and continuously producing 
specific antibody (McHeyzer-Williams and McHeyzer-Williams, 2005). The antigen 
specific memory B cells do not secrete antibody, but constantly migrate between the 
blood circulation and tissues, able to respond rapidly when re-exposed to antigen to 
provide an enhanced adaptive immune response (Good et al., 2009).     
 
1.6. Maintaining immunity 
Immunological memory is the ability of the adaptive arm of the immune system to 
recognise and respond more rapidly to an antigen that it has encountered previously 
with a robust immune response to protect the host from re-infection, control 
persistent infections and to protect offspring from primary infection (Ahmed and 
Gray, 1996).  Adaptive immunity, which is responsible for immunological memory, 
can be broadly divided into two linked compartments, humoral immunity, consisting 
of circulating antibody and the cells involved in their production, or cell mediated 
immunity to kill infected cells (Zinkernagel, 1996).  
 
1.6.1. Maintaining cellular immunity 
The αβ T cells play an essential role in maintaining immunological memory. The 
frequency of T cells that recognise a specific peptide antigen is usually low, with 
lymphocyte circulation increasing the chance of these encounters (Selin et al., 1994). 
On contact with peptide presented on MHC molecules on the surface of antigen 
presenting cells, the specific T-cells proliferate and differentiate generating a large 
number of effector cells that migrate to tissues to help eliminate the specific 
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pathogen. During the contraction phase of the immune response there is a general 
migration of spleen and lymph node T cells to peripheral tissue, a process referred to 
as “diaspora” (Marshall et al., 2001), during which a large number of activated T 
cells undergo apoptosis (Razvi et al., 1995). Some of the primed T cells do not 
undergo apoptosis but develop into either “effector” or “central” memory T cells. 
Compared to naïve T cells, the memory T cells have a higher affinity for the specific 
peptides (Welsh et al., 2004). In addition, downstream signalling on TCR 
engagement is enhanced leading to more rapid induction of effector functions 
compared to naïve T cells (Kersh et al., 2003, Slifka et al., 1999). The “effector” 
memory T cells lack lymph node homing receptors (CCR7
low
) but express receptors 
for homing into inflamed tissue (Sallusto et al., 1999). Upon re-encounter with 
antigen they produce chemokines and cytokines, for example, IFNγ or IL-4 (CD4
+
 
cells) or release stored cytotoxic factors, for example perforin, in the case of CD8
+
 
memory T cells (Sprent and Surh, 2002). The “central” memory T cells express 
lymph node homing receptors (CCR7
high
). These cells have a lower activation 
threshold and cycle more rapidly than “effector” memory T cells (Sallusto et al., 
1999, Zinkernagel et al., 1996). Upon re-encounter with antigen they proliferate and 
differentiate into effector cells, migrate into peripheral tissue and mediate effector 
functions (Welsh et al., 2004). It is not clear how the pool of high frequency memory 
T cells specific for a single peptide are maintained and whether this pool can be 
maintained in the absence of specific antigen stimulation (Lau et al., 1994). 
Lymphocytic choriomeningitis virus (LCMV) infection is non-cytopathic in mice 
and initial control is largely dependent on a cytotoxic T-lymphocyte response, as 
opposed to neutralising antibody (Bachmann and Zinkernagel, 1997, Fehr et al., 
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1996, Lee et al., 2005). The data from mouse adoptive LCMV immune-cell transfer 
studies in the literature seem contradictory. There is evidence for the requirement of 
persisting viral antigen in order to maintain the antiviral protective capacity of the 
transferred cells (Gray and Matzinger, 1991, Oehen et al., 1992), whereas other 
investigators have reported that cytotoxic T lymphocytes persist and maintain 
protective immunity against challenge for up to 2 years in the absence of antigen 
(Lau et al., 1994). Evidence of persisting T-cell memory in humans following 
immunisation with vaccinia virus during childhood seems to support the hypothesis 
that continuous specific antigenic stimulation is not required, however, these studies 
do not demonstrate the absence of persisting antigen (Sprent and Surh, 2002). In 




 memory T cells up 
to 50 years after immunisation and virus-specific CD4
+ 
T cells have been identified 
in smallpox vaccinated individuals with a half-life up to 12 years (Amara et al., 
2004, Crotty et al., 2003, Demkowicz et al., 1996). It is not clear if the detected 
responses are protective. Booster immunisation was recommended every 10 years to 
maintain vaccine efficacy. In addition, persisting memory B cells are also able to 
mount a robust anamnestic antibody response, with no correlation between stable 
antibody titres and T-cell memory (Crotty et al., 2003, Hammarlund et al., 2005). 
However, evidence from a vaccine trial testing a recombinant vaccinia virus 
expressing HIV gp160 identified poor responders on the basis of the long lived T-
cell-memory response following smallpox vaccination compared to vaccinia virus 
naïve individuals, suggesting that the long lived T-cell-memory response is 
protective (Cooney et al., 1991). An additional complication for maintaining an 
effective pool of memory T cells under field conditions is the continuous competing 
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immune challenges which the immune system is subjected to. Deletion of pre-
existing memory T cells occurs during virus induced lymphopaenia (McNally et al., 
2001) and during heterologous viral and bacterial infections (Selin et al., 1996, Smith 
et al., 2002), circumstances during which persisting antigen may be beneficial.           
 
1.6.2. Maintaining humoral immunity 
 Serum antibodies are a critical component for protection against FMDV and there is 
a close correlation between protection from disease after recovery from infection or 
after immunisation and the titre of circulating antibodies (Alexandersen et al., 
2003b). FMDV infection in ruminants elicits an immune response that can provide 
protection for several years (Cunliffe, 1964). Similarly, humoral immunity to viral 
infections can last for decades in humans and for the lifetime of mice (Slifka and 
Ahmed, 1996). As serum antibodies have a short half-life (Talbot and Buchmeier, 
1987), reported to be less than 3 weeks in adult mice (Vieira and Rajewsky, 1988), 
continual replenishment either by long-lived plasma cells, activation of memory B 
cells to differentiate into plasma cells or ongoing recruitment and differentiation of 
naïve B cells into antibody secreting plasma blasts and plasma cells is required to 
maintain stable long-term protective humoral immunity (Wrammert and Ahmed, 
2008).  
 
As discussed under section 1.5, production of long lived plasma cells and memory B 
cells is dependent on the germinal centre reaction. The migration of antibody 
secreting cells from lymphoid organs to peripheral tissue, including the bone 
marrow, is regulated by the expression of adhesion molecules and chemokine 
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receptors. However, the tissue specificity of the adhesion molecules and the 
mechanisms governing recruitment are still not clear (Manz et al., 2005). The 
chemokine receptor CXCR4 has been identified as an important receptor for plasma 
blast migration to bone marrow, attracted to its ligand CXCL12 expressed on bone 
marrow stromal cells (Hargreaves et al., 2001). The plasma blasts can differentiate 
and persist as long-lived plasma cells by competing with established plasma cells for 
a limited number of “plasma cell survival niches” (Odendahl et al., 2005, Tokoyoda 
et al., 2004). Such niches are found predominantly in bone marrow although 
additional niches exist in organised lymphoid tissue, for example, the spleen and in 
inflamed tissue (Manz et al., 2005). Recently, the molecular basis of bone marrow B- 
cell survival niches has begun to emerge, with bone marrow stromal cells and bone 
marrow-resident DCs playing a critical role (Manz et al., 2005, Sapoznikov et al., 
2008). The reticular cells which surround the vascular sinuses (called CAR cells) 
express the chemokine CXCL12 on their long processes, plasma cells express 
CXCR4 and respond by improved survival (Cassese et al., 2003, Hargreaves et al., 
2001, Tokoyoda et al., 2004). B-cell maturation antigen (BCMA) expressed on 
plasma cells and its ligands BAFF and a proliferation activation ligand (APRIL) have 
also been identified as important plasma cell survival factors (Manz et al., 2005). 
Perivascular clusters of bone-marrow resident DCs promote survival of recirculating 
mature B cells through production of macrophage migration-inhibitory factor (MIF) 
(Sapoznikov et al., 2008). Interaction with its receptor CD74-CD44 on B cells 
triggers an antiapoptotic signalling pathway thus promoting B-cell survival (Leng et 
al., 2003). These bone-marrow resident DCs have also been shown to produce BAFF 
and APRIL (Sapoznikov et al., 2008).  
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Memory B cells leave the germinal centre reaction by an unknown mechanism and 
enter the recirculating memory B-cell compartment (McHeyzer-Williams and 
McHeyzer-Williams, 2005). Memory B cells are in a resting state, able to persist in 
the absence of both cell division and signal through the B-cell receptor, and only 
secrete antibody when antigenically stimulated or by polyclonal activation 
(Bernasconi et al., 2002, Maruyama et al., 2000). Memory B cells have been 
detected in cattle by enzyme-linked immunosorbent spot (ELISPOT) assay as cells 
that secrete antibody after in vitro antigen restimulation (Lefevre et al., 2009). 
Memory B cells have increased expression of TNF receptor families and TLR-related 
molecules compared to naïve B cells, subsequently they exhibit enhanced survival, 
enhanced antibody secretion and enter cell division more rapidly than naïve B cells 
(Good et al., 2009). In addition, they have an enhanced ability to stimulate T cells by 
expressing CD80 and CD86 which interact with CD152 expressed on activated T 
cells (Good et al., 2009, Vasu et al., 2003).  
 
Analogous to maintaining T cell memory, the requirement of persisting antigen to 
maintain humoral immunity remains debated. Adoptive transfer studies have clearly 
demonstrated in mice that in hosts with relatively short lifespans, specific antibody is 
continuously replenished by long-lived plasma cells in the absence of memory B 
cells and antigen (Manz et al., 1997, Slifka et al., 1998). However, uncertainty exists 
of the ability of plasma cells alone to maintain protective titres of neutralising 
antibody under conditions of serial infections in animals with longer lifespans 
(Welsh et al., 2004). Persisting antigen, in the form of immune complexes attached 
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to FDCs can provide signal through the B-cell receptor to induce memory B-cell 
proliferation and differentiation into plasma cells for maintaining protective titres of 
antibody (Bachmann and Zinkernagel, 1997, Ochsenbein et al., 2000b). In addition, 
antigen trapped on FDCs can induce naïve B-cell proliferation and differentiation 
into plasma blasts and memory B cells, therefore persisting FDC-bound antigen can 
also play an important role in maintaining humoral immunity by repopulating the 
memory B cell pool (Gray and Skarvall, 1988, Kosco-Vilbois, 2003). This 
hypothesis is particular relevant for the situation in the field because it is not clear 
how the memory B cell pool is restored and maintained after repeated engagement 
with antigen (Welsh et al., 2004). However, antigen-antibody complexes on FDCs 
are reported to have a relatively short half-life of approximately 8 weeks (Tew and 
Mandel, 1979) suggesting this mechanism is not required for sustaining lifelong 
immunity, for example, following smallpox vaccination in humans where antibody 
titres remain nearly constant for up to 75 years after immunisation (Crotty et al., 
2003, Hammarlund et al., 2003). Indeed, late antigen dependent germinal centres, 
which are still detectable up to 100 days after immunisation (Bachmann et al., 1996), 
are not required to maintain antibody titres or B cell memory (Gatto et al., 2007). 
These investigators suggested that the late germinal centre reaction may be important 
for maintaining a flexible, hypermutated B cell repertoire in case of pathogen re-
emergence (Gatto et al., 2007). Elimination of sequestered antigen on FDCs by 
injection of LTβR-Ig fusion proteins on days 9 to 11 post immunisation had a 
detrimental effect on antibody titres in mice, highlighting the importance of 
persisting antigen during the early phase of the B-cell response when germinal 
centres are producing large numbers of plasma and memory B cell precursors (Gatto 
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et al., 2007). These investigators also reported that bone marrow plasma cells do not 
survive for the lifetime of the mouse but decline with a half-life of 3 months (Gatto 
et al., 2007). A similarly short plasma cell half-life of approximately 140 days has 
also been reported in mice depleted of memory B cells by irradiation (Slifka et al., 
1998) highlighting the importance of the size of the memory B-cell compartment and 
memory B-cell survival for maintaining long-term and effective humoral immunity 
(Dörner and Radbruch, 2007, Gatto et al., 2007). An alternative mechanism to 
replenish plasma cells and subsequently maintain neutralising antibody titres has 
been described which involves polyclonal stimulation to sustain memory B-cell 
proliferation and differentiation in the absence of antigen (Bernasconi et al., 2002). 
Memory B-cell differentiation into antibody producing cells can be induced by 
microbial products, for example, lipopolysaccharides via TLR4 and unmethylated 
single-stranded DNA motifs via TLR9. In addition, T cell activation by third party 
antigens can stimulate B cells via CD40/CD40L and in contrast to naïve B cells, the 
cytokine IL-15 can trigger memory B-cell activation in the absence of antigen 
(Bernasconi et al., 2002). The mechanisms by which memory B cells and long-lived 
humoral immunity is maintained remain unclear and are currently active fields of 
research, however it is clear that FDC-bound antigen is pivotal to the germinal centre 
reaction, playing an important role in maintaining humoral immunity.     







2. FMDV persists in the light zone of germinal centres 
2.1. Introduction 
The paucity of our understanding of the mechanisms underlying FMDV persistence 
and the short term duration of protection after vaccination, which contrasts with the 
prolonged duration of immunity after natural infection, are major factors hindering 
global FMDV control policies. Virus is cleared rapidly from blood during the acute 
stage of FMD, coinciding closely with the emergence of an antiviral antibody 
response characterised by high-affinity circulating neutralising antibodies, a crucial 
component of the immune response against FMDV (Alexandersen et al., 2003b). 
This is in contrast to pharyngeal tissue including the soft palate, nasopharynx, 
oropharynx, palatine tonsil and mandibular lymph node, which, despite the high 
titres of circulating virus neutralising antibody, have been shown to contain viral 
RNA for up to 72 days after infection (Zhang and Alexandersen, 2004). The 
significance of continued detection of viral RNA has not been clear since FMDV 
proteins have not been detected, in previous studies in these tissues, following the 
resolution of vesicular lesions. Importantly, FMDV proteins have not been detected 
previously in lymphoid tissue in vivo at any stage of infection and viral proteins have 
not been detected in any tissue following resolution of vesicular lesions. 
 
A number of different pathologically relevant proteins, organisms and their products 
have been shown to be retained on FDCs in lymphoid tissue, for example, human, 
feline and simian immunodeficiency virus (Tenner-Rácz et al., 1985, Toyosaki et al., 
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1993, Ward et al., 1987), the pestivirus bovine viral diarrhoea virus (Fray et al., 
2000), murine leukaemia virus (Hanna et al., 1970, Siegler et al., 1973, Szakal and 
Hanna, 1968), VSV (Bachmann et al., 1996), tetanus (Kosco-Vilbois, 2003) and 
disease-associated prion proteins (McGovern and Jeffrey, 2007). The ability of FDCs 
to trap and retain antigen and infectious virus in a stable conformational state in the 
form of immune complexes for months or even years within germinal centres and 
their intimate association with B cells is a crucial component of the humoral response 
(Haberman and Shlomchik, 2003). FDCs are important for the development of 
follicles during the early immune response, B cell affinity maturation and memory B 
cell development either through the presentation of surface-retained antigen to B 
cells or by supporting B-cell proliferation and differentiation in a non specific 
manner (Haberman and Shlomchik, 2003, Kikuno et al., 2007). Additionally, the 
slow release of antigen from the surface of FDCs is thought to play a role in 
maintaining serum titres of specific antibody and studies have shown that the amount 
of retained antigen can regulate serum immunoglobulin titres (Szakal et al., 1992, 
Szakal et al., 1989, Tew et al., 1980). 
 
2.1.1. The FMDV ‘carrier’ problem 
Over 50% of ruminants exposed to viral challenge, whether vaccinated or not, can 
become „carriers‟ (Alexandersen et al., 2003b). It is not a lifelong infection with 
species and viral strain variation, for example, there are reports of individual cattle 
carrying virus for up to 3.5 years (Hedger, 1968), 9 months in sheep and goats 
(Burrows, 1968) and at least 5 years in Africa buffalo (Condy et al., 1985, Thomson 
et al., 2003). Pigs normally clear virus from oropharyngeal fluid within 3 weeks of 
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infection and are not considered to be involved in „the carrier problem‟. However, 
viral RNA has been detected in cervical lymph nodes, mandibular lymph nodes and 
tonsils of pigs at 28 days post-infection (Zhang and Bashiruddin). Recovery of 
infectious virus from oropharyngeal scrapings of FMD recovered ruminants is 
intermittent and the titre of virus recovered from „carrier‟ animals is low, often 
falling below the titre thought to be necessary for successful transmission to 
susceptible animals (Donaldson and Kitching, 1989). Intermittent virus recovery may 
be related to the heterogeneous nature of oropharyngeal samples with saliva, mucus 
and cells present in varying quantities (Alexandersen et al., 2002). In addition, the 
virus is thought to be associated with cellular material and Freon treatment, to 
remove blocking antibodies and cellular membranes, can increase viral titres by 
several orders of magnitude (Brown and Cartwright, 1960).  
 
2.1.1.1. Evidence of transmission from „carrier‟ animals 
„Carrier‟ African buffalo have been shown to be a source of infection for other 
susceptible species with variable transmission from „carrier‟ buffalo to cattle 
reported under experimental conditions (Bastos et al., 2000, Vosloo et al., 2002). 
This is in contrast to the unknown epidemiological significance of „carrier‟ cattle. 
Transmission from „carrier‟ cattle has not been demonstrated under experimental 
conditions, even under conditions of co-infection with rinderpest and bovine herpes 1 
viruses (McVicar, 1977). In one series of experiments, „carrier‟ cattle were treated 
with dexamethasone in order to depress their immune systems, and kept in contact 
with susceptible cattle, but this had the reverse effect of causing the virus to 
disappear from oropharyngeal scrapings, only to reappear once the treatment was 
 83 
stopped (Ilott et al., 1997). There was no transmission between „carrier‟ and 
susceptible cattle. Despite the uncertainty concerning the capacity of „carrier‟ cattle 
to transmit virus, there is a requirement to identify and remove these animals before a 
country or region can declare freedom from infection and resume international 
animal trade.  
 
2.1.1.2. Sites and proposed mechanisms of FMDV persistence 
In situ hybridization studies have supported the generally accepted hypothesis that 
FMDV persists in the epithelium of the dorsal soft palate and oropharynx dorsal to 
the soft palate in cattle (Alexandersen et al., 2002). These studies identified FMDV 
RNA associated with epithelial cells in the stratum germinativum, but not in the 
more superficial epithelial layers of the dorsal soft palate, up to 82 days post-
infection (Prato Murphy et al., 1999, Zhang and Kitching, 2001). However, viral 
proteins have not been identified in association with this tissue even during the acute 
stage of FMD and the mechanism of persistence at this site is not clear. In addition, it 
is unclear how the virus is excreted into the pharynx or detected by probang 
sampling at these sites.  
 
Various mechanisms have been proposed for the development of FMDV persistence, 
most of the mechanisms described are based on immune evasion strategies that are 
employed by other viruses to establish and maintain persistence. In order for highly 
cytopathic viruses like FMDV to establish persistent infections, they must have 
mechanisms to moderate their replication and to escape the host immune response 
either through evasion or direct suppression (Borrow et al., 1991). It is clear that 
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FMDV is efficient at establishing persistent infections in ruminants, and that FMDV 
is highly immunogenic and does not induce an ineffective immune response in 
„carrier‟ animals. Immunity to FMDV is primarily mediated by neutralising antibody 
and there is no consistent failure or deficiency in the antibody response of animals 
that become persistently infected. Indeed, local and systemic antibody responses are 
prolonged in „carrier‟ animals and it has been shown in FMD convalescent cattle that 
resistance to re-infection and local virus replication in the oropharynx shows a strong 
correlation with a history of persistent infection (McVicar and Sutmoller, 1974, Salt, 
1993, Salt et al., 1996a).     
 
Some viruses are known to persist by residing in “immunologically privileged” sites. 
These sites, which include for example, the eye and central nervous system, are 
characterised by active and passive processes which result in the survival of 
allografts that would otherwise be promptly rejected if placed at other body sites 
(Streilein, 1993). Theiler‟s murine encephalomyelitis virus (TMEV), a picornavirus 
in the genus Cardiovirus, is a neurotropic virus that takes advantage of immune 
privilege and induces a persistent central nervous system infection in mice (Ghadge 
et al., 1998, Ricour et al., 2009). An additional example is herpes simplex virus 
which establishes a latent infection in neurons, taking advantage of the fact that 
neurons do not express MHC class I, thereby avoiding a cytotoxic T-cell response 
(Banks and Rouse, 1992). The epithelium of the dorsal soft palate and adjacent 
oropharynx in the ruminant have been proposed to act as “immunologically 
privileged” sites, able to support FMDV replication and evade serum antibody 
(Alexandersen et al., 2002, Salt, 2004).  
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Viruses can also interfere with the host immune response, to suppress or induce an 
ineffective response and establish persistence. Interference can be caused by active 
infection of cellular components of the immune system, for example, Epstein-Barr 
virus, poliovirus and bovine viral disease virus can establish persistent infections in 
lymphocytes (Deregt and Loewen, 1995, van Loon et al., 1979, Young and 
Rickinson, 2004). FMDV can infect antigen presenting cells of a number of different 
species in vitro, infection of bovine monocyte-derived DCs in vitro has been shown 
to result in cell death and as a consequence, the amount of antigen processed and 
presented by the DCs to T cells is reduced (see sections 1.3.1.4 and 1.3.1.5). 
Infection and impairment of the function of this important antigen presenting cell 
type in vivo may influence elimination of the virus. Interference can also be mediated 
by a number of different virally encoded immune modulators that are capable of 
prejudicing antigen presentation, cytokine function and apoptosis to aid host immune 
evasion (Spriggs, 1996). Viral proteins that regulate antigen presentation can 
interfere with the cellular immune response to prevent destruction by NK cells and 
cytotoxic T cells. MHC class I expression is known to be down-regulated on FMDV 
infected epithelial cells (Sanz-Parra et al., 1998). FMDV is highly cytotoxic and 
analogous to other lytic viruses, infection can results in decreased surface MHC 
expression simply as a result of overall shut-off of host protein synthesis, this 
strategy may diminish the cytotoxic T-cell response, however it does not preserve the 
cell for persistence. FMDV 2BC protein has been shown to block transport of 
proteins through the ER-Golgi pathway (Belsham, 2005, Moffat et al., 2005). The 
ER and Golgi apparatus are important for the delivery of proteins to the surface of 
cells and poliovirus 3A protein, which also blocks this pathway, has been shown to 
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reduce the secretion of cytokines, for example, type I IFN, IL-6 and IL-8 and to 
compromise MHC class I presentation (Dodd et al., 2001). In addition to the 
example of poliovirus, a number of other lytic viruses that are known to persist, for 
example herpesviruses and adenoviruses, have developed similar subtle strategies to 
shut off MHC class I expression (Spriggs, 1996) and analogous to these viruses, 
FMDV would require additional mechanisms to moderate replication to preserve the 
host cell for persistence.  
 
Another proposed mechanism of FMDV persistence in vivo is viral attenuation in 
order to reduce cytolysis of the infected cells (Salt, 1993, Straver et al., 1970). 
“Persistently infected” cell cultures have been established for FMDV (de la Torre et 
al., 1985, Herrera et al., 2008). These cells maintained FMDV RNA with multiple 
genetic variations and large deletions in association with the expression of viral 
proteins, but did not maintain infectious virus. These results should be interpreted 
with caution in relation to the situation in vivo as the persistent infection was 
established in a genetically unstable Syrian hamster tumour cell line and the 
perceived attenuation may be the result of selection of cellular phenotypes with 
increased resistance to FMDV (Martin Hernandez et al., 1994, Stoker and 
MacPherson, 1964). J. Salt (2004) suggested that the co-evolution of FMDV with 
resistant cells reflected in these in vitro infection models may occur in vivo between 
the dividing basal layer cells of the pharyngeal epithelium and persisting FMDV. 
Naturally lytic viruses may also regulate their gene expression to reduce cytolysis 
and interfere with cell metabolism to provide intracellular conditions favourable for 
long term persistence. Latent infections are defined as persistent viral infections of 
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cells in which the viral genome is present, but gene expression is limited and 
infectious virus is not produced (Banks and Rouse, 1992). Latency is best 
demonstrated by the herpesviruses as a strategy to persist and evade immune 
surveillance. There are reports in the literature describing a “latent” form of infection 
with two members of the Picornaviridae family, coxsackieviruses B1 and B2 
(Cunningham et al., 1990, Tam et al., 1991). A role for this method of persistence 
during FMD has not been described (Salt, 2004).   
 
RNA viruses are characterised by a high degree of variation and a high mutation rate, 
subsequently, the genome of FMDV and of other RNA viruses is highly unstable 
(Domingo et al., 2003, Holland et al., 1982). Mutations in the viral genome can lead 
to alterations in surface antigens with subsequent antigenic drift permitting escape 
from immune control. Antigenic variation can be effective for persistence at the 
population level and at the individual level. The best-example of antigenic drift at the 
population level is influenza virus where mutations in the hemagglutination and/or 
the neuramidase glycoproteins lead to sequential epidemics in the population. The 
best-example at the individual level are lentiviruses, for example equine infectious 
anemia and maedi-visna virus (Clements et al., 1988). Similar to other retroviruses, 
the lentiviruses use genomic integration of proviral DNA as a mechanism of 
persistence, however these viruses target end stage cells of the monocyte-
macrophage lineage (Narayan et al., 1982) and must replicate and disseminate to 
other target cells for life-long persistence (Narayan et al., 1982). This mechanism is 
pronounced in the example of equine infectious anemia by sequential episodes of 
acute haemolytic crises that are not neutralised by pre-existing antibody (Clements et 
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al., 1988). FMDV is not detected in the circulation during persistence in cattle and 
recurring episodes of disease are not observed, however, considerable genetic and 
antigenic variation has been detected during persistence in vivo and a myriad of 
different antigenic isotypes of FMDV exist in the field (Cottam et al., 2008, Malirat 
et al., 1994, Vosloo et al., 1996). It has been suggested that antigenic drift in vivo 
under immune pressure can result in the establishment of a new virus population 
(Domingo et al., 1989). However, viral populations tend to fluctuate during 
persistence rather than evolving as a distinct genomic lineage with conserved 
changes (Malirat et al., 1994). These authors also demonstrated that homologous 
post-vaccinal serum consistently neutralised all of the FMDV isolates collected 
throughout the period of persistence. These results have been confirmed by other 
investigators (Salt et al., 1996b) suggesting that antigenic variation may not be a 
means of humoral immune evasion or required to maintain persistence at the 
individual level. In addition, passage of FMDV in cell culture also results in amino 
acid substitutions and alterations in viral antigenicity in the absence of selective 








2.2. Aims of the chapter 
To determine if FMDV is maintained in lymphoid tissue as immune complexes in 
association with FDCs after acute FMD. This was investigated by: 
 describing the morphological characteristics of the organised lymphoid tissue 
in the oropharynx of cattle  
 developing enhanced laser capture microdissection techniques in combination 
with quantitative real time reverse transcription polymerase chain reaction to 
determine FMDV genome localisation and genome quantities after acute 
FMD 
  developing sensitive in situ hybridization techniques with appropriate 
controls to corroborate the laser capture microdissection data 
 describing FMDV protein localisation after acute FMD by confocal 
microscopy using existing MAbs directed against non-structural proteins and 
selected anti-capsid MAbs able to detect FMDV immune complexes 
 attempting to isolate viable virus from lymphoid tissue from 29 days post-
infection using existing virus isolation techniques and new techniques to 
dissociate virus from tissue and to detect immune complexed virus    
  
2.3. Materials and methods 
2.3.1. Experimental procedures 
Animal experiments were carried out at the Institute for Animal Health, Pirbright, in 
biosecure animal isolation units, under project licence PPL70/6212 in accordance 
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with the Home Office Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986. 
 
2.3.1.1. Virus inoculation 
The virus strains used for inoculation were FMDV O UKG 34/2001 and O1 BFS 
1860. The original suspension of O UKG 34/2001 was obtained from a pig at Cheale 
Meats Abattoir, Brentwood, Essex (WRL 17.4.01). This material was used to 
intradermolinguel challenge 2 cattle UI94 and UI95. The material used for 
subsequent inoculations was ground up vesicular epithelium from these 2 cattle 
diluted in M25-phosphate buffer (Appendix 1). 0.2mL of the O UKG 34/2001 
inocolum was administered subepidermo-lingually to donor animals to deliver a 
challenge of approximately 10
5
 tissue culture infectious dose (TCID) 50 (as measured 
by virus titration on bovine thyroid cells) (Snowdon, 1966). These infected donor 
animals were subsequently used to infect other cattle by direct contact challenge. 
FMDV O1 BFS 1860 was provided by T Jackson, IAH. 0.5mL of the original O1 
BFS 1860 BTY tissue culture supernatant was administered subepidermo-lingually to 
donor animals to deliver a challenge of approximately 5 × 10
5
 TCID50 (Snowdon, 
1966). These infected donor animals were subsequently used to infect other cattle by 
direct contact challenge. 
 
2.3.1.2. Sample collection 




Oropharyngeal scrapings were collected at post-mortem using probang sampling 
cups, split into aliquots and stored at −80
o
C (Alexandersen et al., 2002). Tissue 
samples were harvested at post-mortem from infected and non-infected control 
animals. Fresh instruments and gloves, RNaseZap (Ambion, UK) and 70% v/v 
ethanol (VWR International, UK) diluted in nuclease-free water (Ambion, UK) were 
used between tissues and animals to reduce contamination. Portions of the tissue 
were placed into Peel-A-Away Molds (Thermo Electron Corporation, USA) 
containing cryomatrix (Sakura Finetek, NL) and frozen on dry ice. These samples 
were stored at −80
o
C for immunohistochemistry, in situ hybridization and laser 
capture microdissection. Portions of the tissue were placed into 2mL screw cap micro 
tubes containing 1mL (10 × volume) of RNAlater (Ambion, UK). These samples 
were stored at 2 to 8
o
C overnight then moved to storage at −80
o
C for RNA 
extraction. Portions of the tissue were placed into 7mL glass bijoux tubes containing 
50% v/v glycerol (VWR International, UK) in M25-phosphate buffer (Appendix 1) 
and stored at −20
o
C for virus isolation. Portions of the tissue were placed into 4% 
w/v paraformaldehyde (Sigma-Aldrich, UK) in phosphate buffered saline (PBS) 
[central services unit (CSU), IAH], stored overnight at 2 to 8
o
C then transferred to 
1% v/v paraformaldehyde in PBS for paraffin embedding and hematoxylin and eosin 
(H&E) staining (kindly performed by H Eburne, IAH). 
 
2.3.2. Enhanced laser capture microdissection technique 
The membrane-based laser capture microdissection (LCM) protocol was adapted 
from a protocol described previously (Allen et al., 2004). Approximately 7µm thick, 
cryosections were affixed to RNase-free steel framed PET-membrane slides (Leica, 
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UK). The slides were dried for 10 minutes then fixed in 100% cold ethanol (VWR 
International, UK) for 20 seconds. The slides were dried for 5 minutes then stained in 
0.25µm filtered 1% w/v toluidine-blue (Sigma-Aldrich, UK) in nuclease-free water 
(Ambion, UK) for 3 minutes. Slides were rinsed twice in nuclease-free water for 15 
seconds and once in 75% v/v ethanol in nuclease-free water. Slides were dehydrated 
in 100% ethanol, air dried for 5 minutes and transferred immediately to the stage of 
the Leica AS LMD (Leica, Germany) for microdissection. Microdissected tissue 
sections were collected into the caps of 0.2mL RNase-free PCR tubes (Ambion, UK) 
containing 75µL of lysis buffer RLT (RNeasy Micro Kit; Qiagen, UK). Samples 
were vortexed for 30 minutes and stored at −80
o
C until processing. RNA was 
isolated from the samples with the RNeasy Micro Kit with „one column‟ DNase 
treatment (Qiagen, UK), eluted with 15µL nuclease free water, divided into aliquots 
and stored at −80
o
C until processing. Twelve µL of the RNA was used for 
quantitative real-time reverse transcription polymerase chain reaction (rRT-PCR), 
1µL of the RNA was used for total RNA quantification (NanoDrop ND-1000 
photospectrometer; Thermo Scientific, USA).  
   
2.3.3. Synthesis of bovine 28s rRNA standards 
2.3.3.1. RNA extraction and reverse transcription 
Heparinised peripheral blood was collected from a conventionally reared and housed 
British Holstein Friesian. The blood was diluted 1:2 with PBSa (Invitrogen, UK). 
35mL of diluted blood was underlayed with 14mL Histopaque-1077 (Sigma-Aldrich, 
UK) before centrifugation at 1000×g, for 30 minutes at 18
o
C with the centrifuge 
brake off. Cells at the interface were collected and washed by dilution in chilled 
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PBSa and centrifugation at 600×g for 10 minutes at 8
o
C. Cells were resuspended in 
5mL red blood cells lyses buffer (Appendix 1) and held on ice for 5 minutes. Second 
and third washes were carried out by dilution in PBSa and centrifugation at 250×g 
for 8 minutes at 8
o
C. PBMC were counted and total RNA extracted using TRIzol 
Reagent (section 2.3.5.1). Purified total RNA was reverse transcribed using TaqMan 
Reverse Transcription Reagents (section 2.3.6.1).  
 
2.3.3.2. PCR amplification, digestion and ligation into pGEM-11Zf(+) vector  
Amplification of DNA was performed using Pfu DNA polymerase (Stratagene, UK). 
Each 100µL reaction mix contained 200ng of genomic DNA template (NanoDrop 
ND-1000 photospectrometer, Thermo Scientific, USA) and 0.5µM forward and 
reverse primers 28sF and 28sR (Appendix 2) containing restriction enzyme 
recognition sites for EcoRI and BamHI respectively at the 5‟ prime ends. The 
samples were denatured at 94
o
C for 45 seconds, annealed at 55
o
C for 45 seconds and 
extended at 72
o
C for 1 min during 30 cycles in accordance with Stratagene‟s 
suggested cycling parameters. The PCR product was analysed on a 1% agarose gel 
(Appendix 1). After gel purification (Qiaprep Gel Extraction Kit; Qiagen, UK) and 
quantification the product and pGEM-11Zf(+) vector were digested with restriction 
enzymes EcoRI and BamHI (section 2.3.8). The digested products were analysed on 
a 1% agarose gel, purified, quantified and ligated using T4 DNA Ligase (Promega, 
UK). The vector was then transformed (section 2.3.9) into competent DH5α E. coli 
cells (kindly provided by J Seago, IAH).  
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2.3.3.3.  Sequencing, transcription, purification and quantification 
Plasmid DNA containing the 261 base pair PCR product was extracted from 
overnight DH5α E. coli cell cultures (section 2.3.9) using Qiaprep Spin Miniprep 
Kits (Qiagen, UK). Sequencing (section 2.3.7) was performed to ensure that the 
insert contained the correct sequence in the correct orientation. The extracted 
plasmid DNA was linearised by restriction enzyme digestion (section 2.3.8) with 
BamHI (Promega, UK). The linearised DNA product was extracted from the 
digestion reaction using phenol/chloroform/isoamyl alcohol (25:24:21, v/v) and 
concentration by ethanol precipitation (section 2.3.5.3). The purified, linearised DNA 
was analysed on a 1% agarose gel to confirm cleavage (Appendix 1), quantified 
(NanoDrop ND-1000 photospectrometer; Thermo Scientific, USA) and diluted in 
nuclease free water to a concentration of 0.5µg/µL in preparation for transcription. A 
MEGAscript T7 kit (Ambion, USA) incorporating high nucleotide concentrations 
was used for in vitro transcription to ensure ultra-high yield. Each 20µL reaction 
contained 2µL T7 RNA polymerase mix, 1µg linear DNA, 2µL 10 × reaction buffer, 
7.5mM of each ATP, CTP, GTP and UTP solution and nuclease free water. Since the 
expected 295 nucleotide RNA transcript was significantly shorter than the 500 
nucleotide transcript recommended by the kit manufacturers, the reaction was 
modified for optimal transcription by increasing the incubation time to 6 hours at 
37
o
C. The reaction mix was then treated with TURBO DNase twice at 37
o
C for 30 
minutes and purified with DNase inactivation reagent (TURBO DNase Treatment 
and Removal Reagents, Ambion, UK). The purity of the single stranded RNA 
product was estimated by the ratio between the spectrophotometric readings at 
260nm and 280nm on a NanoDrop ND-1000 photospectrometer (Thermo Scientific, 
 95 
USA). The reading at 260nm allowed calculation of the concentration of nucleic acid 
with an optical density (OD) of 1 corresponding to approximately 40µg/mL single-
stranded RNA (Sambrook and Russel, 2001). The molecular weight of the entire 295 
nucleotide product was calculated and number of copies/mL determined according to 
the formula: copies = (6.023 × 10
23
 × g/mL of RNA)/(RNA MW) (Yin et al., 2001). 
A ten-fold dilution series of RNA (nuclease free water; Ambion, UK) was aliquoted 
into small volumes and stored at −80
o
C until needed. 
     
2.3.4. Synthesis of FMDV RNA standards 
FMDV RNA standards were synthesised in vitro from a plasmid (pT7Blue; 
Novagen, USA) containing a 500 base pair insert of the internal ribosomal entry site 
of FMDV O UKG 34/2001 (kindly provided by J Horsington, IAH). The enzyme Bgl 
II was used to linearise the plasmid (section 2.3.8). In vitro transcribed FMDV RNA 
standards were prepared as described for 28s RNA under section 2.3.3.3. 
 
2.3.5. Nucleic acid extraction and purification techniques 
2.3.5.1. RNA extraction using TRIzol Reagent 
Total RNA was isolated with TRIzol Reagent (Invitrogen, UK) using a single-step 
RNA isolation protocol prescribed by Invitrogen (Chomczynski and Sacchi, 1987). 
Samples were added to TRIzol Reagent at a volume ratio of 1:3 using at least 
0.75mL TRIzol Reagent per 5× 10
6
 to 10 × 10
6
 cells. The homogenised samples were 
incubated for 5 minutes at 15 to 30
o
C to allow dissociation of nucleoprotein 
complexes. 0.2mL of chloroform (Sigma-Aldrich, UK) was added to the homogenate 
per 0.75mL TRIzol Reagent. The homogenate was vortexed for 10-15 seconds and 
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centrifuged at 12000 × g for 15 minutes at 2 to 8
o
C to separate the mixture into a 
lower red, phenol-chloroform phase, an organic interphase containing DNA and 
protein and a colourless upper aqueous phase containing RNA. The aqueous phase 
was removed and mixed with 0.5mL isopropyl alcohol (Sigma-Aldrich, UK) per 
0.75mL TRIzol Reagent to precipitate the RNA. 20µg glycogen per mL (Roche, 
Germany) was added as a carrier for the precipitated RNA. The sample was vortexed 
for 5 seconds, incubated on ice for 10 minutes then centrifuged at 12000 × g for 10 
minutes at 2 to 8
o
C. The supernatant was removed and the pellet washed with 75% 
v/v ethanol (VWR International, UK) in nuclease-free water (Ambion, UK), adding 
at least 1mL 75% ethanol per 0.75mL TRIzol Reagent. The sample was vortexed for 
5 seconds and centrifuged at 12000 × g for 10 minutes at 2 to 8
o
C. The supernatant 
was removed and the pellet left to partially dry then dissolved in nuclease-free water. 
   
2.3.5.2. RNA extraction from RNAlater tissue samples 
Tissue samples were defrosted and excess RNAlater (Ambion, UK) removed by 
dabbing the samples on blotting paper. Approximately 20mg (18 to 22mg, variation 
accounted for and corrected during virus quantification) of tissue was added to 
700µL of Tissue Lysis Buffer (MagNA Pure LC, RNA Isolation Kit III, Roche, UK) 
in homogenisation tubes containing Lysing Matrix D (Q-BIOgene, UK). Tissue was 
homogenised by agitation in a FastPrep FP120 agitation centrifuge (Q-BIOgene, UK) 
for 3 × 45 seconds at 6500rpm, then kept at room temperature for 30 minutes to 
equilibrate according to the manufacturer‟s instructions (Ryan et al., 2007). Samples 
were moved to −80
o
C for storage. Total RNA was extracted using the MagNA Pure 
LC, RNA extraction kit III (Roche, UK) and MagNA Pure LC robot (Roche, UK). 
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Genomic DNA was removed by DNase 1 (Roche, UK) treatment and purified RNA 
eluted with 50μL Roche Elution Buffer (Quan et al., 2004, Ryan et al., 2007).  
 
2.3.5.3. DNA extraction, purification and concentration using phenol/chloroform 
/isoamyl alcohol and ethanol 
DNA was extracted from aqueous solutions using phenol/chloroform/isoamyl 
alcohol (25:24:21, v/v) and concentration by ethanol precipitation (Moore and 
Dowhan, 2003). An equal volume of phenol/chloroform/isoamyl alcohol (25:24:21, 
v/v. Invitrogen, UK) was added to 400µL of DNA solution containing no more than 
1mg/mL DNA. The mix was vortexed for 5 seconds and centrifuged at 12000 × g for 
10 minutes at 4
o
C. The aqueous phase containing the DNA was removed, mixed with 
0.5 × volume chloroform (Sigma-Aldrich, UK), vortexed for 5 seconds and 
centrifuged at 12000 × g for 10 minutes at 4
o
C. The aqueous phase was removed and 
mixed with 2.5 × volume ice-cold 100% ethanol (VWR International, UK) and 0.1 × 
volume 3M sodium acetate, pH 5.2 (Sigma-Aldrich, UK). The mix was vortexed and 
placed into a −20
o
C freezer for at least 30 minutes, followed by centrifugation at 
12000 × g for 30 minutes at 4
o
C. The supernatant was removed from the DNA 
precipitate by pipetting. The precipitate was washed once in 70% v/v ice cold ethanol 
in nuclease free water (Ambion, UK) at 12000 × g for 15 minutes at 4
o
C. The 
supernatant was removed and pellet dried before resuspension in nuclease free water. 
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2.3.6. Reverse transcription 
2.3.6.1. TaqMan Reverse Transcription Reagents 
Reverse transcription using TaqMan Reverse Transcription Reagents (Applied 
Biosystems, UK) was carried out at a final volume of 15µL, containing 9µL TaqMan 
Reverse Transcription Reagent reaction mix (Appendix 1) and 6µL RNA (Quan et 
al., 2004, Reid et al., 2001, Zhang and Alexandersen, 2003). The recommended 
template quantity was 3ng to 0.13µg total RNA per 15µL reaction. The reactions 
were incubated on a thermocycler (Eppendorf, UK) at 48
o
C for 45 min followed by 
95
o
C for 5 min. 
 
2.3.7. DNA sequencing 
Sequencing was performed with Dye Terminator Cycle Sequencing Quick-Start kits 
(Beckman Coulter, USA). Plasmid DNA templates were initially pre-heat treated at 
96
o
C for 1 minute. A 100fmol of DNA template was added to the sequencing 
reaction mix containing 3.2pmol of primer, 8µL DTCS Quick Start Master Mix and 
nuclease free water to make up a final reaction volume of 20µL. The reaction was 
subjected to 30 cycles of denaturing at 96
o
C for 20 seconds, annealing at 50
o
C for 20 
seconds and extension at 60
o
C for 4 minutes. On completion of the PCR, 5µL stop 
solution/glycogen mix was added to each reaction, followed by ethanol precipitation 
and two ethanol washes. The air dried product was resuspended in sample loading 
solution and analysed with an automated capillary sequencer CEQ 8800 Genetic 
Analysis System (Bechman Coulter, USA). Three forward and three reverse 
sequencing reactions were run for each DNA sample.   
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2.3.8. Restriction enzyme digestion of DNA 
Restriction digests were performed according to the manufacturer‟s instructions 
(Promega, UK). Generally, DNA samples and plasmid DNA (200ng to 5µg) were 
digested in volumes of 20 to 30µL and incubated in a 37
o
C water bath for 2 to 15 
hours. 
 
2.3.9. Transformation of competent E. coli 
Plasmid vectors were transformed into competent E. coli using a method based on 
the high-efficiency Hanahan transformation method (Sambrook and Russel, 2001). 
50ng of plasmid DNA was added to 50µL of competent cells in a sterile tube and left 
on ice for 30 minutes, after which the tubes were heat shocked in a 42
o
C water bath 
for 90 seconds. The tubes were then placed back on ice for a further 2 minutes, 
800µL SOC media (Appendix 1) was added and the transformation mix was 
incubated on a shaker at 37
o
C for 1 hour. Transformations were performed with 
undigested plasmid and digested plasmid without the insert as positive and negative 
controls respectively. The aliquots of cells were streaked onto Luria-Bertani agar 
plates (Appendix 1) containing the appropriate antibiotic and incubated for 8 to 16 
hours at 37
o
C.  Colonies were selected, suspended and incubated at 37
o
C in Luria-
Bertani broth (Appendix 1) containing the appropriate antibiotic for 8 to 16 hours. 
Aliquots of bacterial cultures were diluted 1:1 (v/v) with sterile glycerol (Sigma-





2.3.10. Quantitative real-time reverse transcription-polymerase chain reaction 
Reverse transcription was performed using TaqMan Reverse Transcription Reagents 
(Applied Biosystems, UK)  as described under section 2.3.6 (Quan et al., 2004, Reid 
et al., 2003, Zhang and Alexandersen, 2004). Each 96-well reverse transcription PCR 
plate (Thermo Scientific, UK) contained triplicate wells of no reverse transcription 
controls (RT controls) and no template controls (NT controls) in addition to duplicate 
wells of FMDV and 28s standard RNA dilution series. RT controls consisted of 
known positive control RNA samples run exactly as the other quantitative rRT-PCR 
reactions, except that the reverse transcription enzyme was omitted. NT controls 
contained nuclease free water in place of RNA template.  5µL of cDNA was used per 
PCR reaction in 96-well optical reaction plates (Stratagene, UK). Duplicate wells of 
PCR buffer controls containing nuclease free water instead of cDNA were included 
on the plates. The PCR reaction was performed as described previously (Quan et al., 
2004, Reid et al., 2001) with SA-UK-IRES-308R/SA-UK-IRES-248F primers and 
UK-IRES-271T probe (Appendix 2) designed by Prof. S Alexandersen specific for O 
UKG 34/2001 (Applied Biosystems, UK). The probe was a linear minor groove 
binding (MGB) TaqMan probe with fluorescent reported dye 6-carboxyfluorescein 
(FAM) attached to the 5‟ end of the probe and the quencher 
carboxytetramethylrhodamine (TAMRA) attached to the 3‟ end. The PCR reaction 
mix (total volume of 25µL/well) contained the forward and reverse primers 
(0.9pmol/µL of each), probe (0.2pmol/µL), and 1 × TaqMan Universal PCR Master 
Mix (Applied Biosystems, UK) containing the passive reference dye 5-carboxy-X-
rhodamine (ROX). The PCR was performed on a Stratagene MX3005p quantitative 




for 2 minutes for optimal uracil-N-glycosylase enzyme activity, then to 95
o
C for 10 
minutes to activate the AMpliTaq Gold DNA polymerase. This was followed by 50 
cycles of 15 seconds at 95
o
C and 60 seconds at 60
o
C to amplify the DNA.  
 
Stratagene MxPro software (Stratagene, USA) was used for data analysis. 
Amplification plots were set to a common baseline, above which any shift in 
fluorescence corresponded to the change in fluorescence due to DNA amplification, 
using the „adaptive method‟ of baseline correction with the baseline set between 
cycle 3 and 15. Data analysed using this method provided a more accurate estimate 
of the starting amount of a sample compared to a manually adjusted baseline 
(Oleksiewicz et al., 2001, Quan et al., 2004). The threshold fluorescence was set 
using the software algorithm amplification-based threshold method. Analysis 
resulted in the assignation of a threshold cycle (Ct) value to each PCR reaction which 
correlated with the initial target concentration. Samples with no detectable 
fluorescence above threshold after 50 cycles were taken to be absolutely negative 
(Oleksiewicz et al., 2001, Quan et al., 2004). Standard curves of Ct values versus 
known copies per standard well were generated by the software, and the quantity of 
copies in test wells calculated by reference to these standard curves.  
 
2.3.11. One step real time reverse transcription-polymerase chain reaction  
RNA extracted from probang samples of O1 BFS 1860 infected cattle was kindly 
analysed by K Ebert (IAH) using the one step FMDV diagnostic rRT-PCR. Duplicate 
wells containing 5µL of negative control, weak positive control, positive control and 
strong positive control RNA were included with sample RNA in duplicate on 96-well 
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optical reaction plates (Stratagene, UK). The PCR reaction was performed as 
described previously (King et al., 2006, Reid et al., 2002, Shaw et al., 2007) to detect 
a conserved sequence within the internal ribosomal entry site using redundant 
primers SA-IR-219-246F/SA-IR-315-293R and SAmulti2-P-IR-292-269R TaqMan 
probe (Appendix 2), and a conserved sequence within the 3D region using primers 
Callahan 3DF/Callahan 3DR and Callahan 3DP TaqMan probe (Appendix 2). The 
PCR reaction mix (25µL/well) contained the forward and reverse primers 
(0.8pmol/µL of each), probe (0.3pmol/µL), 1 × PCR buffer (Invitrogen, UK) and 
0.5µL Superscript/III Platinum Taq enzyme mix (Invitrogen, UK). The PCR was 
performed on a Stratagene MX3005p quantitative PCR instrument (Stratagene, 
USA). The thermal cycle heated the samples to 60
o
C for 30 minutes, then to 95
o
C for 
10 minutes followed by 50 cycles of 15 seconds at 95
o




Stratagene MxPro software (Stratagene, USA) was used for data analysis as 
described under section 2.3.10 except that the threshold was manually adjusted by 
inspecting the amplification pots and samples were expressed as either positive or 
negative based on a modified cut-off Ct of 32 (Shaw et al., 2007).  
 
2.3.12. Statistical analysis of real-time PCR data quantifying FMDV genome 
and 28s rRNA 
Statistical analysis of the data was carried out in consultation with S Gubbins, IAH, 
and S Abeyasekera, Statistical Services Centre, University of Reading. Minitab 
software (Minitab Limited, UK) was used to perform the analysis. The analysis of 
variance (ANOVA) general linear model (Lindman, 1974) was used to determine if 
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there was a statistically significant association between the FMDV genome copies 
expressed as FMDV copies per 10
8
 copies of 28s rRNA and the amount of 28s rRNA 
per PCR reaction. The Fisher‟s exact test was used to determine if there was a 
statistically significant associated between the quantity of FMDV present in germinal 
centre samples and the type of tissue samples. The ANOVA, Tukey simultaneous 
test was used to compare FMDV genome copies per 10
8
 copies of 28s rRNA 
detected in samples of six germinal centres harvested in three replicates from the 
different tissues examined.   
  
2.3.13. Synthesis of FMDV O UKG 34/2001 3D sense and antisense RNA probes 
for in situ hybridization 
2.3.13.1. RNA extraction and reverse transcription 
Tongue vesicular epithelium from an O UKG 34/2001 infected bovine was collected 
at post-mortem into 50% v/v glycerol (VWR International, UK) in M25-phosphate 
buffer (Appendix 1). Supernatant from the homogenised epithelium was used to 
inoculate BTY cells (Appendix 1) kindly provided by S Wilsden (IAH). Total RNA 
was extracted using Trizol Reagent as described under section 2.3.5.1. Purified total 
RNA was reverse transcribed using Superscript III (Invitrogen, UK). An initial 10µL 
reaction containing 1µg/µL RNA, 2µM primer p15 (Appendix 2; MWG, UK), 100ng 
random hexamers (Invitrogen) and 1mM dNTP‟s was denatured at 68
o
C for 3 
minutes then transferred to ice. The reaction volume was increased to 20µL by the 
addition of 1 × Superscript III reaction buffer, 5mM MgCl2, 10mM dithiotritol, 40 
units RNase out (Invitrogen, UK) and 1µL Superscript III enzyme mix. The reaction 
was incubated at 42
o
C for 4 hours and terminated at 85
o
C for 5 minutes.      
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2.3.13.2. PCR amplification, digestion and ligation into pGEM-3Z vector  
Primers FMDV 1F and FMDV 1R (Appendix 2) containing restriction enzyme 
recognition sites EcoRI and BamHI were designed to amplify the 1st 500 bases 
encoding the highly conserved region for the non-structural protein 3D of FMDV O 
UKG 34/2001. These primers were used in conjunction with the Advantage cDNA 
PCR Kit and Polymerase Mix (Clonetech, UK). The PCR reaction mix was 
denatured at 94
o
C for 1 minute followed by 30 cycles of denaturing at 94
o
C for 30 
seconds and annealing/extending at 68
o
C for 1 minute in accordance with 
Clonetech‟s suggested cycling parameters. The PCR product was analysed on a 1% 
agarose gel (Appendix 1). After gel purification (Qiaprep Gel Extraction Kit; Qiagen, 
UK) and quantification (NanoDrop ND-1000 photospectrometer; Thermo Scientific, 
USA) the product and pGEM-3Z vector were digested with restriction enzymes 
EcoRI and BamHI (section 2.3.8).The digested products were analysed on a 1% 
agarose gel, purified, quantified and ligated using T4 DNA Ligase (Promega, UK). 
The vector was then transformed (section 2.3.9) into competent DH5α E. coli cells 
(kindly provided by J Seago, IAH).  
 
2.3.13.3. Sequencing, transcription, purification and quantification 
Plasmid DNA was extracted from overnight DH5α E. coli cell cultures (section 
2.3.9) using Qiaprep Spin Miniprep Kits (Qiagen, UK). Sequencing (section 2.3.7) 
was performed to ensure that the insert contained the correct sequence in the correct 
orientation. The extracted plasmid DNA was linearised by restriction enzyme 
digestion (section 2.3.8). For antisense probe preparation, the plasmid DNA was 
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digested with restriction enzyme EcoRI (promega, UK) and for sense probe 
preparation with BamHI (promega, UK). To ensure high purity of linearised DNA 
required for the DIG RNA labelling reaction, the linear DNA product was extracted 
from the digestion reaction mix using phenol/chloroform/isoamyl alcohol (25:24:21, 
v/v) and concentrated by ethanol precipitation (section 2.3.5.3). The purified, 
linearised DNA was analysed on a 1% agarose gel to confirm cleavage (Appendix 1), 
quantified and diluted in nuclease free water. Digoxigenin–UTP (DIG-UTP) labelled 
RNA probes were produced by in vitro transcription of 1µg linearised DNA (DIG 
RNA Labelling Kits; Roche, UK). SP6 RNA polymerase enzyme was used for 
antisense probe production and T7 RNA polymerase enzyme for sense probe 
production. The kits included DNase I which was used to degrade the DNA template 
after the labelling reaction. The labelling reaction and DNA degradation were 
stopped with 0.2M ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, UK). 
Aliquots of the newly synthesised probes were stored at −80
o
C. Samples of each 
FMDV probe and the kit supplied control probe were analysed on a 1% agarose gel 
to quantify the output of the labelling reaction. To test the efficiency of the labelling 
reaction and to calculate the amount of DIG-labelled FMDV probe, serial dilutions of 
the FMDV probes and control labelled probe were spotted and fixed by UV-light 
onto Hybond-N nylon membrane (Amersham Life Science, UK). The membrane was 
incubated for 30 minutes at 15 to 25
o
C under agitation in TBST blocking buffer 
(Appendix 1). The membrane was removed from the blocking buffer and incubated 
for 30 min at 15 to 25
o
C in TBST blocking buffer containing alkaline phosphatase 
conjugated anti-digoxigenin (DIG) antibody (Roche, UK). The membrane was 
washed 3 times for 10 minutes under agitation in TBST blocking buffer and 
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transferred to detection buffer (Appendix 1) for 10 min. Substrate detection of the 
antibody conjugate was carried out as detailed under section 2.3.16. The optimal 
concentration of the probe was established by comparing the intensity of FMDV 
probe spots to the control probe.  
 
2.3.14. Synthesis of bovine IgG1 sense and antisense RNA probes for in situ 
hybridization 
A pCR2.1 TOPO vector (Invitrogen, UK) carrying a 686 base pair insert encoding 
the hinge, CH2 and CH3 domains of bovine IgG1 was kindly provided by R Aitken, 
University of Glasgow. The insert was removed from the vector using restriction 
enzymes EcoRI and NotI (section 2.3.8) and ligated into the pGEM-3Z vector using 
T4 DNA Ligase (Promega, UK). The vector was then transformed (section 2.3.9) 
into competent DH5 α E. coli cells (kindly provided by J Seago, IAH). Plasmid DNA 
was extracted from overnight DH5α E. coli cell cultures (section 2.3.9) using 
Qiaprep Spin Miniprep Kits (Qiagen, UK). Sequencing (section 2.3.7) was 
performed with primers IgG1F and IgG1R (Appendix 2) to ensure that the insert 
contained the correct sequence in the correct orientation. DIG-UTP labelled RNA 
probes were prepared as described under section 2.3.13.3. NotI restriction enzyme 
digestion and T7 RNA polymerase were used for antisense RNA probe synthesis. 
EcoRI restriction enzyme digestion and SP6 RNA polymerase were used for sense 
RNA probe synthesis. 
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2.3.15. Synthesis  of swine vesicular disease virus antisense RNA probes for in 
situ hybridization 
A pGEM-T vector (Promega, UK) carrying cDNA from position 2414 to 3027 
(region of the structural proteins 1C and 1D) of the swine vesicular disease virus 
(SVDV) genome was kindly provided by E Ryan, IAH (Lin et al., 1997, Prato 
Murphy et al., 1999). Spe I restriction enzyme digestion and T7 RNA polymerase 
were used for antisense RNA probe synthesis as described under section 2.3.13.3.  
 
2.3.16. In situ hybridization procedure 
An optimised in situ hybridization method was developed to detect FMDV (Prato 
Murphy et al., 1999) and optimised for cryosections incorporating tyramide signal 
amplification (TSA) and alkaline phosphatase based visualisation (Yang et al., 
1999).  
 
Approximately 7μm thick cryosections were prepared (Frigocut cryostat; Leica, 
Germany) onto Superfrost Plus microscope slides (VWR International, UK). BHK-
21 cells were cultured (Appendix 1) in vitro directly onto slides using Chamber Slide 
Culture Chambers (Nunc, USA). Slides were air dried and fixed with 4% (w/v) 
paraformaldehyde (Sigma-Aldrich, UK) in nuclease free PBS (Ambion, UK) at 4
o
C 
for 20 minutes. Slides were rinsed with PBS for 5 minutes, dipped briefly into 
nuclease free water (Ambion, UK) then transferred to 100% ethanol (Sigma-Aldrich, 
UK) at 4
o
C for 5 minutes. Endogenous peroxidases were quenched by incubating the 
slides for 20 minutes in 1% (v/v) hydrogen peroxide (Sigma-Aldrich, UK) in 
methanol (Sigma-Aldrich, UK). Slides were then washed twice in PBS for 5 min. 
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Endogenous phosphatases were inactivated by incubation in 0.2M HCl (Sigma-
Aldrich, UK) for 8 minutes. Slides were washed twice in PBS for 5 minutes then 
transferred to acetylation solution (Appendix 1) for 10 minutes under gentle agitation 
to reduce non-specific probe binding to tissue proteins (Hayashi et al., 1978). Slides 
were washed twice with PBS for 5 min under gentle agitation and immediately 
covered with prewarmed pre-hybridization buffer (Appendix 1) at 60
o
C for at least 2 
hours. Probes were mixed with hybridization buffer (Appendix 1) and incubated at 
60
o
C for 20 minutes to ensure that the probe was evenly distributed in the buffer. The 
prehybridization buffer was discarded and sections covered with the hybridization 
buffer for incubation at 65
o
C for 5 min to eliminate probe secondary structure then 
60
o
C for 14 to 16 hours.  
 
The following post-hybridization washes were conducted under gentle agitation: 
Wash solution Temperature Time 
4×SSC and 1mM DTT 60
o
C 5 minutes 
2×SSC and 1mM DTT 60
o
C 30 minutes 




C 30 minutes 
2×SSC and 1mM DTT 60
o
C 30 minutes 
1×SSC 60
o
C 30 minutes 
SSC = SSC buffer (Sigma-Aldrich, UK) 
DTT = Dithiothreitol (Sigma-Aldrich, UK) 
 
For conventional chromagenic detection without TSA, the slides were washed twice 
for 10 minutes in TBS washing buffer (Appendix 1) then blocked in TBST blocking 
buffer (Appendix 1) for 30 minutes. The sections were incubated for 2 hours in a 
suitable dilution of sheep anti-DIG-alkaline phosphatase antibody (Roche, UK) 
diluted in TBST blocking buffer. Slides were washed twice for 10 minutes in TBS 
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washing buffer and incubated for 10 minutes in detection buffer (Appendix 1) 
containing 50mM MgCl2 (Sigma-Aldrich, UK). 
 
PerkinElmer TSA Biotin Kits (PerkinElmer, UK) were used for chromagenic 
detection with TSA following the post-hybridization washes. Sections were blocked 
for 30 minutes at room temperature with TNB buffer (Appendix 1). Sections were 
covered and incubated for 30 minutes with anti-digoxigenin antibody conjugated 
with horseradish peroxidase (Roche, UK) diluted 1:250 in TNB buffer. Slides were 
washed 3 times for 5 minutes in TNT buffer (Appendix 1) and incubated with 
biotinylated-tyramide (PerkinElmer, UK) for 5 minutes. Following three 5 minute 
washes in TNT buffer, the slides were incubated in the dark for 60 minutes with 
streptavidin conjugated with alkaline phosphatase (Roche, UK) diluted 1:750 in TNB 
buffer. Following incubation slides were washed 3 times for 5 minutes in TNT 
buffer.  
 
The slides were incubated for 10 minutes in detection buffer (Appendix 1) followed 
by colour substrate solution (Appendix 1). When colour development was optimal 
(approximately after 2 minutes with TSA and after 30 minutes when using 
conventional chromagenic detection) slides were rinsed in distilled water and 
mounted with aqueous mounting medium (Immu-Mount; Thermo Shandon, USA). 
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2.3.17. Immunofluorescence confocal microscopy 
All data were collected sequentially using a Leica SP2 scanning laser confocal 
microscope (Leica, Germany). M Windsor (IAH) kindly assisted with slide screening 
to detect FMDV capsid.  
 
2.3.17.1. Immunofluorescence labelling method 
Approximately 7μm thick cryosections were prepared (Frigocut cryostat; Leica, 
Germany) onto Superfrost Plus microscope slides (VWR International, UK). 
Sections were air dried and fixed in 100% acetone (Sigma-Aldrich, UK) at −20
o
C for 
5 minutes. Slides were air dried for 20 minutes and used immediately. 
 
Cell cultures were prepared for microscopy onto 13mm cover glass (VWR 
international, UK) and fixed for 45 minutes in 4% (w/v) paraformaldehyde (Sigma-
Aldrich, UK) in PBS (CSU, IAH). Cells were made permeable for internal staining 
by incubation with 0.1% (v/v) Triton X-100 (Sigma-Aldrich, UK) in PBS for 15 
minutes under agitation followed by three 15 minute washes in PBS.   
 
Non specific binding of detection antibodies was blocked by incubation with 5% 
(v/v) normal goat serum (Sigma-Aldrich, UK) in Ca/Mg free PBS (CSU, IAH) for 20 
minutes. Sections were blotted dry and incubated with the primary antibody for 30 
minutes at room temperature. Primary and secondary antibodies were diluted in 5% 
normal goat serum in Ca/Mg free PBS. For purified mouse anti-bovine antibodies a 
solution of 1 to 10μg/mL was initially used. For tissue culture supernatants a starting 
dilution of 1:10 was initially used. Slides were washed 5 times in Ca/Mg free PBS 
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and incubated with the secondary goat anti-mouse isotype-specific secondary 
antibody (Alexa fluor; Molecular Probes, UK) at a working dilution of 1:500 for 20 
minutes in the dark. Slides were washed as before and incubated for 15 minutes with 
a 1:20000 dilution of the DNA-binding stain 4‟-6-diamidino-2-phenylindole (DAPI, 
Sigma-Aldrich, UK) in Ca/Mg free PBS. Slides were washed in Ca/Mg free PBS and 
mounted. Vectorshield (Vector Laboratories, UK) was used to mount slides prepared 
with Alexa fluor 568. Prolong gold (Invitrogen, UK) or Fluoromount G 
(SouthernBiotech, UK) was used for all other secondary antibodies. For each tissue 
section labelled with antibodies of interest, additional sections of the same tissue 
were labelled with isotype matched control antibodies, with secondary anti-mouse 
fluorochrome conjugated antibody only and without primary antibody as controls. 
Tissue sections from infected animals were also labelled in parallel with sections 












2.3.17.2. List of primary antibodies  
Table 1. Primary antibodies.  
Antibody Specificity Isotype Reference 
AD10 FMDV capsid IgG1 (Juleff et al., 2008) 
AV29 Isotype control (chicken antigen) IgG2b Unpublished
1 
AV48 Isotype control (chicken antigen) IgM Unpublished
1 
BF8 FMDV capsid IgG2b (Juleff et al., 2008) 
CC21 CD21 IgG1 (Howard and Morrison, 
1991) 
CC51 CD21 IgG2b (Howard and Morrison, 
1991) 
CC158 MHC class II IgG2a (Howard and Morrison, 
1991) 
CCG33 CD14 IgG1 (Sopp et al., 1996) 
CCG36 CD32 IgG1 Unpublished
2 
CCG37 CD32 IgG2a Unpublished
2 
CNA.42 Light zone FDCs IgM (Lefevre et al., 2007)
3 
D46 Fibrinogen IgG2a (Lefevre et al., 2007)
4 
D9 FMDV VP1 (1D) IgG2a (Brocchi et al., 1983)
5 
FC6 FMDV capsid IgG1 (Juleff et al., 2008) 
IB11 FMDV capsid IgG1 (Juleff et al., 2008) 
ILA21 MHC class II IgG2a (Schuberth et al., 1996)
6 
ILA156 CD40 IgG1 (Haas et al., 2001)
6 
TRT1 Isotype control (turkey 
rhinotracheitis virus) 
IgG1 (Cook et al., 1993) 
TRT3 Isotype control (turkey 
rhinotracheitis virus) 
IgG2a (Cook et al., 1993) 
TRT6 Isotype control (turkey 
rhinotracheitis virus) 
IgG2b (Cook et al., 1993) 
2C2 FMDV 3A IgG2a (De Diego et al., 1997)
5 
3C1 FMDV 3C IgG2a (Brocchi et al., 1998)
5 
10D5 αvβ6 IgG2a (Monaghan et al., 2005)
7 
1 
AV29 and AV48 are MAbs directed against chicken antigens provided by F 
Davison and produced at the IAH (Russell et al., 1997). 
2
 CCG36 and CCG37 MAbs were kindly provided by C Howard and produced at the 
IAH. 
3 
CNA.42 was kindly provided by G Delsol, Toulouse, CHU Purpan, Laboratoire 
d‟anatomie et cytologie pathologiques, France. 
4 
D46 was kindly provided by E Lefevre and produced at the IAH. 
5 
D9, 2C2 and 3C1 were kindly provided by E Brocchi, Istituto Zooprofilattico 
Sperimentale della Lombardia e dell‟Emilia Romagna Reparto Biotecnologie, Italy. 
6
 ILA21 and ILA156 were kindly provided by the International Livestock Research 
Institute, Kenya. 
7
 MAb 10D5 was procured from Chemicon, UK. 
All other MAbs were produced at the IAH. 
 113 
 
2.3.17.3. Monoclonal antibodies specific for conformational, non-neutralising 
epitopes of the FMDV capsid 
B Jones (IAH) kindly provided a panel of culture fluid from antibody-secreting 
hybridoma cells derived from mice immunised with 146 S FMDV type O1 antigen 
(Sucrose gradient purified FMDV was kindly provided by N Ferris, IAH). The panel 
was screened by M Windsor and L Reid (IAH) using a sandwich ELISA with plates 
coated with O1 Manisa antigen. Selected MAbs were screened by 
immunofluorescence confocal microscopy (section 2.3.17) on vesicular lesion 
cryosections harvested from FMDV O UKG 34/2001 infected cattle and in parallel 
on non-infected control tissue cryosections. The selected MAbs were also screened 
on BHK-21 cells (Appendix 1) fixed 5 hours after FMDV O UKG 34/2001 infection 
at multiplicity of infection (MOI) 10, and on mock-infected cells (PBS) by 
immunofluorescence confocal microscopy. The cryosections and cells were screened 
in combination with MAb 2C2 and 3C1 (section 2.3.17.2) as positive controls.   
 
Mouse MAbs IB11, FC6, AD10 and BF8 were selected and screened by virus 
neutralising antibody test performed by P Hamblin (IAH) as described in the Office 
International des Epizooties (OIE) Manual of Diagnostic Tests and Vaccines for 
Terrestrial Animals, 5th edition, 2004. Immunoprecipitation analysis was performed 
by M Windsor, IAH, as previously described (Rouiller et al., 1998). BHK-21 cells 
(Appendix 1) were infected with O1BFS at MOI 5 for four hours in total and pulsed 
with 35S methionine/cysteine for two of these hours. Cells were lysed and 
immunoprecipitated with D9, IB11, FC6, AD10, BF8 and TRT1 (section 2.3.17.2) 
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coupled to protein G sepharose. The MAbs were subsequently screened by western 
blotting analysis by M Windsor (IAH). 
 
2.3.17.4. Detecting FMDV immune complexes  
The ability of MAb IB11 to detect FMDV immune complexes was evaluated in vitro. 
Serum was collected from an animal previously infected with O UKG 34/2001 and 
from a naïve animal. The serum samples were heat treated at 56
o
C for 35 minutes 
and diluted 1/100 in a serum free solution of FMDV type O at 2.2 × 10
7
pfu/mL at 
room temperature for 30 minutes to form immune complexes (Robinson, 2008). 
Approximately 1 × 10
5
 mouse fibroblast 3T3 cells (Appendix 1) expressing bovine 
CD32 (section 2.3.18) were fixed onto glass cover slips in 1% (w/v) 
paraformaldehyde (Sigma-Aldrich, UK) in PBS (CSU, IAH) for 15 minutes. The 
cells were washed three times in PBS for 15 minutes under agitation. The cells were 
incubated at room temperature in serum free media containing a 1/16 dilution of the 
virus-serum solutions for 30 minutes under agitation. The cells were washed three 
times in PBS for 15 minutes under agitation, fixed in 4% (w/v) paraformaldehyde in 
PBS for 35 minutes and labelled for confocal microscopy (section 2.3.17).       
 
2.3.18. Mouse fibroblast 3T3 cells expressing bovine CD32 
2.3.18.1. PCR amplification and TA cloning into pcDNA3.1/V5-His-TOPO vector 
A bacterial colony containing cDNA clone IMAGE: 8083027 of Bos taurus low 
affinity IgG Fc receptor (CD32/FcγRII) mRNA was procured from Geneservice 
limited, UK (NCBI accession BC113215). The colony was streaked onto Luria-
Bertani agar plates and colonies were selected for overnight culture in Luria-Bertani 
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broth as described under section 2.3.9. Plasmid DNA was extracted from overnight 
cell cultures using Qiaprep Spin Miniprep Kits (Qiagen, UK). Amplification of DNA 
was performed using Pfu DNA polymerase (Stratagene, UK). Each 100µL reaction 
mix contained 200ng of DNA template (NanoDrop ND-1000 photospectrometer, 
Thermo Scientific, USA) and 0.5µM forward and reverse primers CD321F and 
CD321R (Appendix 2). The samples were denatured at 94
o
C for 45 seconds, 
annealed at 55
o
C for 45 seconds and extended at 72
o
C for 1 min during 30 cycles in 
accordance with Stratagene‟s suggested cycling parameters. The 3‟ A-overhangs 
were added post-amplification by incubating 50µL of the PCR reaction with 1 unit 
Taq polymerase (Invitrogen, UK) at 72
o
C for 10 minutes. After gel purification 
(Qiaprep Gel Extraction Kit; Qiagen, UK) the product was cloned into the 
pcDNA3.1/V5-His-TOPO mammalian expression vector (Invitrogen, UK) by TA 
cloning performed at a final salt concentration of 200mM NaCl and 10mM MgCl2. 
The vector was transformed (section 2.3.9) into competent One Shot TOP10 E. coli 
(Invitrogen, UK).  
 
2.3.18.2. Digestion, ligation into pcDNA6/V5-His-ABC vector and sequencing 
Plasmid DNA was extracted from overnight E. coli cell cultures using Qiaprep Spin 
Miniprep Kits (Qiagen, UK). The extracted plasmid and pcDNA6/V5-His-ABC 
vector were digested (section 2.3.8) with restriction enzymes HindIII and NotI 
(Promega, UK). The digested products were analysed on a 1% agarose gel 
(Appendix 1), gel purified (Qiaprep Gel Extraction Kit, Qiagen, UK) and ligated 
using T4 Ligase (Promega, UK). The vector was then transformed (section 2.3.9) 
into competent One Shot TOP10 E. coli (Invitrogen, UK). Sequencing (section 2.3.7) 
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was performed to ensure that the inserts contained the correct sequence in the correct 
orientation. 
 
2.3.18.3.  Transfection of mouse fibroblast 3T3 cells and selection of mouse 
fibroblast 3T3 cells expressing bovine CD32 
Plasmid DNA was transfected into mouse fibroblast 3T3 cells (Appendix 1) using 
Lipofectamine 2000 (Invitrogen, UK). Stable cell lines were selected with G418 
(1mg/mL, Gibco, UK) or Blasticidin S HCl (20µg/mL, Invitrogen, UK) 
approximately 24 hours after transfection. The degree of CD32 expression was 
evaluated by fluorescence activated cell sorting (FACS) analysis (section 2.3.20) and 
by immunofluorescence confocal microscopy (section 2.3.17) using primary 
antibodies specific for bovine CD32 (Table 1). 
 
2.3.19. BHK-21 cells expressing CD32 and CD32tail− mutant 
2.3.19.1. Mutagenesis 
The Bos taurus low affinity IgG Fc receptor (CD32/FcγRII) amino acid sequence 
(NCBI accession BC113215) was aligned with the Homo sapien amino acid 
sequence (Stuart et al., 1987) to identify the extracellular, transmembrane and 
cytoplasmic domains of bovine CD32. Point mutations were chosen at the 5‟ end of 
the cytoplasmic domain to introduce two stop codons to replace an arginine and a 
lysine code. These point mutations were based on a Homo sapien CD32 mutant 
lacking the cytoplasmic domain (Peltz et al., 1988, Tuijnman et al., 1992). The 
QuickChange Site-Directed Mutagenesis Kit performed with Pfu Turbo DNA 
polymerase (Stratagene, UK) was used to introduce point mutations with 
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CD32Fmutant and CD32Rmutant primers (Appendix 2). Both pcDNA3.1/V5-His-
TOPO and pcDNA6/V5-His-ABC containing the CD32 insert were mutated. 
Following temperature cycling, the products were treated with DpnI endonuclease 
specific for methylated DNA for parental DNA template digestion. The remaining 
vectors containing the desired mutations were then transformed (section 2.3.9) into 
XL1-Blue (Invitrogen, UK) cells. Sequencing (section 2.3.7) was performed to 
ensure that the inserts contained the correct sequence in the correct orientation. 
 
2.3.19.2. Transfection of BHK-21 cells and selection of BHK-21 cells expressing 
bovine CD32 
BHK-21 cells (Appendix 1) were transfected and selected as described under section 
2.3.18.3. In addition, the ability of BHK-21 cells or BHK-21 cells expressing either 
CD32 or the CD32tail− mutant, to mediate efficient endocytosis of immune 
complexed ovalbumin was compared (Miettinen et al., 1992). IgG was purified from 
heat treated sera (56
o
C for 35 minutes) of ovalbumin vaccinated cattle using a 
HiTrap protein G HP column (Amersham Biosciences, UK). Fluorescein 
isothiocynate (FITC) ovalbumin (Molecular Probes, UK) was suspended in PBS 
(CSU, IAH) to a final concentration of 25mg/mL. Purified antibody (4mg/mL) was 
diluted 1/50 in the resuspended ovalbumin and incubated at room temperature for 30 
minutes to form immune complexes (Robinson, 2008). 5 × 10
5
 cells were held on ice 
for 15 minutes then exposed to FITC-ovalbumin, or FITC-ovalbumin immune 
complexes at 4
o
C for 1 hour. Cells were subsequently held on ice to assess 
background fluorescence, or at 37
o
C to measure uptake. After 30 minutes cells were 
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washed extensively with ice cold FACS wash buffer before immediate flow 
cytometric analysis (section 2.3.20) using ice cold solutions.   
 
2.3.19.3.  Virus neutralising antibody test 
Serum samples from 13 days or more post FMDV O UKG 34/2001 infection were 
heat inactivated at 56
o
C for 1 hour and analysed by the virus neutralising antibody 
test to measure the ability of the serum to neutralise a fixed dose of virus on BHK-21 
cells (Appendix 1) and BHK-21 cells expressing CD32. The tests were performed as 
described in the Office International des Epizooties (OIE) Manual of Diagnostic 
Tests and Vaccines for Terrestrial Animals, 5th edition, 2004 (Golding et al., 1976), 
under the guidance of P Hamblin, IAH, with modifications. The tests were performed 
in triplicate wells of flat-bottomed Nunc TC microwell 96 FSI plates (Fisher 
Scientific, UK). The test sera was diluted across the plate in serum free medium, 
50µL of titrated O UKG virus stock (P Hamblin, IAH) was added to each well and 
plates were incubated at 37
o
C for 1 hour. The virus stock was titrated on BTY cells 
(Snowdon, 1966) and diluted so that each 50 µL unit volume of virus suspension 
contained 100 TCID50. A cell suspension at 1 × 10
6 
cells/mL was made up in 
medium containing 10% (v/v) fetal calf serum (Autogen Bioclear, UK). 50µL of the 
cell suspension (0.5 × 10
5
 cells) was added to each well. The following duplicate 
control wells were included on the plate to ensure the assays were valid: negative 
serum (kindly provided by P Hamblin, IAH), serum free medium and cells, medium 
and cells. The plates were incubated at 37
o
C with readings taken at 24, 48 and 72 
hours for cytopathic effect. After 72 hours the plates were stained with 0.4% (w/v) 
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naphthalene black (Searle Diagnostics, UK) in PBS (CSU, IAH) containing 8% (w/v) 
citric acid crystals (Sigma-Aldrich, UK).    
 
2.3.20. Flow cytometry  
2.3.20.1. Flow cytometry to detect surface proteins 
Adherent cells were detached with non-enzymatic Cell Dissociation Solution 
(Sigma-Aldrich, UK) to minimise damage to surface proteins. Cell suspensions were 
stained with MAbs as described previously (Howard et al., 1988, Howard et al., 
1989). Approximately 3 × 10
5
 cells per well (U bottom 96 microwell plates; Sigma-
Aldrich, UK) were stained for flow cytometric analysis. All washes and antibody 
dilutions were carried out in FACS wash buffer (Appendix 1). Cells were pelleted 
and washed once by centrifugation at 250×g at 8
o
C for 4 minutes, before staining 
with the appropriate primary antibodies in conjunction with isotype control primary 
antibodies, for 15 minutes at room temperature (Table 1). Unbound primary antibody 
was removed by washing the cells twice before incubation with goat anti-mouse 
isotype-specific secondary antibody (Alexa fluor; Molecular Probes, UK) for 15 
minutes at room temperature in the dark. Following two further washes the cells 
were fixed in 1% (w/v) paraformaldehyde (Sigma-Aldrich, UK) in PBS (CSU, IAH) 
at room temperature. Fluorescence data were collected using a Becton Dickenson 
FACScalibur with Cellquest software (Becton Dickinson, UK). Cells were gated on 
their FSC/SSC profile with a minimum of 10000 viable cells being collected in each 




2.3.20.2. Flow cytometry to detect intracellular proteins 
To detect intracellular proteins, cells were transferred to 96-well plates before 
fixation in 1% (w/v) paraformaldehyde in PBS for 15 minutes. The cells were then 
permeabilised by washing twice in FACS wash buffer containing 0.1% saponin 
(Sigma-Aldrich, UK). Staining proceeded as per detection of surface proteins with 
the exception that all washes were carried out in the presence of 0.1% saponin, and 
all antibodies were diluted in FACS wash buffer containing 0.1% saponin. 
  
2.3.21. Virus isolation procedures 
2.3.21.1. Tissue homogenisation  
Tissue samples were homogenised manually by grinding in sterile sand with a mortar 
and pestle in a 10% (w/v) suspension of M25-phosphate buffer (Appendix 1). The 
suspension was either centrifuged at 1800×g for 10 minutes or treated with 50% (v/v) 
Freon (Sigma-Aldrich, UK) (Alexandersen et al., 2002) or n-octyl-β-d-
glucopyranoside (NOG, Sigma-Aldrich, UK) before centrifugation. The tissue 
supernatants were removed for further processing.  
 
NOG was added to the tissue homogenate to solubilise membrane proteins. NOG 
was added to a final concentration of 30mM and incubated on ice for 20 minutes 
(Han and Tanzer, 1979, Lazo and Quinn, 1980). Following centrifugation, the 
supernatant was passed through a 0.45µm filter and dialysed using a 30000 
molecular weight cut off Slide-A-Lyzer Dialysis Cassette (Thermo Scientific, USA) 
in M25-phosphate buffer at 4
o
C overnight (Saito and Tsuchiya, 1984). The dialysed 
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solution was removed for further processing or concentrated using a 30000 molecular 
weight cut off Vivaspin Column (Sartorius, UK) before further processing. 
 
2.3.21.2. Low density cell preparations 
Tonsil and lymph node samples were placed in petri dishes, cut into small blocks and 
teased apart using forceps, needles and steel mesh. A portion of the tissue cell 
preparations were digested with RPMI (Roswell Park Memorial Institute, CSU, IAH) 
containing 10% (v/v) fetal calf serum (Autogen Bioclear, UK), 4mM Glutamine, 
10U/mL penicillin, 10U/mL streptomycin (CSU, IAH), 5mM EDTA (pH 7.4, Sigma-
Aldrich, UK), 0.1mg/mL DNase type 1 (Sigma-Aldrich, UK) and 2mg/mL 
collagenase type 4 (Sigma-Aldrich, UK). Digestion was performed at 4
o
C under 
agitation for 1 hour (Schriever et al., 1989). Digested and non-digested cell 
preparations were centrifuged at 650×g for 25 minutes at 8
o
C over a discontinuous 
gradient of 1.02g/mL and 1.04g/mL Percoll (Sigma-Aldrich, UK). Cells were 





2.3.21.3. Virus isolation on CD32 expressing cells  
Bovine monocyte-derived macrophages (MΦ) were generated from CD14
+
 PBMC 
following a protocol developed by L Robinson, IAH, using bovine recombinant 
granulocyte-macrophage colony-stimulating factor (Norimatsu et al., 2003). Isolated 
PBMC (section 2.3.3.1) were mixed with anti-human CD14 microbeads (Miltenyi 
Biotech, UK) at 25µL per 10
8
 cells and incubated at room temperature for 10 




C for 8 minutes and resuspended in 3mL of chilled column wash buffer 
[FACS sheath fluid (BD Biosciences, UK) with 2% v/v fetal calf serum (Autogen 
Bioclear, UK), 0.22µm filtered]. The MidiMACS LS column (Miltenyi Biotech, UK) 
was placed in a magnet and washed with 3mL of column wash buffer to remove 
preservatives before the labelled cells were added. Trapped, unlabelled cells were 
flushed through with a total of 7.5mL column wash buffer. To collect the bound, 
labelled cells the column was removed from the magnet and 5mL chilled MΦ 
medium [RPMI-1640 (Gibco, UK), 10% v/v fetal calf serum, 50µg/mL gentamycin 
(Sigma-Aldrich, UK), 0.5µM 2-mercaptoethanol (Sigma-Aldrich, UK), 0.2U/mL 
bovine recombinant granulocyte-macrophage colony-stimulating factor (Serotec, 
UK)]  was pushed through. Cells were counted on a haemocytometer (Assistant, 
Germany) and their viability assessed by trypan blue staining (Sigma-Aldrich, UK). 
Freshly isolated monocytes were seeded into culture vessels at 1×10
6
 cells per mL 
MΦ medium and incubated at 37
o
C, 5% CO2. After 3 days fresh medium was added 
to cells. Cells were harvested at 6 days with Cell Dissociation Solution (Sigma-
Aldrich, UK). 
 
MΦ, and BHK-21 cells (Appendix 1) expressing CD32 (section 2.3.19) were 
prepared in 24 well plates on glass cover slips and as monolayers in six well plates. 
To assess the suitability of CD32 expressing cells for detecting lymphoid tissue 
associated FMDV, cell monolayers in 6 well plates were spiked with 100µL 
homogenised mandibular lymph node or palatine tonsil supernatants from a control 
animal before incubation with dilutions of FMDV, immune complexed FMDV, or 
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mock-infected (section 2.3.17.4). Cells were exposed for 6 hours before flow 
cytometry to detect FMDV 3A (section 2.3.20.2, Table 1).  
 
CD32 expressing cells were inoculated with tissue homogenates and cell suspensions 
from infected animals, prepared as described under sections 2.3.21.1 and 2.3.21.2. 
After 6 hours at 37
o
C the glass cover slips were labelled for immunofluorescence 
confocal microscopy (section 2.3.17) to detect FMDV 3A. The cell cultures in 6 well 
plates were either used for flow cytometry (section 2.3.20) or scraped and suspended 
in culture fluid for virus isolation using bovine thyroid (BTY) cells (section 
2.3.21.4).  
 
2.3.21.4. Virus isolation on bovine thyroid cells 
The infectivity of probang samples, tissue homogenates and cell suspensions 
prepared as described under sections 2.3.21.1 and 2.3.21.2 and CD32 expressing cell 
suspensions (section 2.3.21.3) was determined by inoculation of monolayers of 
primary BTY cells (Appendix 1) (Snowdon, 1966). Two hundred µL of the 
supernatant or suspension was added to each monolayer tube of BTY cells kindly 
provided by S Wilsden (IAH). Three tubes were used per sample and incubated at 
37
o
C on roller drums. Cell monolayers were examined for cytopathic effect at 24, 48 
and 72 hours post inoculation. If there was no cytopathic effect after 72 hours, the 
cell culture supernatant was used to inoculate a second batch of BTY tubes. An 
ELISA, kindly performed by G Hutchings (IAH) was used to confirm the presence of 





The morphological characteristics of the lymphoid tissue associated with the soft 
palate, palatine tonsils and pharyngeal tonsils, and the germinal centre morphology 
of the spleen, mandibular, lateral retropharyngeal and bronchial lymph nodes were 
examined on H&E stained and immunofluorescence labelled sections harvested 15 
days post-contact infection and from non-infected control animals (IAH, Compton).  
  
The soft palate forms part of the roof of the mouth directly behind the hard palate, 
between the oral cavity and pharynx (Liebler-Tenorio and Pabst, 2006). The 
pharyngeal surface of the soft palate (referred to as the dorsal soft palate) is covered 
with respiratory epithelium (there is a transition from rostral to caudal of 
pseudostratified columnar epithelium to stratified, squamous, non-keratinised 
epithelium) which is continuous with that of the nasopharynx. The organised 
mucosa-associated lymphoid tissue (MALT) of the dorsal soft palate harvested from 
FMDV infected animals contained distinct secondary follicles characterised by 
germinal centres, the germinal centres were orientated with the light zone towards 
the apical surface (Figure 4). The organised MALT was sparsely distributed in the 
dorsal soft palate harvested from control animals, however, the morphology of the 
MALT was as described above for the infected animals. 
 
The oral surface of the soft palate (referred to as the ventral soft palate) is covered 
with stratified, squamous, keratinised epithelium continuous with the epithelium of 
the oral cavity. The tonsils of the soft palate consist of cryptolymphatic units that are 
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associated with the ventral soft palate. The cryptolymphatic units consist of epithelial 
crypts (invaginations of stratified, squamous, non-keratinised epithelium forming 
blind ended crypts) surrounded by lymphoid follicles and interfollicular areas. 
Germinal centres were observed in the cryptolymphatic units harvested from FMDV 
infected animals and from non-infected control animals (Figure 4).  
 
The palatine tonsils are located within the lamina propria of the lateral oropharyngeal 
walls. The stratified, squamous, non-keratinised epithelium forming the pharyngeal 
wall, invaginates into the tonsil to form the tonsilar sinus and blind-ended crypts 
(Palmer et al., 2009). The sub-epithelial compartments of the palatine tonsils 
harvested from FMDV infected animals contained germinal centres, the germinal 
centres were orientated with the light zone towards the epithelial crypts (Figure 5). 
Palatine tonsils harvested from non-infected control animals contained fewer 
germinal centres than those harvested from FMDV infected animals, however, the 
morphology of the palatine tonsil was as described above for the infected animals. 
 
The pharyngeal tonsils are located in the roof of the nasopharynx and are covered by 
pseudostratified columnar epithelium. Pharyngeal tonsils harvested from FMDV 
infected animals contained germinal centres in the absence of crypts. The germinal 
centres were orientated with the light zone towards the epithelium (Figure 5). 
Pharyngeal tonsils harvested from non-infected control animals contained fewer 
germinal centres than those harvested from FMDV infected animals, however, the 




Figure 4.  H&E stained sections of soft palate.    
H&E stained sections of soft palate harvested 15 days post-intradermolingual 
challenge. (a) Section of the dorsal soft palate. Salivary glands (SG) and germinal 
centres (GC) were located within the connective tissue of the lamina propria below 
the respiratory epithelium (E). The germinal centres were orientated with the light 
zone towards the apical surface. (b) Section of the ventral soft palate highlighting the 
stratified, squamous, keratinised epithelium (E). (c) Cryptolymphatic unit (black 
arrow) located in the lamina propria below the epithelium of the ventral soft palate 
(E). (d) Germinal centres (GC) were associated with the crypt epithelium (CE) within 
the cryptolymphatic units. Salivary glands (SG) were located within the connective 
tissue of the lamina propria surrounding the cryptolymphatic units. Scale bars 




Figure 5. H&E stained sections of palatine and pharyngeal tonsils. 
H&E stained sections of palatine tonsil and pharyngeal tonsil harvested 15 days post-
intradermolingual challenge. (a) The germinal centres (GC) of the palatine tonsils 
were orientated with the light zone towards the stratified, squamous, non-keratinised 
crypt epithelium (CE). Salivary glands (SG) were located in the connective tissue 
within the lamina propria of the pharyngeal wall. (b) The germinal centres (GC) of 
the pharyngeal tonsil were orientated with the light zone towards the pseudostratified 





























The morphology of the mandibular and lateral retrophayngeal lymph nodes harvested 
from FMDV infected cattle was typical of enlarged inflammatory lymph nodes 
consistent with a reactive process (Willard-Mack, 2006), in comparison to the nodes 
harvested from non infected control animals, with follicular hyperplasia and 
prominent germinal centres within secondary follicles (Figure 6). Mandibular and 
lateral retrophayngeal lymph nodes harvested from non-infected control animals 
contained fewer germinal centres than those harvested from FMDV infected animals, 
however, the morphology of the lymph node was as described above for the infected 
animals. 
 
 The bronchial lymph nodes harvested from FMDV infected cattle were only mildly 
reactive compared to that of control animals, containing a small number of prominent 
germinal centres compared to the mandibular and lateral retropharyngeal lymph 
nodes of infected animals (Figure 6).  
 
The spleens of FMDV infected cattle were only mildly hyperplastic and the 
morphology was similar to that of control animals, with a small number of prominent 
germinal centres associated with the splenic white pulp (Figure 7). 
 
The microanatomy of germinal centres within harvested lymphoid tissues was 
examined by immunofluorescence confocal microscopy. The microanatomy of the 
germinal centres was similar in all the lymphoid tissue harvested during the study 
with clearly distinguishable dark and light zones (Figure 8), with the light zone 
characteristically associated with a greater degree of CD21 expression (Imal and 
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Yamakawa, 1996). The integrin αvβ6 was not detected within germinal centres 
(Figure 9). Interestingly, integrin αvβ6 expression was detected on cells in the 




















Figure 6. H&E stained sections of mandibular, lateral retropharyngeal and bronchial lymph 
nodes. 
H&E stained sections of mandibular, lateral retropharyngeal and bronchial lymph 
nodes harvested 15 days post-intradermolingual challenge. (a) Mandibular lymph 
node and (b) lateral retropharyngeal lymph node sections with prominent germinal 
centres (GC) associated with secondary follicles. (c) The bronchial lymph nodes 
harvested from FMDV infected cattle contained a small number of prominent 
germinal centres (GC) compared to the mandibular and lateral retropharyngeal 




Figure 7. H&E stained spleen section. 
H&E stained spleen section harvested 15 days post-intradermolingual challenge 




Figure 8.  Germinal centre microanatomy. 
Mandibular lymph node cryosections harvested from an animal 38 days post-contact 
infection. (a) Dark zone FDCs stained red (anti-fibrinogen MAb D46). (b) CD21 
expressing cells stained gray (anti-CD21 MAb CC51). (c) Nuclei stained blue 
(DAPI). (d) Merge image of (a) and (b). The dark zone (DZ) is stained red. The light 
zone (LZ) is characterised by a high degree of CD21 expressing cells (gray). (e) 
Merge image of a cryosection stained with isotype control MAbs (anti-turkey 
rhinotracheitis virus MAbs TRT3 and TRT6) highlighting the high degree of 
autofluorescence associated with bovine germinal centres. Nuclei stained blue 





Figure 9. Integrin αvβ6 expression in the palatine tonsil. 
Palatine tonsil cryosections harvested from an animal 38 days post-contact infection. 
(a) Palatine tonsil crypt epithelium cells express the αvβ6 integrin (green, anti-αvβ6 
MAB 10D5). Green fluorescence in the adjacent germinal centre is due to 
autofluorescence associated with bovine germinal centres. No αvβ6 was detected in 
germinal centres. (b) CD21 expressing cells stained gray (anti-CD21 MAb CC51). 
(c) Merge image of (a) and (b) with nuclei stained blue (DAPI). (d) to (f) A 
consecutive cryosection stained with isotype control MAbs. (d) No specific signal 
detected in palatine tonsil crypt epithelial cells with isotype control MAb TRT3 
(green, anti-turkey rhinotracheitis virus). (e) No specific signal detected with isotype 
control MAb AV29 (gray, anti-chicken antigen). (f) Merge image of (d) and (e) with 
nuclei stained blue (DAPI). (d) to (f) Green and gray fluorescence in the adjacent 
germinal centre is due to autofluorescence associated with bovine germinal centres. 














     
2.4.2. Laser capture microdissection 
2.4.2.1. Detecting FMDV genome 
The ability to detect FMDV genome in laser microdissected tissue samples by rRT-
PCR was initially evaluated using tongue epithelium cryosections harvested from 
cattle 3 days post-intradermolingual challenge (n = 4 animals) and from control cattle 
(n = 2). FMDV genome was detected consistently in epithelium samples laser 
dissected from the edge of FMDV lesions (n = 8 samples). Ct values ranged from 
23.64 to 28.68. No signal was detected in the control tissue samples (n = 8) after 50 
cycles.   
 
2.4.2.2. Quantifying 28s rRNA 
The ability to detect 28s rRNA was initially validated on PBMC (section 2.3.3.1) and 
laser microdissected mandibular lymph node and palatine tonsil samples. A dilution 




 PBMC were analysed in triplicate by rRT-PCR 
(Oleksiewicz et al., 2001), approximately 100 PBMC contain 10
8
 copies of 28s 
rRNA.    
 
2.4.2.3. Tissue areas targeted for laser capture microdissection 
The germinal centres and epithelium of the dorsal soft palates and pharyngeal tonsils 
(Liebler-Tenorio and Pabst, 2006) were targeted for LCM (Figure 10). The germinal 
centres, interfollicular regions, glandular epithelium and crypt epithelium of the 
palatine tonsils were targeted for LCM (Figure 11). The germinal centres and 
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interfollicular regions of the mandibular and lateral retropharyngeal lymph nodes 
were targeted for microdissection (Figure 12). The germinal centres and non-
germinal centre regions of the splenic white pulp were targeted for LCM (Figure 12). 
Three replicates of the different tissue regions (germinal centres, epithelium etc) each 













Figure 10. Regions of the dorsal soft palate and pharyngeal tonsil targeted for LCM. 
Dorsal soft palate (DSP) and pharyngeal tonsil cryosections stained with toluidine 
blue highlighting regions targeted during LCM. (a) Dorsal soft palate germinal centre 
and (b) epithelium targeted for LCM. (c) Pharyngeal tonsil germinal centre and (d) 
epithelium targeted for LCM. Scale bars represent 200µm.   
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Figure 11. Regions of the palatine tonsil targeted for LCM. 
Palatine tonsil cryosection stained with toluidine blue highlighting regions targeted 
during LCM. (a) Germinal centre, (b) interfollicular region, (c) glandular epithelium 
and (d) crypt epithelium targeted for LCM. Scale bars represent 200µm. 
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Figure 12. Regions of the mandibular lymph node, lateral retrophryngeal lymph node and 
spleen targeted for LCM. 
Mandibular lymph node (MLN), lateral retropharyngeal lymph node (RPLN) and 
spleen cryosections stained with toluidine blue highlighting regions targeted during 
LCM. (a) Mandibular lymph node germinal centre and (b) interfollicular region 
targeted for LCM. (c) Lateral retropharyngeal lymph node germinal centre and (d) 
interfollicular region targeted for LCM. (e) Germinal centre and (f) non-germinal 




2.4.2.4. Analysis of laser capture microdissected samples collected from animals 38 
days post-contact infection 
Tissues harvested from four cattle 38 days post-contact exposure to FMDV O UKG 
34/2001 were selected for LCM (section 2.4.2.3). Probang samples collected at post-
mortem were confirmed negative for FMDV by virus isolation and rRT-PCR.  
FMDV genome and 28s rRNA were quantified by rRT-PCR analysis of laser 
microdissected samples. FMDV genome was detected consistently within the 
germinal centre samples obtained by LCM (Table 2, Figure 13 to Figure 18). No 
FMDV genome was detected in the epithelium of the dorsal soft palates and 
pharyngeal tonsils (Figure 13 and Figure 14). No FMDV genome was detected in the 
crypt epithelium, glandular epithelium and interfollicular regions of the palatine 
tonsils or the interfollicular regions of the mandibular lymph nodes and lateral 
retropharyngeal lymph nodes (Figure 15 to Figure 17). No FMDV genome was 
detected in the non-germinal centre regions of the splenic white pulp (Figure 18). No 
FMDV genome could be detected in germinal centre samples obtained by LCM from 
non-infected control animals. The R squared values (assessment of the fit of the 
standard curve line to the data points) ranged from 0.992 to 0.999 for the FMDV 
quantitative rRT-PCR reactions and from 0.998 to 0.999 for the 28s rRNA 
quantitative rRT-PCR reactions. The efficiency of the FMDV reactions ranged from 
87.2 to 108.4% and for the 28s rRNA reactions from 86.3 to 93.3%. The number of 
copies of 28s rRNA per each PCR reaction are summarised in Figure 19. There was 
no statistically significant association between FMDV genome copies expressed as 
FMDV copies per 10
8
 copies of 28s rRNA and amount of 28s rRNA per reaction (P 
= 0.206; ANOVA, general linear model). There was a statistically significant 
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association between the quantity of FMDV genome present in germinal centre 
samples and the type of tissue (P = 0.0039, Fisher‟s exact test). Significantly more 
FMDV genome copies per 10
8
 copies of 28s rRNA were detected in replicates of six 
germinal centres from mandibular lymph nodes, compared to similar replicates 
harvested from other tissue (Mandibular lymph node compared to lateral 
retropharyngeal lymph node [P = 0.0014], mandibular lymph node compared to 
palatine tonsil [P = 0.0376], mandibular lymph node compared to pharyngeal tonsil 
[P = 0.0392] and mandibular lymph node compared to dorsal soft palate [P = 
0.0148]; ANOVA, Tukey simultaneous test). The spleen samples were not included 
in the statistical analysis.   
 
Table 2. Laser microdissected GC samples processed by quantitative rRT-PCR to detect 
FMDV. 






values of positive 
replicates** 
DSP 9 3 38.74 to 46.24 
Pharyngeal 
tonsils 
6 6 36.76 to 40.22 
Palatine tonsils 7 5 35.73 to 39.92 
RPLN 12 0 34.68 to 37.01 
MLN 12 0 35.64 to 40.03 
Spleen 4 8 40.77 to 45.74 
* 38 days post-contact infection (n = 4 animals). Only germinal centre samples were 
found to contain FMDV genome after 50 cycles. 
** by rRT-PCR to detect FMDV genome. 
DSP = dorsal soft palate. 
RPLN = lateral retropharyngeal lymph node. 











Figure 13.  FMDV genome detected in laser microdissected dorsal soft palate samples. 
Dorsal soft palate samples analysed at 38 days post-contact infection by LCM in 
combination with quantitative rRT-PCR to detect FMDV genome. FMDV genome 
was restricted to germinal centre (GC) samples (n = 4 animals, each bar represents 6 
microdissected samples). No fluorescent signal above threshold was detected in 








Figure 14. FMDV genome detected in laser microdissected pharyngeal tonsil samples. 
Pharyngeal tonsil samples analysed at 38 days post-contact infection by LCM in 
combination with quantitative rRT-PCR to detect FMDV genome. FMDV genome 
was restricted to germinal centre (GC) samples (n = 4 animals, each bar represents 6 
microdissected samples). No fluorescent signal above threshold was detected in 






Figure 15. FMDV genome detected in laser microdissected palatine tonsil samples. 
Palatine tonsil samples analysed at 38 days post-contact infection by LCM in 
combination with quantitative rRT-PCR to detect FMDV genome. FMDV genome 
was restricted to germinal centre (GC) samples (n = 4 animals, each bar represents 6 
microdissected samples). No fluorescent signal above threshold was detected in 
interfollicular (non GC), crypt epithelium (crypt epith) or glandular epithelium 





Figure 16.  FMDV genome detected in lateral retropharyngeal lymph node samples. 
Lateral retropharyngeal lymph node samples analysed at 38 days post-contact 
infection by LCM in combination with quantitative rRT-PCR to detect FMDV 
genome. FMDV genome was restricted to germinal centre (GC) samples (n = 4 
animals, each bar represents 6 microdissected samples). No fluorescent signal above 









Figure 17. FMDV genome detected in laser microdissected mandibular lymph node samples. 
Mandibular lymph node samples analysed at 38 days post-contact infection by LCM 
in combination with quantitative rRT-PCR to detect FMDV genome. FMDV genome 
was restricted to germinal centre (GC) samples (n = 4 animals, each bar represents 6 
microdissected samples). No fluorescent signal above threshold was detected in 








Figure 18. FMDV genome detected in laser microdissected splenic samples. 
Splenic samples analysed 38 days post-contact infection by LCM in combination 
with quantitative rRT-PCR to detect FMDV genome. FMDV genome was restricted 
to germinal centre (GC) samples (n = 4 animals, each bar represents 6 microdissected 
samples). No fluorescent signal above threshold was detected in non-germinal centre 






Figure 19.  Copies of 28s rRNA per PCR reaction. 
Boxplot summarising the number of copies of 28s rRNA per PCR reaction for each 
region of tissue sampled by LMD (n = 4 animals. Each plot depicts the data for 12 
PCR reactions). GC = germinal centre. MLN = mandibular lymph node. Palatine T = 
palatine tonsil. RPLN = lateral retropharyngeal lymph node. Pharyngeal T = 
pharyngeal tonsil. Spleen non GC = non germinal centre region of the splenic white 














2.4.3. In situ hybridization 
For in situ hybridization with unamplified conventional chromagenic detection, a 
dilution of 200ng/mL of RNA probe was found to be optimal. Optimal probe 
concentrations for TSA were tenfold lower than those used for unamplified 
chromagenic detection (Schaeren-Wiemers and Gerfin-Moser, 1993). Probe 
concentration is an essential parameter to consider for improving signal-to-noise 
ratio. Even at lower probe concentrations the signal remained equally intense, this 
observation is consistent with the hypothesis that in the absence of RNases, signal 
intensity is limited by the abundance of the target RNA rather than by the probe 
concentration. 
 
The prepared hybridization buffer was replaced with the hybridization buffer 
supplied in the mRNA Locator in situ Hybridization Kits (Appendix 1). The buffers 
in this kit are optimised for use with radiolabelled RNA probes. DIG labelled probes 
and 33P labelled probes behave with similar kinetics and may be used under similar 
hybridization conditions (Sambrook and Russel, 2001). RNase digestion significantly 
decreased non-specific background and was incorporated into the protocol even 
though there have been reports in the literature of loss of signal intensity and its use 
is probably dependent on the nature of the tissue under investigation (Yang et al., 
1999). Treatment with proteinase K did not offer any increase in signal or reduction 
in noise and was not used routinely (Wilkinson and Nieto, 1993).   
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2.4.3.1. Comparison of tyramide signal amplification with conventional chromagenic 
detection 
In situ hybridization protocols were compared and optimised on consecutive 
pharyngeal tonsil cryosections harvested from an animal 38 days post-contact 
infection using IgG1 RNA probes (Figure 20). Using biotinyl-tyramide and 
streptavidin conjugated to alkaline phosphatase introduced an additional round of 
amplification which enhanced the signal intensity compared to conventional 
chromagenic detection. 
 
2.4.3.2. Validation of FMDV 3D RNA probes 
The FMDV 3D antisense RNA probe was validated on infected and mock infected 
BHK-21 cells (section 2.3.17.3). In addition, the probe was validated on frozen 
coronary band epithelium sections harvested from animals 4 days post-contact 
challenge and from non-infected control animals (Figure 21 and Figure 22). Despite 
the obvious signal obtained when detecting positive strand viral RNA in infected 





Figure 20. Comparison of tyramide signal amplification with conventional chromagenic 
detection.   
Tyramide signal amplification and conventional chromagenic detection protocols 
were compared and optimised on consecutive pharyngeal tonsil cryosections, 
harvested from an animal 38 days post-contact infection, using IgG1 RNA probes. 
(a) and (b) IgG1 antisense probe detected with the tyramide signal amplification 
protocol, deposits of blue-black chromagen were detected in target cells with low 
background signal after developing for 2 minutes. (c) and (d) IgG1 antisense probe 
detected with conventional chromagenic protocol after developing for 2 minutes. No 
blue-black deposit associated with target cells. (e) Background signal with tyramide 
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signal amplification after developing for 30 minutes (IgG1 sense probe). (f) IgG1 
antisense probe detected with conventional chromagenic protocol after developing 
for 30 minutes. Deposits of blue-black chromagen are associated with the target cells 
but high background signal makes the detection of rare mRNA difficult. Scale bars 




Figure 21. FMDV 3D RNA probe validation on infected and mock-infected BHK-21 cells. 
(a) Positive signal after in situ hybridization with 3D antisense RNA probe on BHK-
21 cells fixed 5 hours after FMDV O UKG 34/2001 infection at MOI 10. (b) Lack of 
specific signal on infected cells after in situ hybridization with swine vesicular 
disease (SVD) antisense probe. (c) Lack of specific signal on mock-infected cells 
after in situ hybridization with 3D antisense probe. (d) Positive, cytoplasmic blue-
black chromagen deposit on infected cells after in situ hybridization with FMDV 3D 
antisense probe. (e) Faint blue-black chromagen deposit (arrow) after in situ 
hybridization with FMDV 3D sense probe. Scale bars represent: (a) and (b), 500µm; 




Figure 22. FMDV 3D RNA probe validation on infected and non-infected tissue. 
The FMDV 3D RNA probes were validation on coronary band epithelium 
cryosections harvested from an animal 4 days post-contact infection and from a 
control animal. (a) and (b) Positive staining of coronary band epithelium harvested 
from an infected animal after in situ hybridization with FMDV 3D antisense RNA 
probe. (c) and (d) Lack of specific staining of infected coronary band epithelium 
after in situ hybridization with swine vesicular disease (SVD) antisense and FMDV 
3D sense RNA probes respectively. (e) No staining was detected in non-infected 
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control tissue after in situ hybridization with FMDV 3D antisense RNA probe. Scale 

























2.4.3.3. Analysis of tissue samples harvested 3 days post-infection 
Tissue samples harvested 3 days post FMDV O UKG 34/2001 intradermolingual 
challenge were examined by in situ hybridization and tissue samples collected into 
RNAlater were analysed by quantitative rRT-PCR (Table 3). Clear staining, 
following in situ hybridization with FMDV 3D antisense RNA probe, was only 
observed in mandibular lymph node (Figure 23) and palatine tonsil sections as small, 
punctate isolated areas of blue-black chromagen deposition.  
          

















DSP 4 0 2 11.47-11.68 
MLN 4 3 4 8.38-12.9 
Palatine tonsil 4 2 4 9.55-12.96 
Pharyngeal tonsil 4 0 2 11.97-12.71 
RPLN 4 0 1 11.91 
BLN 4 0 3 8.53-12.15 
* Quantitative rRT-PCR analysis of tissue samples collected into RNAlater. 
DSP = dorsal soft palate. 
MLN = mandibular lymph node. 
RPLN = lateral retropharyngeal lymph node. 




Figure 23. In situ hybridization analysis of mandibular lymph node cryosections harvested 3 
days post-infection.     
Consecutive mandibular lymph node cryosections harvested 3 days post-
intradermolingual challenge. (a) Isolated areas of punctate staining (black arrows) 
after in situ hybridization with FMDV 3D antisense RNA probe. (b) Positive staining 
after in situ hybridization with IgG1 antisense RNA probe. (c) and (d) No staining 
was observed after in situ hybridization with SVD antisense or FMDV 3D RNA 










2.4.3.4. Analysis of tissue samples harvested from 14 to 38 days post-contact 
infection 
Tissue samples harvested from 14 to 38 days post FMDV O UKG 34/2001 contact 
infection were examined by in situ hybridization and tissue samples collected into 
RNAlater were analysed by quantitative rRT-PCR (Table 4). FMDV 3D RNA was 
identified by in situ hybridization in germinal centres of mandibular lymph node 
(Figure 24), lateral retropharyngeal lymph node (Figure 25) and palatine tonsil 
sections (Figure 26) but not in other compartments of these tissues. 
 
















DSP 10 0 2 9.34-10.32 
MLN 10 4 8 6.32-11.5 
Palatine tonsil 10 2 4 10.54-11.36 
Pharyngeal tonsil 10 0 3 7.76-10.24 
RPLN 10 1 2 7.5-10.3 
BLN 10 0 0 0 
* Quantitative rRT-PCR analysis of tissue samples collected into RNAlater. 
DSP = dorsal soft palate. 
MLN = mandibular lymph node. 
RPLN = lateral retropharyngeal lymph node. 




Figure 24. In situ hybridization analysis of mandibular lymph node cryosections harvested 38 
days post-infection and from a non-infected control animal.     
(a) to (e) Consecutive mandibular lymph node cryosections harvested 38 days post- 
contact infection. (a) FMDV 3D antisense RNA probe detecting sense FMDV 3D 
RNA. (b) Lack of staining after in situ hybridization with FMDV 3D sense RNA 
control probe. (c) Higher power image of staining associated with FMDV 3D 
antisense RNA probe. (d) Positive staining of IgG1 mRNA in germinal centre B cells 
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after in situ hybridization with IgG1 antisense RNA positive control probe. (e) Lack 
of staining after in situ hybridization with SVD antisense RNA control probe. (f) 
Lack of staining after in situ hybridization with FMDV 3D antisense RNA probe on 
a mandibular lymph node cryosection harvested from a non-infected control animal. 
Scale bars represent: (a), (b) and (d), 200µm; (c), 50µm; (e) and (f), 500µm. 
 
 
Figure 25. In situ hybridization analysis of lateral retropharyngeal lymph node cryosections 
harvested 22 days post-infection and from a non-infected control animal.     
(a) to (e) Consecutive lateral retropharyngeal lymph node cryosections harvested 22 
days post-contact infection. (a) FMDV 3D antisense RNA probe detecting sense 
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FMDV 3D RNA. (b) Lack of staining after in situ hybridization with FMDV 3D 
sense RNA control probe. (c) Higher power image of staining associated with FMDV 
3D antisense RNA probe. (d) Positive staining of IgG1 mRNA in germinal centre B 
cells after in situ hybridization with IgG1 antisense RNA positive control probe. (e) 
Lack of staining after in situ hybridization with SVD antisense RNA control probe. 
(f) Lack of staining after in situ hybridization with FMDV 3D antisense RNA probe 
on a lateral retropharyngeal lymph node cryosection harvested from a non infected 








 Figure 26. In situ hybridization analysis of palatine tonsil cryosections harvested 32 days post-
infection and from a non-infected control animal.     
(a) to (e) Palatine tonsil cryosections harvested 32 days post-contact infection. (a) 
FMDV 3D antisense RNA probe detecting sense FMDV 3D RNA (black arrows). (b) 
Lack of staining after in situ hybridization with FMDV 3D sense RNA control probe. 
(c) Higher power image of staining associated with FMDV 3D antisense RNA probe. 
(d) Positive staining of IgG1 mRNA in germinal centre B cells after in situ 
hybridization with IgG1 antisense RNA positive control probe. (e) Lack of staining 
after in situ hybridization with SVD antisense RNA control probe. (f) Lack of 
staining after in situ hybridization with FMDV 3D antisense RNA probe on a 
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Palatine tonsil cryosection harvested from a non-infected control animal. Scale bars 





















2.4.4.  Immunofluorescence confocal microscopy 
2.4.4.1. Selection of monoclonal antibodies specific for conformational, non-
neutralising epitopes of the FMDV capsid 
MAbs IB11, FC6, AD10 and BF8 (Table 1) were able to immunoprecipitate FMDV 
capsids, yet were unable to detect FMDV proteins by western blot and were non-
neutralising (Juleff et al., 2008). The MAbs readily detected virus in bovine tongue 
during acute FMDV O UKG 34/2001 infection (Figure 27 to Figure 31) and in virus 
infected BHK-21 cells (Figure 32).  
 
 
2.4.4.2. Detecting FMDV immune complexes 
MAb IB11 was able to detect immune complexed FMDV in vitro on the surface of 
paraformaldehyde fixed mouse fibroblast 3T3 cells (Appendix 1) expressing bovine 









Figure 27. Infected tongue epithelium stained with isotype control antibodies. 
Infected tongue epithelium cryosections harvested 4 days post-contact challenge. (a) 
No signal was detected with isotype control MAbs TRT3 (red, anti-turkey 
rhinotracheitis virus) or TRT1 (green, anti-turkey rhinotracheitis virus). (b) No signal 
was detected with isotype control MAbs TRT3 (red) or AV29 (green, anti-chicken 
antigen). Nuclei stained blue (DAPI). Scale bars represent 80µm.   
 163 
 
Figure 28. Infected and non-infected tongue epithelium stained with MAbs IB11 and 2C2. 
(a) to (c) Infected tongue epithelium cryosections harvested 4 days post-contact 
challenge. (a) FMDV capsids stained green (anti-FMDV capsid MAb IB11). (b) 
FMDV non-structural protein 3A stained red (anti-FMDV 3A MAb 2C2). (c) Merge 
image of (a) and (b) highlighting the co-localisation of FMDV capsid and 3A 
proteins. (d) No signal was detected with MAbs IB11 (green) or 2C2 (red) on non-
infected control tissue. Nuclei stained blue (DAPI), scale bars represent 80µm.  
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Figure 29. Infected and non-infected tongue epithelium stained with MAbs FC6 and 2C2. 
(a) to (c) Infected tongue epithelium cryosections harvested 4 days post-contact 
challenge (a) FMDV capsids stained green (anti-FMDV capsid MAb FC6). (b) 
FMDV non-structural protein 3A stained red (anti-FMDV 3A MAb 2C2). (c) Merge 
image of (a) and (b) highlighting the co-localisation of FMDV capsid and 3A 
proteins. (d) No signal was detected with MAbs FC6 (green) or 2C2 (red) on non-




Figure 30. Infected and non-infected tongue epithelium stained with MAbs AD10 and 2C2. 
(a) to (c) Infected tongue epithelium cryosections harvested 4 days post-contact 
challenge. (a) FMDV capsids stained green (anti-FMDV capsid MAb AD10). (b) 
FMDV non-structural protein 3A stained red (anti-FMDV 3A MAb 2C2). (c) Merge 
image of (a) and (b) highlighting the co-localisation of FMDV capsid and 3A 
proteins. (d) No signal was detected with MAbs AD10 (green) or 2C2 (red) on non-




Figure 31. Infected and non-infected tongue epithelium stained with MAbs BF8 and 2C2. 
(a) to (c) Infected tongue epithelium cryosections harvested 4 days post-contact 
challenge. (a) FMDV capsids stained green (anti-FMDV capsid MAb BF8). (b) 
FMDV non-structural protein 3A stained red (anti-FMDV 3A MAb 2C2). (c) Merge 
image of (a) and (b) highlighting the co-localisation of FMDV capsid and 3A 
proteins. (d) No signal was detected with MAbs BF8 (green) or 2C2 (red) on non-
infected control tissue. Nuclei stained blue (DAPI), scale bars represent 80µm. 
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Figure 32. Anti-FMDV MAb validation on infected and mock-infected BHK-21 cells. 
Cells were fixed and labelled 5 hours after mock-infection (PBS) or FMDV O UKG 
34/2001 infection at MOI 10. (a) to (c) FMDV capsid stained green (anti-FMDV 
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capsid MAb IB11), FMDV non-structural protein stained red (anti-FMDV 3A MAb 
2C2). (d) No signal detected with MAbs IB11 (green) or 2C2 (red) on mock-infected 
cells. (e) to (g) FMDV capsid stained green (anti-FMDV capsid MAb AD10), 
FMDV non-structural protein stained red (anti-FMDV 3A MAb 2C2). (h) No signal 
detected with MAbs AD10 (green) or 2C2 (red) on mock-infected cells. (i) to (k) 
FMDV capsid stained green (anti-FMDV capsid MAb FC6), FMDV non-structural 
protein stained red (anti-FMDV 3A MAb 2C2). (l) No signal detected with MAbs 
FC6 (green) or 2C2 (red) on mock-infected cells. (m) to (o) FMDV capsid stained 
green (anti-FMDV capsid MAb BF8), FMDV non-structural protein stained red 
(anti-FMDV 3A MAb 2C2). (p) No signal detected with MAbs BF8 (green) or 2C2 
(red) on mock-infected cells. (q) Merge image of FMDV infected cells stained with 
isotype control MAbs TRT3 (red, anti-turkey rhinotracheitis virus) and TRT1 (green, 
anti-turkey rhinotracheitis virus). (r) Merge image of FMDV infected cells stained 
with isotype control MAbs TRT3 (red) and AV29 (green, anti-chicken antigen). No 
signal was detected with the isotype control MAbs. Nuclei stained blue (DAPI). 










Figure 33. Detecting FMDV immune complexes in vitro on the surface of mouse fibroblast cells. 
(a) to (c) Mouse fibroblast 3T3 cells expressing bovine CD32 were 
paraformaldehyde fixed, washed and incubated with FMDV immune complexes 
prepared by incubating FMDV with heat inactivated cattle polyclonal immune 
serum. Cells were subsequently washed, fixed and stained. (a) FMDV capsid stained 
green (anti-FMDV capsid MAb IB11). (b) CD32 stained red (anti-CD32 MAb 
CCG37). (c) Merge image of (a) and (b), FMDV capsid stained green, CD32 stained 
red and nuclei stained blue (DAPI). (d) to (f) Cells prepared as described above 
except FMDV was incubated with non-immune cattle serum. (d) No FMDV capsid 
was detected (green, anti-FMDV capsid MAb IB11). (e) CD32 stained red (anti-
CD32 MAb CCG37). (f) Merge image of (d) and (e), no FMDV capsid (green) 
detected, CD32 stained red and nuclei stained blue (DAPI). (g) to (i) Cells prepared 
as described above with FMDV immune complexes. (g) No FMDV non-structural 
protein 3A (green, anti-FMDV 3A MAb 2C2) was detected, consistent with lack of 
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FMDV replication and internalisation by fixed cells. (h) CD32 stained red (anti-
CD32 MAb CCG36). (i) Merge image of (g) and (h), no FMDV non-structural 
protein 3A (green) detected, CD32 stained red and nuclei stained blue (DAPI). Scale 






















2.4.4.3. Analysis of tissue samples collected from 1 to 4 days post-infection 
The dorsal soft palates, pharyngeal tonsils, palatine tonsils, lateral retropharyngeal 
lymph nodes and mandibular lymph nodes were harvested from 8 cattle on days 1 to 
4 post intradermolingual challenge and from a non-infected control animal. 
Cryosections were screened with MAbs directed against FMDV capsid to determine 
the ability of the MAbs (Table 1) to detect FMDV in tissue not associated with 
vesicle formation. In addition, the sections were labelled with MAbs directed against 
3A proteins, with consecutive sections labelled with isotype control MAbs (Table 1). 
No signal was detected with MAbs directed against FMDV on tissue from non-
infected control animals, tissue harvested on day 1 post-infection (n = 2) or on dorsal 
soft palate, pharyngeal tonsil or lateral retropharyngeal lymph node sections.  
 
FMDV capsid and 3A proteins were consistently detected in the palatine tonsil crypt 
epithelium from days 2 to 4 post-infection, a region of the palatine tonsil shown to 
express the integrin αvβ6 (n = 6 animals. Figure 9 and Figure 34). FMDV 3A and 
capsid proteins co-localised in the cytoplasm of infected cells. A small number of 
infected cells were consistently detected in the cortex of mandibular lymph nodes 
with FMDV capsid and 3A MAbs, from days 2 to 4 post-infection (n = 6 animals, 
Figure 35). The phenotype of the cells was investigated by labelling cryosections 
with MAbs directed against FMDV in combination with MAbs specific for CD21, 
MHC class II, CD14, CD40 and the integrin αvβ6 (Table 1). It was not possible to 
determine the phenotype of the infected cells on cryosections due to the expression 
of these markers by the encircling cells, as highlighted in Figure 36, with the infected 
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cell closely associated with a population of cells expressing CD21. The infected or 
encircling cells did not express the integrin αvβ6 (Figure 35).  
 
FMDV capsid was detected in the light zone of mandibular lymph node germinal 
centres as early as 3 to 4 days post intradermolingual challenge (n = 4 animals,  
Figure 37). No FMDV 3A was detected in association with the diffuse punctate 
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Figure 34.  FMDV replicates in the palatine tonsil crypt epithelium. 
(a) to (f) Palatine tonsil cryosections harvested 4 days post-intradermolingual 
challenge. (a) FMDV 3A protein (red, anti-FMDV 3A MAb 2C2) and (b) FMDV 
capsid protein (green, anti-FMDV capsid MAb IB11) were detected in the palatine 
tonsil crypt epithelium. (c) Merge image of (a) and (b). FMDV 3A stained red, 
FMDV capsid stained green, nuclei stained blue (DAPI). (d) to (f) Higher power 
images highlighting the cytoplasmic pattern and co-localisation of FMDV 3A (red, 
anti-FMDV 3A MAb 2C2) and FMDV capsid protein (green, anti-FMDV capsid 
MAb IB11). (f) Merge image of (d) and (e), FMDV 3A stained red, FMDV capsid 
stained green, nuclei stained blue (DAPI). Scale bars represent: (a) to (c), 50µm; (d) 






Figure 35. FMDV replicates in cells in the cortex of mandibular lymph nodes. 
(a) to (i) Mandibular lymph node cryosections harvested 4 days post-
intradermolingual challenge. (a) A small number of infected cells were detected in 
the lymph node cortex with MAb 2C2 (red, anti-FMDV 3A) and (b) MAb IB11 
(green, anti-FMDV capsid). (c) Merge image of (a) and (b). FMDV 3A stained red, 
FMDV capsid stained green, nuclei stained blue (DAPI).  (d) Higher power image of 
the mandibular lymph node cortex highlighting cytoplasmic FMDV 3A (red, anti-
FMDV 3A MAb 2C2) and (e) capsid (green, anti-FMDV capsid MAb IB11). (f) 
Merge image of (d) and (e). FMDV 3A stained red, FMDV capsid stained green, 
nuclei stained blue (DAPI). Merge image highlights the cytoplasmic co-localisation 
of FMDV 3A and FMDV capsid in the mandibular lymph node cortex during the 
acute stages of infection. (g) No integrin αvβ6 (red, anti-αvβ6 MAb 10D5) was 
detected in the cortex of the mandibular lymph node. (h) FMDV capsid stained green 
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(anti-FMDV capsid MAb IB11). (i) Merge image of (g) and (h). No integrin αvβ6 
(red) was detected in associated with FMDV capsid (green). Nuclei stained blue 





Figure 36. Cells supporting FMDV replication in mandibular lymph nodes were in close 
association with cells expressing CD21. 
Mandibular lymph node cryosection harvested 4 days post-intradermolingual 
challenge. (a) FMDV 3A stained green (anti-FMDV 3A MAb 2C2). (b) CD21 
expressing cells stained red (anti-CD21 MAb CC21). (c) Merge image of (a) and (b). 




Figure 37. FMDV capsid detected in the light zone of mandibular lymph node germinal centres 
harvested 4 days post-intradermolingual challenge. 
(a) to (c) Mandibular lymph node cryosection harvested 4 days post-
intradermolingual challenge. (a) Fibrinogen, associated with dark zone FDCs, stained 
red (anti-fibrinogen MAb D46). FMDV capsid stained green (anti-FMDV capsid 
MAb IB11). (b) Higher power image of the diffuse punctate pattern of viral capsid 
(green, anti-FMDV capsid MAb IB11) associated with cells in the germinal centre 
light zone. (c) CD21 stained gray (anti-CD21 MAb CC51). (d) Mandibular lymph 
node cryosection harvested from a non-infected control animal. Fibrinogen stained 
red (anti-fibrinogen MAb D46). No signal was detected with MAb IB11 (green, anti-
FMDV capsid MAb). Nuclei stained blue (DAPI), scale bars represent: (a), (c) and 




2.4.4.4. Analysis of tissue samples collected from 29 to 38 days post-contact 
infection 
To determine whether viral RNA detected by LCM and in situ hybridization was 
associated with viral structural and non-structural proteins; cryosections from the 
dorsal soft palates, pharyngeal tonsils, palatine tonsils, lateral retropharyngeal lymph 
nodes and mandibular lymph nodes collected from 29 to 38 days post-contact 
infection were analysed with MAbs directed against FMDV capsid, 3A and 3C 
proteins (Table 1).  
 
The anti-FMDV capsid MAbs gave a diffuse punctate pattern of positive labelling 
which was restricted to germinal centres within lymphoid tissue and confined to the 
light zone within the germinal centre from 29 days post-infection (Table 5, Figure 
38, Figure 39). In contrast, the FMDV non-structural proteins 3A and 3C could not 
be detected in any of the tissue from animals after 28 days post-contact infection. 
The diffuse punctate pattern of labelled viral capsid was shown to be localised to the 
light zone FDC network by co-labelling with an antibody specific for light zone 
FDCs (Figure 40). Analysis of in situ hybridization and immunohistochemistry 
showed a consistent punctate pattern (Figure 41). The punctate labelling pattern 
observed in Figure 41 is consistent with the distribution pattern of iccosomes on 
FDCs (Szakal et al., 1988). This pattern is in contrast to the diffuse cytoplasmic 
labelling pattern of cells observed during acute infection in vivo and in infected cells 




Table 5. Immunohistochemical analysis of tissue 29 to 38 days post-contact infection for FMDV 
capsid and non-structural proteins. 
Tissue Number of animals sampled FMDV capsid +ve GCs* 
DSP 17 0 
Pharyngeal tonsils  10 0  
Palatine tonsils 10 6 
RPLN 10 8 
MLN 22 22 
Tissue was negative by immunohistochemical analysis for FMDV non-structural 
proteins.   
* Number of animals with germinal centres (GCs) positive for FMDV capsid. 
DSP = dorsal soft palate. 
RPLN = lateral retropharyngeal lymph node. 




Figure 38. FMDV capsid was restricted to lymphoid tissue germinal centres from 29 days post-
infection. 
(a) to (d) Mandibular lymph node germinal centre sections harvested 38 days post-
contact infection, the white markers demarcate the germinal centre light zones. (a) 
FMDV capsid stained green (anti-FMDV capsid MAb IB11), dark zone FDCs 
stained red (anti-fibrinogen MAb D46). FMDV capsid is restricted to the germinal 
centre light zone. (b) Dark zone FDCs stained red (anti-fibrinogen MAb D46). No 
specific signal detected in the germinal centre light zone with isotype primary control 
MAb TRT1 (green, anti-turkey rhinotracheitis virus). A higher power image of (a) 
and (b) is displayed in Figure 39. (c) No signal detected in the germinal centre light 
zone with FMDV non-structural protein 3A (green, anti-FMDV 3A MAb 2C2). 
FMDV non-structural proteins could not be detected by immunohistochemical 
analysis of tissue from 29 to 38 days post-contact infection. (d) No primary or 
secondary antibodies highlighting autofluorescence associated with bovine germinal 
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centres. The majority of the autofluorescent signal is restricted to the germinal centre 








Figure 39. FMDV capsid detected in mandibular lymph node germinal centres. 
(a) and (b) Mandibular lymph node germinal centre sections harvested 38 days post-
contact infection, the white markers demarcate the germinal centre light zones. (a) 
FMDV capsid labelled green (anti-FMDV capsid MAb IB11), dark zone FDCs 
labelled red (anti-fibrinogen MAb D46). FMDV capsid is restricted to the germinal 
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centre light zone. (b) Dark zone FDCs labelled red (anti-fibrinogen MAb D46), no 
specific signal detected in the germinal centre light zone with isotype primary control 
MAb TRT1 (green, anti-turkey rhinotracheitis virus). (c) to (e) Mandibular lymph 
node germinal centre section harvested 38 days post-contact infection, the white 
markers demarcate the germinal centre light zone. (c) FMDV capsid stained green 
(anti-FMDV capsid MAb IB11). (d) No FMDV 3C protein detected in the germinal 
centre light zone (red, anti-FMDV 3C MAb 3C1). (e) Merge image of (c) and (d). 
Nuclei stained blue (DAPI).  FMDV capsid (green) is restricted to the germinal 
centre light zone. The majority of the autofluorescent signal is restricted to the 






Figure 40. The diffuse punctate pattern of viral capsid was shown to be localised to the light 
zone FDC network by co-staining with an antibody specific for light zone FDCs. 
(a) to (c) A mandibular lymph node cryosection harvested 38 days post-contact 
infection. (a) FMDV capsid stained green (anti-FMDV capsid MAb IB11). (b) Light 
zone FDC network stained red (anti-light zone FDC MAb CNA.42). (c) Merge 
image of (a) and (b) highlighting the diffuse punctate pattern associated with FMDV 
capsid (green) linked to the light zone FDC network (red). Nuclei stained blue 
(DAPI). (d) to (f) Mandibular lymph node cryosection harvested from a non-infected 
control animal. (d) No signal detected using MAb IB11 (green, anti-FMDV capsid). 
(e) Light zone FDC network stained red (anti-light zone FDC MAb CNA.42). (f) 
Merge image of (d) and (e). No FMDV capsid (green) detected, light zone FDC 
network stained red, nuclei stained blue (DAPI).  (g) to (i) A mandibular lymph node 
cryosection harvested 38 days post-contact infection. (g) No signal detected with 
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isotype matched control MAb TRT1 (green, anti-turkey rhinotracheitis virus). (h) No 
signal detected with isotype matched control MAb AV48 (red, anti-chicken antigen). 







Figure 41. High power images comparing the pattern of FMDV detected 38 days post-contact 
infection by immunohistochemical analysis and by in situ hybridization.  
(a) and (b) Mandibular lymph node cryosections harvested 38 days post-contact 
infection. (a) FMDV capsid stained green (anti-FMDV capsid MAb IB11), nuclei 
stained blue (DAPI). (b) No signal detected with isotype matched control MAb 
TRT1 (green, anti-turkey rhinotracheitis virus), nuclei stained blue (DAPI). (c) 
Mandibular lymph node cryosection harvested from a non-infected control animal. 
No signal detected with MAb IB11 (green, anti-FMDV capsid), nuclei stained blue 
(DAPI). Scale bars represent 5µm. (d) to (f) Mandibular lymph node cryosections 
harvested 38 days post-contact infection and analysed by in situ hybridization with 
(d) FMDV 3D antisense RNA probe, (e) swine vesicular disease (SVD) antisense 
RNA control probe and (f) FMDV 3D sense RNA control probe. No counterstain, 
scale bars represent 50µm. Panels (a) and (d) highlight the similar diffuse punctate 
staining pattern using in situ hybridization to detect FMDV 3D RNA and MAb IB11 






2.4.5. Virus isolation  
2.4.5.1. Evaluation of CD32 expressing cells used for virus isolation 
The ability of BHK-21 cells or BHK-21 cells expressing either bovine CD32 or 
bovine CD32tail− mutant (Peltz et al., 1988) to bind and phagocytose IgG-coated 
particles was evaluated by uptake studies of immune complexed FITC-ovalbumin 
(Figure 42). BHK-21 cells expressing CD32 were able to bind and phagocytose 
immune complexed FITC-ovalbumin. BHK-21 cells expressing CD32tail− mutant 
were able to bind immune complexed FITC-ovalbumin but ingestion of IgG coated 
particles was inefficient, which is consistent with published data for isoforms of 
CD32 lacking the cytoplasmic domain (Tuijnman et al., 1992). Non-transfected 
BHK-21 cells did not bind or internalise immune complexed FITC-ovalbumin.   
 
The virus neutralisation test was used to compare the ability of serum from 4 animals 
13 days or more post-infection, to neutralise virus in the presence of BHK-21 cells 
and BHK-21 cells expressing CD32. An example of an assay is displayed in Figure 
43. The serum was consistently less efficient, by one or two doubling dilutions, at 
neutralising virus in the presence of BHK-21 cells expressing CD32, suggesting that 
these cells were more susceptible to virus in the presence of specific antibody 
compared to standard BHK-21 cells.   
 
Monolayers of MΦ (kindly provided by L Robinson who also kindly helped with the 
analysis of these experiments) and BHK-21 cells expressing CD32 were spiked with 
homogenised palatine tonsil and mandibular lymph node supernatants from a control 
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animal. The cells were subsequently exposed to FMDV or FMDV immune 
complexes for 6 hours and analysed by flow cytometry for viral non-structural 
proteins (Figure 44). Immune complexed FMDV was readily detectable in MΦ by 
flow cytometry at MOI 1 in the presence of homogenised lymph node supernatants. 
BHK-21 cells expressing CD32 were more susceptible to virus in the presence of 
specific antibody as shown by the virus neutralisation test. However, detection of 
immune complexes in these cells by flow cytometry in the presence of lymphoid 
tissue homogenates was not sufficiently sensitive due to a high degree of background 
staining detected with isotype control MAbs. Therefore, only MΦ were used for the 
detection of FMDV in lymphoid tissue by flow cytometry. 
 
2.4.5.2. Virus isolation from tissue samples collected 29 to 38 days post-contact 
infection 
The palatine tonsils, lateral retropharyngeal lymph nodes and mandibular lymph 
nodes of 8 animals were harvested between 29 and 38 days post-contact infection for 
processing in preparation for virus isolation as described under section 2.3.21. No 
FMDV 3A was detected in CD32 expressing cell lines and no virus was isolated on 
BTY cells. An example of a negative flow cytometry data set for the detection of 
FMDV 3A in a tissue homogenate of a mandibular lymph node harvested 29 days 
post-contact infection and inoculated onto MΦ, is displayed in Figure 45.   
 




Figure 42. Binding and phagocytosis studies of BHK-21 cells or BHK-21 cells expressing CD32 
and CD32tail− mutant. 
(a) and (b) The percentages of viable BHK-21 cells used for subsequent phagocytosis 
studies expressing CD32 (BHK-21 CD32) or CD32tail− mutant (BHK-21 CD32tail− 
mutant) were evaluated by flow cytometry. Cells were labelled with anti-CD32 MAb 
CCG36 (red line) or isotype control MAb TRT1 (black line). The markers represent 
the percentages of gated cells labelled with MAb CCG36. (c) and (d) The ability of 
BHK-21 cells or BHK-21 cells expressing either (c) bovine CD32 or (d) bovine 
CD32tail− mutant to bind and phagocytose IgG-coated particles was evaluated by 
uptake studies of immune complexed FITC-ovalbumin.  (c) and (d) BHK-21 cells did 
not bind or phagocytose immune complexed FITC-ovalbumin after incubation at 
37
o
C for 30 minutes (blue lines). (c) BHK-21 cells expressing CD32 were able to 
bind immune complexed FITC-ovalbumin at 4
o
C (black line) and phagocytose 
immune complexed FITC-ovalbumin at 37
o
C (red line, 28.4%). (d) BHK-21 cells 
expressing CD32tail− mutant were able to bind immune complexed FITC-ovalbumin 
at 4
o
C (black line) but ingestion of IgG coated particles at 37
o








Figure 43. A comparison of the ability of serum to neutralise a fixed dose of virus in the 
presence of BHK-21 cells and BHK-21 cells expressing CD32. 
An example of a virus neutralisation test used to compare the ability of serum from 
an animal 13 days post-infection, to neutralise virus in the presence of BHK-21 cells 
and BHK-21 cells expressing CD32. The serum was consistently less efficient at 
neutralising virus in the presence of BHK-21 cells expressing CD32, suggesting that 
these cells were more susceptible to virus in the presence of specific antibody 




Figure 44. MΦ spiked with homogenised lymph node supernatant and exposed to FMDV and 
FMDV immune complexes.  
Monolayers of MΦ in 6 well plates were spiked with homogenised mandibular 
lymph node supernatants from a control animal and either (a) mock-infected, (b) 
exposed to FMDV at MOI 10 or (c) to (e), exposed to FMDV immune complexes 
formed with immune serum at MOI 10 to MOI 0.1. Cells were exposed for 6 hours, 
labelled with anti-FMDV 3A MAb 2C2 (blue line) or isotype control MAb TRT3 
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(black line). The markers represent the percentages of gated cells labelled with MAb 
2C2. Immune complexed FMDV was detectable at MOI 1 in the presence of 




Figure 45. Flow cytometry analysis of MΦ inoculated with mandibular lymph node homogenate 
harvested 29 days post-contact infection. 
Monolayers of MΦ in 6 well plates were inoculated with 100µL of mandibular 
lymph node homogenate harvested 29 days post-contact infection. Cells were 
exposed for 6 hours, followed by flow cytometry to detect FMDV 3A. (a) Cells 
labelled with secondary MAb only (1.19%). (b) Cells labelled with isotype control 
Mab (1.56%). (c) Cells labelled with isotype control MAb (black line) and anti-
FMDV 3A MAb 2C2 (blue line). The marker represents the percentage of gated cells 
labelled with MAb 2C2 (2.21%). No virus was detected in MΦ scrapings by 





2.5. Discussion  
We have shown that FMDV genome, using LCM and quantitative rRT-PCR, can be 
detected consistently in germinal centres within the dorsal soft palate, pharyngeal 
tonsil, palatine tonsil, lateral retropharyngeal lymph node and mandibular lymph 
node at 38 days post-contact infection. Also, FMDV genome in these tissues was 
restricted to the germinal centre. These findings were confirmed with in situ 
hybridization studies, which revealed FMDV 3D RNA in germinal centres of 
lymphoid tissue but not in other compartments of these tissues. Using MAbs specific 
for conformational, non-neutralising epitopes of the FMDV capsid, we identified 
viral structural proteins restricted to the light zone FDC network of germinal centres 
within mandibular lymph nodes, lateral retropharyngeal lymph nodes and palatine 
tonsils up to 38 days post-contact infection, but not in the dorsal soft palates or 
pharyngeal tonsils. The inability to detect FMDV capsid in the dorsal soft palates and 
pharyngeal tonsils by immunohistochemistry is in contrast to the clear detection of 
FMDV genome by LCM. This inconsistency may be a consequence of differences in 
assay sensitivity or genomic RNA persisting longer than virus (Simon et al., 2007). 
The diffuse punctate pattern of labelled viral capsid in tissue from 29 to 38 days post-
infection, similar to the FMDV genome staining pattern detected by in situ 
hybridization, was in contrast to the diffuse cytoplasmic pattern observed in cells 
during acute infection in vivo and in infected cells in vitro.  
 
The mandibular lymph nodes had notably more germinal centres containing FMDV 
capsid compared to the lateral retropharyngeal lymph nodes and palatine tonsils. This 




copies of 28s rRNA in replicates of six germinal centres from mandibular lymph 
nodes, compared to similar replicates harvested from other tissues. FMDV capsid 
was detected in mandibular lymph node germinal centres of all animals examined 
between 29 to 38 days post-contact infection (n = 22), including five animals where 
FMDV could not be recovered by virus isolation or detected by rRT-PCR analysis of 
oropharyngeal scrapings collected at post-mortem 29 to 34 days post-infection using 
probang sampling cups (Alexandersen et al., 2002). These results indicate that virus 
is likely to persist in all cattle to some degree following infection. This predilection 
to the mandibular lymph node is not surprising because afferent lymphatics of the 
mandibular lymph nodes in cattle drain the oral cavity and tongue, which are 
important sites of viral replication during the acute phase of infection. However, 
these results do not support findings from previous studies which reported detection 
of viral RNA by in situ hybridization and whole tissue quantitative rRT-PCR in the 
dorsal soft palate epithelium in „carrier‟ animals (Prato Murphy et al., 1999, Zhang 
and Alexandersen, 2004, Zhang and Kitching, 2001). We did not detect viral RNA in 
the epithelial compartments of all the tissues examined either by LCM and 
quantitative rRT-PCR or in situ hybridization, although we routinely detected viral 
RNA and capsid in germinal centres of these tissues.  
     
Although MAbs specific for FMDV non-structural proteins could detect infected 
cells in vitro and in vivo during the acute phase of infection, no FMDV non-structural 
proteins were detected in any of the tissues examined from 29 days post-contact 
infection. The absence of detectable FMDV non-structural proteins indicates that the 
presence of viral RNA is not associated with active viral replication (Brocchi et al., 
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1998, De Diego et al., 1997). The finding of close co-localisation of viral RNA and 
capsid conformational epitopes, in the absence of non-structural proteins, supports 
the hypothesis that FMD viral particles or immune complexes are maintained in 
germinal centre light zones in a non-replicating state.  
 
Interestingly, FMDV capsid was detected in the light zone of mandibular lymph node 
germinal centres as early as 3 to 4 days post intradermolingual challenge (n = 4). 
FMDV is known to use members of the integrin family to initiate infection 
(Monaghan et al., 2005). Current evidence from in vitro and in vivo studies indicates 
that αvβ6 integrin serves as the major cellular receptor for FMDV. Since the 
distribution of αvβ6 expression in cattle, namely in epithelial cells in the tongue, 
interdigital skin and coronary band (Monaghan et al., 2005) correlates closely with 
the sites of FMDV replication, it is thought to determine the tissue tropism of the 
virus. We have shown by immunofluorescence confocal microscopy that αvβ6 is not 
expressed in germinal centres, indicating that the early localisation of FMDV to 
germinal centre light zones is independent of αvβ6 expression. Binding of virus to 
light zone germinal centre cells during the early stages of infection may play an 
important role in facilitating a FMDV B-cell response (Allen and Cyster, 2008, Gatto 
et al., 2007, Kikuno et al., 2007). 
 
The results of these studies have important implications for understanding both the 
mechanism of viral persistence and the ability of FMDV infection to stimulate long-
lasting antibody responses. FDCs are known to be non-endocytic cells capable of 
capturing and retaining antigen in the form of immune complexes for long periods of 
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time (Haberman and Shlomchik, 2003, Mandel et al., 1980). Retention of immune 
complexed FMDV particles within lymphoid tissue represents a possible source of 
the infectious material detected by pharyngeal sampling of infected cattle either by 
direct harvesting of mucosal associated lymphoid tissue germinal centres or sampling 
of secondary cells, for example macrophages, DCs or B cells, able to support a low 
level virus replication cycle in the presence of high titres of neutralising antibodies 
(Mason et al., 1993, Rigden et al., 2002, Robinson, 2008). Of the tissue examined in 
the present study, only material from the palatine tonsils and pharyngeal tonsils are 
likely to be represented in probang samples. Viral RNA was detected in germinal 
centres of palatine tonsils and pharyngeal tonsils but capsid antigen was only 
detected in germinal centres of palatine tonsils making this tissue a likely source of 
infectious virus detected by probang sampling in cattle. However, it must be stressed 
that there are other areas of lymphatic tissue represented in probang samples which 
were not examined during the present study, for example, the lingual tonsils which 
have been shown to contain FDCs (Rebmann and Gasse, 2008).  
 
FDCs are notoriously difficult cells to isolate and work with, infectious FMDV could 
not be isolated from the lymphoid tissue during these studies, most likely due to 
technical difficulties extracting virus from the tissue and working with the bovine 
system. Retention of other viruses such as HIV in a replication-competent state 
within the light zone of germinal centres has been reported and the next step will 
require the development and interrogation of murine model systems (Smith et al., 
2001). The previous observation that dexamethasone treatment suppresses the ability 
to detect FMDV in oropharyngeal scrapings (Ilott et al., 1997) is consistent with the 
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hypothesis that the germinal centre is the reservoir for infectious virus, since 
glucocorticoid administration to mice is known to result in atrophy of the FDC 
network (Murray et al., 2004). The recrudescence of virus in pharyngeal scrapings 
after dexamethasone treatment could be a consequence of the failure of the treatment 
to completely eliminate structures capable of maintaining viable virus. FDC-trapped 
HIV has been shown to represent a significant reservoir of infectious and highly 
diverse HIV, demonstrating greater genetic diversity than most other tissues, 
providing drug-resistant and immune-escape quasispecies that contribute to virus 
transmission, persistence and diversification (Keele et al., 2008). Retention of intact 
FMDV particles on the FDC network would therefore provide an ideal mechanism of 
maintaining a highly cytopathic and lytic virus like FMDV extracellularly in a non-
replicating, native, stable non-degraded state (Smith et al., 2001, Tew and Mandel, 
1979). This reservoir could serve as the source of genetically diverse viral mutants 
(quasispecies), detected in „carrier‟ animals (Domingo et al., 2002, Vosloo et al., 
1996), able to infect susceptible cells that come into contact with the FDC network. 
 
FMDV infection in ruminants elicits an immune response that can provide protection 
for several years (Cunliffe, 1964) and the degree of protection correlates well with 
specific SNTs (Alexandersen et al., 2003b). This is in contrast to vaccination, with 
current FMDV vaccines prepared with inactivated virus and adjuvants, providing 
short term duration of SNTs and protection (Doel, 2005). Long-term maintenance of 
elevated, specific antibody titres in mice following acute VSV infection has been 
shown to be associated with the co-localisation of antigen with specific memory B 
cells within long-lived germinal centres (Bachmann et al., 1996). VSV is a cytolytic 
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virus that does not persist in an infectious form in mice, thus highlighting the 
function of FDC trapping and retention serving as a long-term repository of 
immunogenic antigen for maintenance of SNTs. Hence, efficient retention within the 
germinal centres of intact viral capsids, as opposed to the constituent viral proteins, 
may be a requirement for sustaining antibody responses relevant for providing 
protection against challenge. Indeed, in a recent review of the functional significance 
of antigen retained on FDCs, Kosco-Vilbois suggests the observation that B-cell 
responses are independent of FDC-associated antigen is only valid in mice that are 
immunised with forms of antigen that leave persistent depots (Kosco-Vilbois, 2003). 
Therefore, we believe that long-term antibody responses detectable after FMDV 
infection are maintained in part by antigen persisting on FDCs. Based on the 
evidence presented here we suggest the persistence of FMDV after acute infection is 
both a consequence of the host immune response and a requirement for the long-term 











3. FMDV can induce a specific and rapid CD4+ T-cell-independent 
neutralising isotype class switched antibody response in naïve cattle 
3.1. Introduction 
Experimental FMDV infection is characterised by a short incubation period of 1 to 3 
days followed by pyrexia, formation of vesicles and a short viraemic phase with 
clinical resolution and virus clearance coinciding closely with the emergence of 
serum neutralising antibodies (Alexandersen et al., 2003b). There is a close 
correlation between protection from disease after recovery from infection or after 
immunisation and the titre of circulating antibodies (Alexandersen et al., 2003b). 
However, ruminants exposed to virus, whether vaccinated or not can carry FMDV in 
the oropharynx for years, following resolution of the acute infection (Alexandersen 
et al., 2002). Because of their importance, a number of studies have examined the 
classes and subclasses of circulating neutralising antibody. Specific IgM has been 
detected in the serum from 3 to 7 days post-infection and specific IgG1 and IgG2 
have been detected from 4 days post-infection (Doel, 2005, Salt et al., 1996a) with 
neutralising titres of circulating antibody persisting up to 4.5 years post-infection 
(Cunliffe, 1964).      
 
In contrast to the well defined role of humoral immune responses, the contribution of 
T-cell-mediated responses to immunity and their role in the induction of protective 
B-cell responses to FMDV in the natural host species are poorly understood. 
Observations in murine infection models indicate that acute cytopathic viral 
infections frequently induce T-I antibody responses. It has been proposed that such 
rapid antibody responses are required to facilitate control of virus spread through the 
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circulation and to ensure host survival, in contrast to non-cytopathic viruses like 
LCMV in mice where initial control is largely dependent on cytotoxic T lymphocyte 
responses, as opposed to neutralising antibody (Bachmann and Zinkernagel, 1997, 
Fehr et al., 1996, Lee et al., 2005). The kinetics of the early antibody response to 
FMDV is consistent with the responses seen for other rapidly replicating cytolytic 
viruses. The example of VSV in mice demonstrates an early T-I B-cell response 
where circulating, neutralising IgM can be detected as early as 48 hours post-
infection followed by a rapid and efficient switch to a long-lived and protective IgG 
response (Bachmann and Zinkernagel, 1997, Hangartner et al., 2006). Borca et al. 
reported that the protective immune response against FMDV in a murine 
experimental model was T-I (Borca et al., 1986). However, a role for T cells in the 
induction of antibody responses in ruminants has been suggested, based on the 
demonstration of FMDV-specific CD4
+
 T-cell-proliferative responses following 
infection or vaccination with virus or peptide (Blanco et al., 2001, Collen and Doel, 
1990, Gerner et al., 2007). Until recently, CD8
+
 T-cell responses to FMDV in 
livestock had only been demonstrated in infected animals, but the T-cell proliferation 
assays employed were unable to demonstrate whether or not the detected responses 
were class I MHC-restricted (Childerstone et al., 1999). Recently, Guzman et al used 
IFN-γ production to demonstrate virus-specific MHC class I-restricted CD8
+
 T-cell 
responses in cattle infected or vaccinated with FMDV, but the role of these CD8
+
 T 
cells in immunity to FMDV infection is still not known (Guzman et al., 2008). There 
is an abundant γδ T cell population in ruminants, γδ T cells make up between 10 to 
15% of PBMC in adult cattle, with even greater numbers (up to 50%) reported in 
juvenile animals (Clevers et al., 1990, Pollock and Welsh, 2002). However, there is 
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no clear consensus on the role of these cells in immunity to infections in ruminants. 
Most of the γδ T cells in the blood of young ruminants express WC1, a molecule 
shown to modulate γδ T cell activation (Hanby-Flarida et al., 1996, Pillai et al., 
2007, Takamatsu et al., 1997), whereas many of the γδ T cells in lymphoid tissues 
are WC1
-
 (MacHugh et al., 1997). FMDV vaccine antigen has been shown to induce 
proliferation and cytokine production in naïve pig γδ T cells, suggesting that these 
cells could contribute to the early immune response to FMD vaccination (Takamatsu 
et al., 2006).  
  
The three major subpopulations of bovine T lymphocytes identified in the circulation 
and secondary lymphoid organs of cattle can be effectively depleted in vivo by 
administering the appropriate mouse MAbs (Howard et al., 1989, Naessens et al., 
1998). Administering relatively low doses (0.1 to 0.3 mg/kg) of MAbs to calves has 
been shown to effectively deplete peripheral blood and spleen T-lymphocyte 
populations but sparse numbers of target cells have been shown to persist in the 
lymph nodes at these doses (Naessens et al., 1998). Administering anti-CD4 MAbs at 
this low dose range to cattle has been shown to significantly alter the host response to 
pathogens, for example, CD4 depletion during bovine virus diarrhoea virus infection 
resulted in extension of the duration of viraemia and an increase in titre of the virus 
in blood (Howard et al., 1992). Similar doses administered during respiratory 
syncytial virus infection in calves increased the extent of pulmonary lesions and 
suppressed the antibody response (Naessens et al., 1998, Taylor et al., 1995, Thomas 
et al., 1996). In addition, a possible role of γδ T cells in the immune response to the 




 cells, using a WC1-specific mouse MAb at this low dose range 
(Kennedy et al., 2002). Depletion of peripheral lymph node T lymphocytes is 
difficult to achieve, doses of 2mg/kg are required to deplete CD4
+
 T cells from these 
tissues (Naessens et al., 1998). Depletion of circulating CD8
+
 T cells is also difficult 
to achieve (Howard et al., 1989, Howard et al., 1992). Partial depletion, at relatively 
low doses has been shown to significantly influence the host immune response to 
pathogens, for example, administering 20mg of anti-CD8 MAb in total to 6 day old 
calves over a 5 day period has been shown to induce partial depletion of circulating 
CD8
+
 cells. The partially depleted calves excreted significantly more rotavirus than 
the control calves, implying a role for CD8
+
 cells in limiting primary rotavirus 
infection (Oldham et al., 1993). In addition, incomplete CD8
+
 cell depletion with 
higher doses of anti-CD8 MAbs administered to approximately 9 day old calves (40 
mg MAb in total administered over 10 days) demonstrated that CD8
+
 T cells play a 
dominant role in recovery from respiratory syncytial virus infection (Taylor et al., 
1995). Nasopharyngeal excretion of respiratory syncytial virus was prolonged in 
calves depleted of CD8
+
 cells, the depleted calves also presented more severe 
pulmonary lesions and virus could be isolated from lung washes for a longer period 






3.2. Aims of the chapter 






 T lymphocytes play a dominant role in the 
resolution of FMDV infection in naïve calves.  
This was investigated by: 
 the application of T lymphocyte depletion protocols in calves using subset 






 T cells during 
the early stages of infection with FMDV 
 monitoring the extent of T-cell depletion from the circulation and from 
peripheral lymph nodes 
 comparing clinical FMD progression compared to control, non-depleted 
animals 
 monitoring virus clearance by quantitative rRT-PCR and by virus isolation 
 monitoring the virus neutralising antibody response 
 analysing the profile of the FMDV-specific antibody isotype response 
 monitoring the antibody response to viral non-structural proteins and G-H 
loop peptides 
 
3.3. Materials and methods 
3.3.1. Experimental procedures 
Animal experiments were carried out at the Institute for Animal Health under project 
licence number PPL70/6212 as described under section 2.3.1. A total of 12 cattle, 2 
to 4 months of age, were used in the studies. In an initial experiment, eight cattle 
were allocated into 4 pairs, each of which received anti-CD4, anti-CD8, anti-WC1 or 
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an isotype-matched control MAb over a period of 3 days, starting the day before 
virus challenge. Doses of 3mg, 21.5mg and 21mg diluted in PBS (CSU, IAH) were 
administered intravenously to each calf on days -1, 0 (challenge day) and 1 
respectively, giving a total dose of approximately 0.76mg of antibody per kg body 
weight. In a second experiment, 4 cattle were divided into pairs that received either 
anti-CD4 or a control MAb over a 4 day period starting 2 days before challenge. The 
animals were given 20mg of MAb on day -2 and 45mg on each of the following 3 
days, giving a total dose of approximately 2.58mg of antibody per kg body weight. 
Cattle were challenged with FMDV by subepidermo-lingual injection of 0.2ml of 10
5
 
TCID50 into each of two sites with the cattle-adapted type O UKG 34/2001 strain of 
virus (section 2.3.1.1). Clinical observations were conducted daily and scored until 
resolution of disease. The right prescapular lymph node was removed from animals 
in the second experiment five days post-challenge, under sedation and local 
anaesthetic. Clotted blood and heparinised blood were collected at intervals 
throughout the study and at post-mortem on day 30 for animals in experiment 1 and 
on day 29 for animals in experiment 2. Mandibular lymph node and probang samples 
were collected at post-mortem. 
 
3.3.2. Clinical scoring system 
Clinical signs of FMD and rectal temperatures were scored as described in Table 6, 
using a modified subjective scoring system based on a method described previously 
(Quan et al., 2004). Cattle could score a maximum of 22 points, with the sum of the 
coronary band lesions divided by 2 to prevent the clinical score being dominated by 
foot lesions. 
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Table 6. Clinical scoring system. 
Clinical signs Clinical score * 
0 = none 
1 = elevated temperature/congestion or healing vesicle 
2 = vesicle 
Coronary band lesions ** 
  
  
  3 = severe lesion (up to detachment of heal or equivalent) 
0 = none 
1 = elevated temperature/congestion or healing vesicle 




  3 = severe lesion  
0 = none 
1 = elevated temperature/congestion or healing vesicle 
2 = vesicle 
Dental pad, oral cavity or muzzle 
(nose and mouth) lesions 
  
  3 = severe lesion  
0 = none 
1 = elevated temperature/congestion or healing vesicle 
2 = vesicle 
Teat or udder lesions *** 
  
  
  3 = severe lesion  
0 = none 
1 = lame 
Lameness 
  
  2 = recumbent 
0 = none 
1 = serous 




  3 = necrotic 
0 = temperature < 39.5
o
C 
1 = temperature ≥ 39.5
o









* Cattle could score a maximum of 22 points. 
** Coronary band lesions were scored for each foot. The sum of the coronary band 
lesion scores were divided by 2 to prevent the clinical scores being dominated by 
foot lesions. 
*** All experimental animals were male.  
 
3.3.3. Mouse monoclonal antibodies used for depletion 
The MAbs used for depletion, which are described in the proceedings of the First 
International Workshop on Bovine, Sheep, and Goat leukocyte Differentiation 
Antigens (Howard and Morrison, 1991), were CC8 (anti-CD4), IL-A11 (anti-CD4), 
CC63 (anti-CD8) and CC15 (anti-WC1). MAb TRT3 raised against turkey 
rhinotracheitis virus was administered to control animals (Cook et al., 1993). During 
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experiment 1, anti-CD4 treated animals received MAb CC8 only, whereas during 
experiment 2, anti-CD4 treated animals received a combination of CC8 and IL-A11. 
All MAbs were murine IgG2a, and all of the hybridomas were produced at the IAH, 
except IL-A11 which was provided by the International Livestock Research Institute, 
Nairobi. MiniPERM (Sigma-Aldrich, UK) hybridoma tissue culture supernatants, 
prepared with pre-absorbed serum, were kindly provided by B Jones, IAH.  HiTrap 
Protein G HP columns (Amersham Biosciences, UK) were used for purification and 
dialysis membrane bags (Medical International, UK) were used for dialysis in Ca/Mg 
free PBS (CSU, IAH) to desalt the eluate. An Ultraspec 2001 Pro spectrophotometer 
(Biochrom, UK) was used for protein quantification and Vivaspin 15R columns 
(Sartorius, UK) were used to concentrate the sample if required.  
  
3.3.4. Preparation of mononuclear cells from tissue and blood 
Mononuclear cells were prepared from samples of prescapular lymph nodes by 
slicing the tissue into small fragments which were gently teased apart using forceps 
and a needle in PBS (CSU, IAH) containing 5% (v/v) fetal calf serum (Autogen 
Bioclear, UK). The tissue fragments were then disrupted through sterile gauze with a 
syringe. Viable mononuclear cells were isolated from these lymph node suspensions 
and from heparinised peripheral blood by diluting them with an equal volume of PBS 
and underlaying them with 13ml Histopaque 1077 (Sigma-Aldrich, UK) before 
centrifugation at 1000×g for 30 minutes at 18
o
C with the centrifuge brake off. Cells 
at the interface were collected, washed three times by dilution in PBS and 
centrifugation at 250×g for 8 minutes at 8
o
C. Cells were counted on a 
haemocytometer (Assistant, Germany) and their viability assessed by trypan blue 
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staining (Sigma-Aldrich, UK). Cells were subsequently analysed by flow cytometry 
and additional aliquots were stored at −80
o
C in 10% (v/v) dimethylsulphoxide 
(Sigma-Aldrich, UK) in fetal calf serum. 
 
3.3.5. Flow cytometry 
Blood mononuclear cells (M Windsor and L Reid, IAH, kindly assisted with the 
analysis) were analysed by flow cytometry to evaluate the degree of lymphocyte 
depletion, using the following MAbs: CC30 (anti-CD4), CC58 (anti-CD8) and CC39 
(anti-WC1) (Howard and Morrison, 1991). MAb CC37 (anti-CD21) was used as a 
positive control and MAb TRT1, raised against turkey rhinotracheitis virus, as an 
isotype-matched negative control (Cook et al., 1993, Howard and Morrison, 1991). 
Lymph node mononuclear cells were analysed by L Reid (IAH) by flow cytometry 
using MAbs CC30 to evaluate the degree of CD4 depletion in combination with 
positive control MAb CC37 and negative control MAb TRT1. All MAbs were 
murine IgG1 produced at the IAH.  
 
Cell suspensions were stained with MAbs to detect surface proteins by flow 
cytometry as described under section 2.3.20.1. A minimum of 10000 viable cells 
were analysed in each sample, in addition, 100000 viable PBMC were analysed on 
day 1 in duplicate in experiment 1 and on days 0 and 4 in triplicate in experiment 2 
to assess CD4
+
 T-cell depletion.  
 
Preliminary studies, using blood and lymph node mononuclear cells from non-
infected animals, were undertaken to determine if the MAbs used for depletion 
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blocked the staining of MAbs of the respective specificities used for evaluating the 
degree of lymphocyte depletion. Mononuclear cells were prepared from samples of 
prescapular lymph nodes and heparinised blood as described under section 3.3.4. 
Approximately 3 × 10
5
 cells per well were placed into U bottom 96 microwell plates 
(Sigma-Aldrich, UK). The cells were pelleted by centrifugation at 250×g for 4 min at 
8
o
C and resuspended in complete RPMI media (CSU, IAH) containing 10% (v/v) 
fetal calf serum (Autogen Bioclear, UK). The cells were incubated with the MAbs 
used for depletion (section 3.3.3) for 1 hour or for 20 hours at 37
o
C. After the 
incubation period, cells were washed with FACS wash buffer (Appendix 1) and 
stained with the IgG1 MAbs, used for evaluating the degree of lymphocyte depletion, 
diluted in FACS wash buffer (section 2.3.20.1). Cells were subsequently washed 
twice before incubation with goat anti-mouse IgG2a and IgG1 specific secondary 
MAb (Alexa fluor, Molecular Probes, UK) for 15 minutes at room temperature in the 
dark for flow cytometry analysis (section 2.3.20.1). 
 
3.3.6. Immunofluorescence confocal microscopy 
Prescapular lymph node samples were snap frozen in cryomatrix (Sakura Finetek, 
NL) and stored at −80
o
C until processed. Ten approximately 7µm thick acetone fixed 
cryosections from different regions of the prescapular lymph nodes of each animal 
were labelled (section 2.3.17.1) with the following murine MAbs: CC30 (anti-CD4), 
MM1A (anti-CD3, IgG1), CC51 (anti-CD21, IgG2b) (Howard and Morrison, 1991) 
and isotype-matched control MAbs TRT1 and AV29 (a MAb directed against 
chicken CD4 antigen, IgG2b) (Kwong et al., 2002). Acetone fixed cryosections of 
mandibular lymph nodes were labelled with IB11, a murine MAb shown to be 
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specific for conformational, non-neutralising epitopes of the FMDV capsid (Juleff et 
al., 2008) in combination with CC51, a dark zone follicular dendritic cell marker 
D46 (anti-ovine fibrinogen, IgG2a) (Lefevre et al., 2007) and isotype-matched 
control MAbs TRT1, TRT3 (IgG2a) (Cook et al., 1993) and AV29 (Table 1). All 
MAbs used for confocal microscopy were produced at the IAH. Goat anti-mouse 
Molecular Probes Alexa-Fluor-conjugated secondary antibodies (Invitrogen, UK) 
were used for detection and as a control in the absence of primary antibody. Stack 
images were analysed to detect CD4
+
 T-cell depletion. All data were collected 
sequentially using a Leica SP2 scanning laser confocal microscope. 
 
Preliminary studies, on 7µm thick cryosections of prescapular lymph node harvested 
from non-infected animals, were undertaken to determine if the MAbs used for 
depletion blocked the staining of MAbs used for analysis. Specifically to determine if 
the reactivity of MAb CC30 used to evaluate the degree of CD4
+
 depletion in  
experiment 2, was blocked by the MAbs CC8 and IL-A11 used for depletion. 
Immunofluorescence labelling was performed as described under section 2.3.17.1. 
Sections were incubated with the MAbs used for depletion for 30 minutes at room 
temperature. Slides were washed 5 times with Ca/Mg free PBS (CSU, IAH) and 
incubated with the MAbs used for detection for 30 minutes at room temperature. 
Slides were washed 5 times in Ca/Mg free PBS and incubated with the secondary 
goat anti-mouse IgG2a and IgG1 secondary antibodies (Alexa fluor, Molecular 
Probes, UK) at a working dilution of 1:500 for 20 minutes in the dark, washed and 
mounted as described under section 2.3.17.1.   
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3.3.7. Quantitative real-time reverse transcription-polymerase chain reaction 
Total nucleic acid was extracted from serum and probang samples using a MagNA 
Pure LC Total Nucleic Acid Isolation Kit (Roche, UK) and MagNA Pure LC robot 
(Roche, UK) (Shaw et al., 2007, Shaw et al., 2004). Two hundred µL of sample was 
added to 300µL of Lysis/Binding Buffer (Roche, UK). The lysate was mixed by 
pipetting and transferred to a sample cartridge in the MagNA Pure LC robot. 
Genomic DNA was removed by DNase 1 treatment (Roche, UK) and purified RNA 
eluted with 50µL Roche Elution Buffer. A quantitative rRT-PCR method specific for 
FMDV O UKG 34/2001 was used to quantify the FMDV genome copies in serum 
and in probang samples as described under section 2.3.10. Fifty PCR cycles were 
carried out and samples that did not have a detectable signal above threshold after 50 
cycles were taken to be negative (Quan et al., 2004). Samples with threshold cycle 
values greater or equal to 39 were designated „borderline‟ and were subsequently 
retested to confirm their positive/negative status (Reid et al., 2003).  
 
3.3.8. Virus isolation and antigen detection ELISA 
The presence of virus in serum and in probang samples was determined by 
inoculation of monolayers of primary BTY cells (Snowdon, 1966) with 200µL of 
sample and examination for cytopathic effect 24, 48 and 72 hours post-inoculation as 
described under section 2.3.21.4. An ELISA, kindly performed by G Hutchings 
(IAH) was used to confirm the presence of FMDV (Ferris and Dawson, 1988). 
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3.3.9. Virus neutralising antibody test 
Serum samples were examined for anti-FMDV neutralising antibodies as described 
in the Office International des Epizooties (OIE) Manual of Diagnostic Tests and 
Vaccines for Terrestrial Animals, 5th edition, 2004 (Golding et al., 1976). The tests 
were performed under the guidance of P Hamblin, IAH. Serum was inactivated at 
56
o
C for 1 hour before testing. Starting from a ¼ dilution, sera were diluted in serum 
free medium in a two-fold, dilution series across flat-bottomed Nunc TC microwell 
96 FSI plates (Fisher Scientific, UK) in duplicate wells at a volume of 50µL. Fifty 
µL of titrated O UKG virus stock provided by P Hamblin, IAH (containing 
approximately 1 × 10
2
 TCID50 as titrated on a virus control plate) was added to each 
well and plates were incubated at 37
o
C for 1 hour. A cell suspension at 1 × 10
6 
IB-
RS-2 cells per mL was made up in medium containing 10% (v/v) fetal calf serum 
(Autogen Bioclear, UK). Fifty µL of the cell suspension (0.5 × 10
5
 cells) was added 
to each well. Duplicate wells containing cells with negative serum (kindly provided 
by P Hamblin, IAH), serum free medium (also used for diluting the virus stock) and 
medium were included on the plates as cell controls. Reference serum control plates 
containing standard 21-day convalescent serum (kindly provided by P Hamblin, 
IAH) were run in parallel with test plates. The plates were incubated at 37
o
C with 
readings taken at 24, 48 and 72 hours for cytopathic effect. After 72 hours the plates 
were stained with 0.4% (w/v) naphthalene black (Searle Diagnostics, UK) in PBS 
(CSU, IAH) containing 8% (w/v) citric acid crystals (Sigma-Aldrich, UK). Positive 
wells (where the virus has been neutralised and the cells remain intact) were seen to 
contain blue-stained cell sheets, negative wells were empty. Titres were expressed as 
the final dilution of serum present in the serum/virus mixture where 50% of wells 
 210 
were protected (Karber, 1931). The tests were considered valid when the cell sheets 
in the cells controls were intact and the reference serum was within twofold of its 
expected titre. Sera with titres greater than or equal to 1/45 were considered positive 
(Golding et al., 1976).     
 
3.3.10. 3ABC non-structural protein ELISA 
Serum samples were examined for the presence of antibodies directed against the 
non-structural 3ABC protein of FMDV, using the commercially available Ceditest 
FMDV-NS blocking ELISA (Cedi-Diagnostic, NL). The test was performed with 
negative, weak positive and positive controls supplied with the kit in duplicate and 
the test serum samples were analysed in triplicate. The OD was read at 450nm on a 
MRX Dynex Technologies reader (Dynex, UK). Samples were considered positive if 
the percentage inhibition was ≥ 50 (Sorensen et al., 1998). 
 
3.3.11. Isotype-specific ELISA for the detection of anti-FMDV antibodies 
An anti-FMDV sandwich ELISA was used to measure specific IgG1, IgG2 and IgM 
in serum samples (Mulcahy et al., 1990). The test samples were analysed with M 
Windsor, IAH. Ninety-six-well Maxisorb Nunc Immunoplates (Sigma-Aldrich, UK) 
were coated overnight at 2 to 8
o
C with a 50µL solution of rabbit anti-FMDV 
serotype-specific hyperimmune antiserum (kindly provided by N Ferris, IAH) diluted 
1:5000 in 0.1M carbonate/bicarbonate buffer (CSU, IAH). Coated plates were 
washed 4 times in 0.05% (v/v) Tween-20 (Sigma-Aldrich, UK) in PBS (CSU, IAH) 
then incubated with 50µL of pre-titrated inactivated O1 Manisa FMDV whole viral 
antigen in excess (kindly provided by N Ferris, IAH). This step and all subsequent 
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incubation steps were carried out at 37
o
C for 1 hour. Plates were washed and blocked 
with a 1mg/mL solution of sodium casein (Sigma-Aldrich, UK) in PBS. Test serum 
and antibodies were diluted in the sodium casein solution. Plates were washed and 
50µL of duplicate threefold dilution series of each serum sample were added at a 
starting dilution of 1/50. Antibody isotypes were detected with 50µL of a 1/500 
dilution of MAbs to bovine IgG1 (B37), IgG2 (B192) and IgM (B67) obtained from 
the Department of Veterinary Medicine, Bristol University. This was followed by 
incubation with 50µL of a 1/1000 dilution of horseradish peroxidase-conjugated 
rabbit anti-mouse IgG (DakoCytomation, UK). After a final wash, plates were 
incubated at room temperature with 50µL of OPD substrate (Sigma, UK) diluted in 
H2O (CSU, IAH). The reaction was stopped with 50µL of a 1.84M solution of 
sulphuric acid (Sigma-Aldrich, UK). To avoid competition between IgM and IgG, all 
samples destined for anti-IgM analysis were first absorbed on plates coated with goat 
anti-bovine IgG (1mg/ml, Southern Biotech, UK) then transferred to the viral antigen 
coated plates. The OD was read at 492nm on a MRX Dynex Technologies reader 
(Dynex, UK). Wells were only considered positive if they were greater than 1.5 
times the mean background OD for that dilution. Antibody titres were expressed as 
the reciprocal of the last positive dilution. 
 
3.3.12. Indirect peptide ELISA 
Serum samples from animals in both experiments receiving anti-CD4 or TRT3 MAbs 
were examined for the presence of antibodies directed against the VP1135-156 G-H 
loop on the surface of FMDV capsids (M Windsor, IAH, kindly assisted with the 
analysis). A peptide encompassing amino acid residues 135 to 156 of FMDV O UKG 
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34/2001 (KYGESPVTNVRGDLQVLAQKAA) was kindly produced by L Hunt, 
IAH. A second peptide, kindly provided by V Fowler, IAH, encompassing the same 
residues of FMDV O1BFS (RYSRNAVPNLRGDLQVLAQKVA) was used for 
analysis to confirm that our results were consistent with previously published data 
(Fowler et al., 2008). The indirect peptide ELISA was performed as previously 
described (Fowler et al., 2008) with modifications. Ninety-six-well Maxisorb Nunc 
Immunoplates (Sigma-Aldrich, UK) were coated overnight at 4
o
C with 100μL/well 
peptide (at a concentration of 4µg/mL for O UKG peptide and 2µg/mL for O1BFS 
peptide) (Fowler et al., 2008) in PBS (CSU, IAH), washed 4 times in 0.05% (v/v) 
Tween-20 (Sigma-Aldrich, UK) in PBS and blocked with PBS containing sodium 
casein (Sigma-Aldrich, UK) at 1mg/mL. This step and all subsequent incubation 
steps were carried out at 37
o
C for 1 hour. Sera were added in duplicate at 50μL per 
well starting at 1/50 with tripling dilutions in PBS sodium casein, incubated, washed 
and detected with horseradish peroxidase-conjugated goat anti-bovine IgG (Southern 
Biotech, UK). Plates were washed and visualised with OPD substrate (Sigma-
Aldrich, UK) diluted in H2O (CSU, IAH). Reactions were stopped with 1.84M 
sulphuric acid (Sigma-Aldrich, UK) and absorbance read at 490nm on a MRX Dynex 
Technologies reader (Dynex, UK). Wells were only considered positive if they were 
greater than 1.5 times the mean background OD for that dilution. Antibody titres 
were expressed as the reciprocal of the last positive dilution. 
 
3.3.13. Statistical analysis 
Statistical analysis was performed under the guidance of S Gubbins, IAH. To 
investigate the effect of immune cell depletion on the titres of FMDV-specific 
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antibody measured by the Ig isotype-specific ELISA, a Gompertz function was used 
to describe the antibody titre, Y, as a function of time, 
10log ( ) exp( exp( ( ))),Y t  
Where κ is the upper asymptote (i.e. maximum titre), β is the rate of increase in titre 
and δ is the delay parameter. The parameters (κ, β and δ) were estimated using the 
least-squares regression. Parallel curve analysis (Ross, 1990) of the data from 
individual animals was used to identify significant (p<0.05) differences in the 
parameters amongst treatment groups (i.e. TRT3, anti-WC1, anti-CD4 and anti-CD8 
groups), starting from a model in which all parameters differed amongst animals. 
The analysis was performed using MATLAB (MathWorks, USA). The non-
parametric Kruskal-Wallis test (Kruskal and Wallis, 1952) was used to test the 
hypothesis that the different treatment groups had the same distribution of onset of 
virus neutralising antibody titres post-infection. The analysis was performed using 
the R Project for Statistical Computing. The ANOVA general linear model 
(Lindman, 1974) was used to determine if there was a statistically significant 
association between the peak level of viraemia measured by quantitative rRT-PCR, 
expressed as genome copies per mL serum, and the treatment group (i.e. TRT3, anti-
WC1, anti-CD4 and anti-CD8 groups). Minitab software (Minitab Limited, UK) was 




3.4.1. Efficiency of T cell subset depletion 
In preparation for the in vivo T-cell depletion studies, the potential cross reactivity 
between the MAbs used for depletion and those used for detection was investigated.  
Flow cytometry (Figure 46) and immunofluorescence confocal microscopy (Figure 
47 and Figure 48) studies, using blood and lymph node mononuclear cells and 
prescapular lymph node cryosections from non-infected animals confirmed that the 
MAbs used for depletion did not block the staining of MAbs of the respective 
specificities used for evaluating the degree of lymphocyte depletion. 
 
Administration of anti-CD4 MAbs resulted in a rapid reduction in the percentage of 
circulating CD4
+
 cells within 24 hours, from 11% and 10.8% to 0.15% and 0.17% 
respectively for the 2 animals (RZ53 and RZ54) in experiment 1, and from 18.4% 
and 26% to 0.02% and 0.17% for the 2 animals (VT74 and VT75) in experiment 2. 
This depletion was confirmed by analysis of 100000 viable cells in duplicate, 
collected from experiment 1 animals on day 1 post-infection (RZ53 = 0.04 and 
0.05% CD4
+
 cells and RZ54 = 0.04 and 0.04% CD4
+
 cells) and in triplicate for 
experiment 2 animals on days 0 and 4 post-infection (Day 0: VT74 = 0.05% [±0.02] 
and VT75 = 0.04% [±0.01] CD4
+
 cells. Day 4: VT74 = 0.06% [±0.01] and VT75 = 
0.03% [±0.01] CD4
+
 cells. Values expressed as mean [± standard deviation]). 
Depletion was maintained for 7 days post-infection with percentages of CD4
+
 cells 
consistently below or equal to background nonspecific binding detected with the 
isotype control MAbs, after which the numbers of CD4
+
 cells gradually increased 
(Figure 49, Table 1). A similar level and duration of depletion was observed 
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following treatment with anti-WC1 MAb, the numbers of circulating WC1
+
 cells in 
the two animals (RZ51 and RZ52) in experiment 1 decreased from 11.7% and 22.3% 
on day −1 to 0.06% and 0.06% on day 0 respectively and maintained at these low 
levels until day 7 (Figure 49, Table 7). In contrast, treatment with anti-CD8
+
 MAb 
resulted in more gradual and only partial depletion; the numbers of circulating CD8
+
 
cells in the two treated animals (RZ55 and RZ56) decreased from 4.0% and 9.4% on 
day -1, to 3.1% and 5.7% on day 0, and to 1.3% and 4% on day 7 respectively 
(Figure 49, Table 1). During acute infection in the anti-CD4, anti-WC1 and anti-CD8 
MAb treated animals, there were no major changes in the proportion of the T-cell 
subsets not targeted for depletion or CD21
+
 B cells, consistent with the specificity of 
these MAbs (Figure 50 and Figure 51) (Howard and Morrison, 1991). In addition, 
there were no major changes in the proportions of the T-cell subsets (or CD21
+
 B 
cells) in animals receiving the control antibody during acute infection, although some 
fluctuation in the percentage representation of each subset was observed during the 
course of the studies (Table 1, Figure 49 and Figure 52). 
 
Immunohistological examination of prescapular lymph nodes surgically removed 
from experiment 2 animals on day 5 post-infection, demonstrated the absence of 
CD4
+
 cells throughout the node (although CD3
+
 cells were still readily detectable), 
including the cortex and follicles, paracortical area, and the medullary cords and 
sinuses of both anti-CD4 MAb treated animals (Figure 53 to Figure 55). These 
analyses used both 10 separate sections and stacking of images from the confocal 
microscopy examinations, to confirm that the CD4
+
 cell depletion was indeed 
throughout the node. These findings were supported by flow cytometry analysis of 
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lymph node cell suspensions (kindly performed by L Reid, IAH), in which the 
percentages of CD4
+
 T cells were comparable to that detected with the isotype 
























Figure 46. The MAbs used for depletion did not block the staining activity of MAbs of the 
respective specificities used for evaluating the degree of lymphocyte depletion by flow 
cytometry.  
(a) to (c) Prescapular lymph node and (d) to (h), PBMC from a non-infected control 
animal evaluated by flow cytometry. The cells were incubated with the IgG2a MAbs 
used for depletion (section 3.3.3) for 20 hours at 37
o
C followed by staining with the 
IgG1 MAbs used to evaluate the degree of lymphocyte depletion (section 3.3.5). (a) 
and (d) Cells were gated on their forward scatter (FSC) and side scatter profiles 
(SSC), % represent the number of positive cells within the gate. (b) and (e) 
Background staining detected with isotype control MAbs TRT3 (IgG2a) and TRT1 
(IgG1). (c) and (f) Anti-CD4 MAbs CC8 and IL-A11 (depletion MAbs) and CC30 
(detection MAb). (g) Anti-CD8 MAbs CC63 (depletion MAb) and CC58 (detection 
MAb). (h) Anti-WC1 MAbs CC15 (depletion MAb) and CC39 (detection MAb). The 
MAbs used for depletion did not block the staining of MAbs of the respective 
specificities used for evaluating the degree of lymphocyte depletion after a 20 hour 
incubation period (these results were corroborated by flow cytometry analysis 








Figure 47. The anti-CD4 MAbs used for depletion did not block the staining activity of the anti-
CD4 MAb used to evaluate the degree of lymphocyte depletion.  
(a) to (f) Cryosections of the T cell zone of a prescapular lymph node harvested from 
a non-infected control animal. The cryosections were incubated with the anti-CD4 
MAbs [(a) CC8 or (d) CC8 and IL-A11 (red)] used for depletion for 30 minutes 
followed by washing and incubation with the anti-CD4 MAb [(b) and (e) CC30 
(green)] used for detection. (c) Merge image of (a) and (b). (f) Merge image of (d) 
and (e). Nuclei stained blue in merge images (DAPI), scale bars represent 40µm.  
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Figure 48. The anti-WC1 and anti-CD8 MAbs used for depletion did not block the staining 
activity of the MAbs of the respective specificities used for evaluating the degree of lymphocyte 
depletion.  
(a) to (f) Cryosections of the cortex of a prescapular lymph node harvested from a 
non-infected control animal. The cryosections were incubated with the MAbs used 
for depletion [(a) anti-WC1 MAb CC15 or (d) anti-CD8 MAb CC63 (red)] for 30 
minutes followed by washing and incubation with the MAbs used to evaluate 
depletion [(b) anti-WC1 MAb CC39 or (e) anti-CD8 MAb CC58 (green)]. (c) Merge 
image of (a) and (b). (f) Merge image of (d) and (e).  Nuclei stained blue in merge 

























 cells in peripheral blood*  
Experiment 1. Days post-intradermolingual challenge. 
-1 0 4 7 9 13 
RZ53 CD4 11.0 0.2 0.0 0.3 4.6 12.6 
RZ54 CD4 10.8 0.2 0.1 0.0 4.7 10.6 
RZ57 Control 15.7 16.2 9.0 13.1 14.9 20.3 








 cells in peripheral blood* 
Experiment 1. Days post-intradermolingual challenge. 
-1 0 4 7 9 13 
RZ51 WC1 11.7 0.1 0.1 0.2 0.9 1.2 
RZ52 WC1 22.3 0.1 0.0 0.4 1.7 2.3 
RZ57 Control 9.0 7.1 6.0 9.7 8.4 5.9 








 cells in peripheral blood* 
Experiment 1. Days post-intradermolingual challenge. 
-1 0 7 9 13 
RZ55 CD8 4.0 3.1 1.3 2.0 2.2 
RZ56 CD8 9.4 5.7 3.7 2.7 3.9 
RZ57 Control 7.4 6.4 8.1 6.4 6.9 








 cells in peripheral blood* 
Experiment 2. Days post-intradermolingual challenge. 
-2 -1 0 1 3 4 5 6 7 9 13 
VT74 CD4 18.4 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 4.0 
VT75 CD4 26.0 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.4 1.5 5.4 
VT76 Control 20.0 17.7 19.1 10.7 17.3 15.0 19.8 20.2 18.8 21.8 16.6 
VT77 Control 28.4 22.0 22.7 17.1 24.1 21.4 15.9 30.8 21.0 34.3 32.9 
*  A minimum of 10000 viable cells were analysed in each sample by flow 
cytometry, in addition, 100000 viable PBMC were analysed on day 1 in duplicate in 
experiment 1 and on days 0 and 4 in triplicate in experiment 2 to assess CD4
+
 T-cell 
depletion (see section 3.4.1). Percentages have been decreased to one decimal place. 
MAbs (anti-CD4 MAb CC8, anti-WC1 MAb CC15, anti-CD8 MAb CC63, control 
anti-turkey rhinotracheitis MAb TRT3) were administered to experiment 1 animals 
over three days starting the day before FMDV challenge. MAbs (anti-CD4 MAbs 
CC8 and IL-A11, control anti-turkey rhinotracheitis MAb TRT3) were administered 




Figure 49. Effect of MAb administration on the percentage of T lymphocyte subpopulations in 
peripheral blood measured by flow cytometry. 
(a) to (c) Experiment 1 animals, MAbs were administered over three days starting the 
day before FMDV challenge. (a) Percentage CD4
+
 cells in anti-CD4 MAb treated 
animals (RZ53 and RZ54) and a control animal (RZ57). (b) Percentage WC1
+
 cells 
in anti-WC1 MAb treated animals (RZ51, RZ52) and a control animal (RZ57). (c) 
Percentage CD8
+
 cells in anti-CD8 MAb treated animals (RZ55, RZ56) and a control 
animal (RZ57). (d) Experiment 2 animals. Percentage CD4
+
 cells in anti-CD4 MAb 
treated animals (VT74, VT75) and a control animal (VT77). MAbs were 




Figure 50. Effect of anti-CD4 MAb administration on the percentage of T lymphocyte 
subpopulation in the peripheral blood not targeted for depletion, measured by flow cytometry.   
(a) to (b) Experiment 1 animals, MAbs were administered over three days starting 
the day before FMDV challenge. (c) and (d) Experiment 2 animals, Mabs were 
administered over four days starting two days before FMDV challenge. ♦ = WC1+ 
cells, = CD8
+
 cells and × = CD21+ cells. Administering anti-CD4 MAbs did not 




Figure 51. Effect of anti-WC1 and anti-CD8 MAb administration on the percentage of T 
lymphocyte subpopulation in the peripheral blood not targeted for depletion, measured by flow 
cytometry.   
(a) to (d) Experiment 1 animals, MAbs were administered over three days starting 
the day before FMDV challenge (RZ51 and RZ52, anti-WC1 MAb. RZ55 and RZ56, 
anti-CD8 MAb). ♦ = WC1+ cells, □ = CD4+ cells, = CD8+ cells and × = CD21+ 
cells. Administering anti-WC1 or anti-CD8 MAbs did not result in non-specific 
depletion of other cell types. 
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Figure 52. Effect of TRT3 MAb administration on the percentage of T lymphocyte 
subpopulation in the peripheral blood not targeted for depletion, measured by flow cytometry. 
a) to (b) Experiment 1 animals, MAbs were administered over three days starting the 
day before FMDV challenge. (c) and (d) Experiment 2 animals, Mabs were 
administered over four days starting two days before FMDV challenge. ♦ = WC1+ 
cells, □ = CD4+ cells, = CD8+ cells and × = CD21+ cells. Administering MAb 
TRT3 did not result in non-specific depletion. In addition, there were no major 
changes in the proportions of the lymphocyte subsets during acute infection, 
although some fluctuation in the percentage representation of each subset was 
observed during the course of the studies. 





Figure 53. Effect of anti-CD4 MAb injection on the target cell population in lymphoid tissue.  
(a) to (d) Immunofluorescence confocal microscopy images of prescapular lymph 
node cortices from experiment 2: anti-CD4 MAb (VT74, VT75), and TRT3 control 
MAb (VT76, VT77) injected animals biopsied at 5 days post-infection. CD4
+
 
lymphocytes stained green (MAb CC30), CD21
+
 cells stained red (MAb CC51). 





 T cells were readily detectable in cryosections of prescapular lymph nodes 
biopsied at 5 days post-intradermolingual challenge.  
(a) to (d) Immunofluorescence confocal microscopy images of prescapular lymph 
node cortices from experiment 2: anti-CD4 MAb CC8 and IL-A11 (VT74, VT75), 
and TRT3 control MAb (VT76, VT77. Anti-turkey rhinotracheitis virus) injected 
animals. CD3
+
 lymphocytes stained green (anti-CD3 MAb MM1A), CD21
+
 cells 
stained red (anti-CD21 MAb CC51). Scale bars represent 40µm. 
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Figure 55. The anti-CD4 MAbs used for depletion could not be detected in the prescapular 
lymph node cryosections harvested at 5 days post-intradermolingual challenge.  
Cryosections harvested at 5 days post-intradermolingual challenge from experiment 
2: CC8 and IL-A11 (anti-CD4 MAbs, IgG2a isotype) treated animals VT74 (a) to (c), 
and VT75 (d) to (f). (a) and (d) Autofluorescence (green) associated with bovine 
lymph nodes. (b) and (e) No signal above background detected with anti-IgG2a 
secondary MAb (red). (c) Merge image of (a) and (b). (f) Merge image of (d) and (e). 











3.4.2. Effect of lymphocyte depletion on development of clinical FMD 
The clinical scores for all animals following FMDV infection, representing a 
measure of the induction, severity and resolution of clinical signs, are displayed in 
Figure 56. All cattle succumbed to disease within 1 to 3 days post-challenge. T-cell 
depletion had no adverse effect on the onset, magnitude or resolution of clinical signs 
following infection. Milder clinical scores were recorded for one of the CD4 depleted 
animals (RZ53), however, it is unlikely that this observation is significant 
considering the spectrum of clinical signs seen after FMDV challenge (Alexandersen 





Figure 56. Effect of lymphocyte depletion on development of clinical FMD.  
The clinical scores, consisting of rectal temperature and clinical signs of FMD (Table 
6), are displayed for experiment 1 animals (a) and experiment 2 animals (b). The data 
related to the anti-CD4 MAb treated animals are highlighted in blue. T-cell depletion 






3.4.3. Effect of lymphocyte depletion on viral clearance 
All animals were confirmed viraemic 24 hours post-infection by virus isolation and 
quantitative rRT-PCR. The results of daily quantitative measures of viral genome in 
serum determined by rRT-PCR are presented in Figure 57. High levels of viral 
genome were detected in serum collected on days 1, 2 and 3 in all groups of animals 
and subsequently declined in all groups. Viral genome was no longer detectable in all 
except two animals, one control and one CD8
+
 T-cell-depleted animal, by day 7 after 
infection. No serum samples were collected on day 8, but samples from the two 
remaining positive animals were negative for viral genome on day 9. There was no 
significant difference in the peak level of viraemia, as measured by rRT-PCR, 
between any of the different MAb-treated groups (P = 0.297, ANOVA. General 
linear model). By inspection, one cannot rule out a minor influence of WC1
+
 cell 
depletion on the duration of viraemia as measured by rRT-PCR (Figure 57), although 
it was not possible to assess the significance of this observation due to the small 
group size. Live virus was isolated from serum samples of animals treated with anti-
CD4 and anti-CD8 MAb up to 4 days post-infection, and from animals treated with 
anti-WC1 and control MAb up to 3 days post-infection. No live virus or viral 
genome was detected in probang samples at post-mortem by virus isolation and rRT-
PCR. FMDV capsid protein was detected by immunofluorescence confocal 
microscopy in germinal centres of mandibular lymph nodes harvested from all 
animals at post-mortem (day 30 for animals in experiment 1 and on day 29 for 
animals in experiment 2) with data from the anti-CD4 MAb treated animals 




Figure 57. Effect of lymphocyte depletion on viraemia.  
Viral genome was detected by rRT-PCR in serum samples collected from day 0 to 7 
and day 9 post-infection. Genome copies per mL serum are displayed in panel (a) for 
anti-CD4 MAb treated and (b) TRT3 control MAb treated animals from both 
experiments, (c) anti-WC1 MAb treated and (d) anti-CD8 MAb treated animals from 





Figure 58.  FMDV capsid detected in the light zone of mandibular lymph node germinal centres 
at post-mortem.  
(a) to (d) Mandibular lymph node cryosections harvested at post-mortem from anti-
CD4 MAb treated animals on day 30 for experiment 1 (RZ53, RZ54. Anti-CD4 MAb 
CC8) and on day 29 for experiment 2 (VT74, VT75. Anti-CD4 MAbs CC8 and IL-
A11). Panels are merge images of fibrinogen, associated with dark zone FDCs, 
stained red with MAb D46, FMDV capsid stained green with MAb IB11 and nuclei 
stained blue (DAPI). Scale bars represent 50µm.  
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Figure 59. No signal detected in the light zone of control mandibular lymph node germinal 
centre cryosections. 
(a) Mandibular lymph node cryosection harvested at post-mortem on day 29 from 
experiment 2, anti-CD4 MAb (anti-CD4 MAbs CC8 and IL-A11) treated animal 
VT74. Fibrinogen, associated with dark zone FDCs, stained red with MAb D46. No 
signal could be detected with isotype control MAb TRT1 (anti-turkey rhinotracheitis 
virus) stained green. (b) Mandibular lymph node from a non-infected control animal. 
Fibrinogen stained red (anti-fibrinogen MAb D46). No signal detected with anti-















3.4.4. Effect of lymphocyte depletion on virus neutralising antibody 
The results of virus neutralising antibody assays of serum samples are displayed in 
Figure 60. Titres of ≥ 45 (considered positive) were attained by 5 days post-infection 
in all 4 control animals, by 4 to 7 days in the animals treated with anti-CD4 MAb and 
by 5 to 6 days in the animals treated with the anti-WC1 and anti-CD8 MAb. There 
were no obvious differences in the onset of detectable neutralising antibody in the 
calves receiving the different antibody treatments. In particular, the onset of 
detectable neutralising antibody titres post-infection was not significantly different in 
the calves treated with anti-CD4 antibody and control antibody (P = 0.11,  
Kruskal-Wallis test). The complete data set of virus neutralising antibody titres can 








Figure 60. Effect of lymphocyte depletion on virus neutralising antibody.  
Virus neutralising antibody titres are displayed in panel (a) for anti-CD4 MAb 
treated and (b) TRT3 control MAb treated animals from both experiments, (c) anti-
WC1 MAb treated and (d) anti-CD8 MAb treated animals from experiment 1. A titre 












Table 8. Virus neutralising antibody titres of experiment 1 (RZ51 to RZ58) and experiment 2 
(VT74 to VT77) animals. 
 
RZ57 RZ58 VT76 VT77 RZ53 RZ54 VT74 VT75 RZ51 RZ52 RZ55 RZ56
0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0 0 0 0
4 0 32 0 0 0 16 0 45 22 32 16 22
5 64 64 64 90 16 45 22 64 64 32 45 32
6 90 64 128 128 32 45 64 178 90 90 90 64
7 90 64 128 128 90 90 90 128 90 90 90 45
9 256 64 256 178 64 64 128 90 45 64 90 128
13 256 178 128 355 64 178 90 178 128 178 128 178
16 355 178 355 1024 90 178 512 1024 256 512 256 256
21 355 355 708 708 90 355 512 1024 256 355 512 256
23 512 512 708 1024 178 708 512 708 256 512 512 512
27 512 355 708 1024 178 355 708 708 512 256 178 355




















3.4.5. Effect of lymphocyte depletion on the antibody response to FMDV non-
structural proteins 
Serum samples collected at 3to 6 day intervals, from days 0 to day 29 (experiment 2) 
or 30 (experiment 1) post-infection, were analysed for the presence of antibodies 
against the FMDV non-structural protein 3ABC. The kinetics of the antibody 
response to 3ABC in animals receiving anti-CD8 or anti-WC1 MAb were similar to 
that of the control animals, with antibody initially detected on days 6 to 16 and 
maximum titres were detected on day 29 or 30. In contrast, three out of the four anti-
CD4 MAb treated animals had no detectable antibodies against 3ABC throughout the 
29 to 30 days and the fourth animal (VT75) remained negative until day 29. Titres of 
anti-3ABC antibodies in serum samples obtained at the time of post-mortem (days 29 
or 30) are shown in Figure 61. These results indicate that depletion of CD4
+ 
T cells 
during the phase of acute FMDV replication ablates the antibody response to non-










Figure 61. Effect of lymphocyte depletion on the response to FMDV non-structural protein 
3ABC.  
By day 29/30 post-infection, three anti-CD4 MAb treated animals had no detectable 
antibody response to the FMDV non-structural protein 3ABC. Samples were 
considered positive if the percentage inhibition was ≥ 50 (Sorensen et al., 1998). 
Control: TRT3 MAb treated animals from both experiments. CD4: anti-CD4 MAb 
treated animals from both experiments. VT75: an experiment 2 higher antibody dose 















3.4.6. Effect of lymphocyte depletion on the isotype of FMDV-specific antibody 
responses 
Serum samples collected daily during the first 7 days of infection and at 2 to 5 day 
intervals up to day 29 (experiment 2) or 30 (experiment 1) post-infection were 
analysed using an ELISA with reagents specific for bovine IgM, IgG1 and IgG2, to 
determine the kinetics of the various isotypes generated by the FMDV-specific 
antibody response. Comparison of the kinetics of antibody titres over time by parallel 
curve analysis (see section 3.3.13) did not reveal any statistically significant 
differences between the responses of animals in MAb-treated groups and those in the 
control MAb-treated groups (P values of 0.44, 0.43 and 0.61 for IgM, IgG1 and IgG2 
respectively). Examples of the profiles of the FMDV-specific antibody responses of 
the 3 anti-CD4 MAb treated animals with no detectable antibody response to FMDV 
3ABC and a control animal are displayed in Figure 62. IgG antibody isotypes were 
detected 5 to 7 days after infection indicating rapid isotype switching in all animals. 
Indeed, in some cases specific IgG2 antibodies were detected earlier than IgM 
antibodies. Antibody isotype class switching occurred during the phase of CD4
+
 T-





Figure 62. Effect of lymphocyte depletion on the isotype of FMDV-specific antibody responses.  
Examples of the FMDV-specific antibody isotype profiles are displayed in panel (a) 
and (b), for experiment 1 and (c), for experiment 2 anti-CD4 MAb treated animals 
with no detectable antibody response to FMDV 3ABC. (d) TRT3 control MAb 
treated animal from experiment 2. IgG1 = , IgG2 = □, IgM = ♦. Efficient antibody 
isotype class switching occurred during the period of CD4
+













3.4.7. Effect of lymphocyte depletion on the antibody response to G-H loop 
peptides 
Serum samples from animals receiving anti-CD4 MAbs and those receiving the 
control MAbs in both experiments were examined using an indirect ELISA for the 
presence of IgG antibodies to O UKG 34/2001 and O1BFS VP1135-156 peptide, which 
represent a superficial loop exposed on the surface of the viral capsid. No antibodies 
directed against the peptides were detected pre-challenge. Titres of antibody specific 
for the peptides detected prior to the re-appearance of circulating CD4
+
 T cells 
following depletion (day 7 post-infection for experiment 1, day 9 for experiment 2 - 
Figure 49), and following CD4
+
 T cell repopulation (day 16) are displayed in Figure 
63. By the end of the period of CD4
+
 cell depletion, the 4 infected control animals all 
showed detectable antibody responses to the O UKG G-H loop peptide at day 7 
(experiment 1) or day 9 (experiment 2). In contrast, antibody was undetectable in two 
of the CD4 T-cell-depleted animals and present at a very low titre in the other 2 
depleted animals at these time points. By day 16, the titre of antibody in 3 of the 
depleted animals was still less than in the controls (however, due to the small 
numbers of animals it was not possible to determine if the difference was statistically 
significant). These findings were corroborated by the data for the O1BFS peptide 






Figure 63. Effect of lymphocyte depletion on the antibody response to G-H loop peptides.   
No antibodies directed against the peptides were detected pre-challenge. (a) the IgG 
antibody response of experiment 1, CD4 depleted animals to FMDV O UKG 
34/2001 VP1135-156 G-H loop peptide was absent or substantially less than that of the 
control animals by day 7 post-infection. By day 16, a stage when CD4 cells were 
repopulating, the levels of antibody in the CD4 depleted animals were less than or 
equal to that of the controls. (b) The antibody response of experiment 2 CD4 
depleted animals was similarly absent or substantially less than that of the control 
animals by day 9 post-infection. Although CD4 cells were repopulating by day 16 
post-infection, the response of the experiment 2, CD4 depleted animals was still 
substantially less than that of the controls. (c) and (d) These findings were 
corroborated by the data for the O1BFS peptide performed using 2µg/mL peptide as 
previously described (Fowler et al., 2008). These results indicate that the antibody 
response to the G-H loop was inhibited by CD4
+





These data confirm that depletion of CD4
+
 lymphocytes from the blood circulation 
and superficial lymph nodes can be achieved in cattle by administering sufficient 
quantities of specific mouse MAbs. The application of different CD4 depletion 
protocols in calves during the early stages of infection with FMDV was found to 
result in similar, substantial ablation of IgG antibody responses to non-structural 
viral proteins but had little impact on the antibody responses to sites on the surface of 
the virus particles that induce neutralising antibodies. Depletion of CD4 T cells also 
had no significant effect on the course of viraemia or the clinical severity of disease 
associated with FMDV infection. Milder clinical scores were recorded for one of the 
CD4 depleted animals (RZ53), however, it is unlikely that this observation is 
significant considering the spectrum of clinical signs seen after FMDV challenge 
(Alexandersen et al., 2003b). There was no CD4 T-cell depletion in control animals 
following FMDV infection which contrasts with the significant lymphopenia 
reported in swine following FMDV infection (Bautista et al., 2003). 
 
Although administration of anti-WC1 antibody was also found to result in profound 
depletion of circulating WC1
+ 
γδ T cells, such depletion did not have any measurable 
effect on the course of infection with FMDV or specific antibody responses to the 
virus. The role of these cells in protection against infectious agents in ruminants is 
unclear. Epithelial tissue contains large numbers of γδ T cells (Howard et al., 1989) 
and these cells have been proposed to play a role in controlling intracellular 
infections, promoting a Th1-biased immune response (Pollock and Welsh, 2002) and 
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non-MHC restricted NK-like cytotoxicity (Brown et al., 1994, Daubenberger et al., 
1999). Previous reports of WC1
+
 T-cell depletion studies in cattle have shown an 
enhanced antibody response to non-replicating antigen, and an enhanced PBMC 
proliferative response to non-specific mitogens in animals depleted of this population 
(Howard et al., 1989). These results were supported further by the detection of 
enhanced local and systemic IgM and IgA antibody responses following respiratory 
syncytial virus infection in WC1
+
 depleted calves (Taylor et al., 1995). The enhanced 
antibody responses reported in these previous studies may be as a result of higher 
levels of antigen at the early stages of infection (Taylor et al., 1995) or as a result of 
greater Th2-bias in the immune response suggested by higher levels of IL-4, lower 
levels of IFN-γ and reduced levels of IgG2 antibody (Kennedy et al., 2002). By 
inspection, one cannot rule out a minor influence of WC1
+
 cell depletion on the 
duration of viraemia as measured by rRT-PCR (Figure 57), although it was not 
possible to assess the significance of this observation due to the small group size. 
Overall, our findings suggest that WC1
+
 γδ T cells do not play a major role in the 
resolution of clinical signs and control of viraemia after acute FMDV infection in 
cattle. 
 
Application of a similar protocol to deplete CD8
+
 T cells was less successful, 
resulting in only partial depletion of the circulating population, which had no 
discernible effect on the response to FMDV. This result is consistent with previous 
evidence that MAb-mediated depletion of bovine CD8
+
 T cells is more difficult to 
achieve than for other T-cell subsets (Naessens et al., 1998, Oldham et al., 1993, 
Taylor et al., 1995, Villarreal-Ramos et al., 2003). Therefore, it was not possible to 
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conclusively evaluate the influence of CD8
+
 T cells on the course of infection with 
FMDV or early responses to the virus. However, partial depletion of CD8
+
 T cells 




 T-cell depletion did not influence the development of FMDV neutralising 
antibody. Antiviral antibody responses may be classified as T-D or T-I based on the 
requirement for CD4
+
 T cell help for antibody production.  T-I type I antigens are 
mitogenic agents, for example lipopolysaccharides, that activate Toll-like receptors 
to elicit polyclonal B cell activation (Obukhanych and Nussenzweig, 2006). Type II 
T-I antigens are complex structures, typically rigid two dimensional arrays 
comprising repeating epitopes displayed at 5 to 10nm intervals, that engage and 
cross-link the immunoglobulin receptors on the surface of B cells generating strong 
activation signals. These stimulatory activities result in antibody production in the 
absence of specific T cell help but may depend upon accessory signals from antigen 
presenting cells or T cells for B-cell activation (Bachmann and Zinkernagel, 1997, 
Hangartner et al., 2006, Mond et al., 1995, Morrissey et al., 1981). Some viral 
capsids fall into this category. However, non-oligomerised viral proteins released 
from dying cells or disrupted virus particles generally act as T-D antigens.  
 
The T-dependency of antibody responses of cattle to a number of defined antigens 
and viral pathogens has been confirmed in several previous studies (Howard et al., 
1992, Naessens et al., 1998, Taylor et al., 1995). CD4
+
 lymphocyte depletion with 
MAb doses as low as 0.3mg/kg has been shown to result in a significant reduction in 
the antibody response of calves to human red blood cells and ovalbumin (Howard et 
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al., 1989, Naessens et al., 1998). The same dose of MAb administered to calves 
subsequently infected with respiratory syncytial virus resulted in a marked 
suppressive effect on the antibody response and increased viral pathology (Naessens 
et al., 1998, Taylor et al., 1995). Similar results have been reported after infection 
with non-cytopathic bovine viral diarrhoea virus, where incomplete circulating 
CD4
+
-lymphocyte depletion resulted in a delayed antibody response and longer 
duration and higher titre of circulating virus (Howard et al., 1992). Furthermore, 
depletion of CD4
+
 lymphocytes in cattle previously vaccinated with commercial 
FMDV vaccine has been shown to ablate T-cell-proliferative responses to FMDV 
antigen, indicating depletion of memory T cells (Naessens et al., 1998). While 
Naessens et al. depleted blood and splenic CD4
+ 
cells with 0.2mg/kg MAb, they 
needed 2mg/kg to deplete CD4
+
 cells from peripheral lymph nodes. It is therefore 
likely that 2.58mg/kg MAb was effective at depleting the cells from peripheral 
lymph nodes, confirmed in our analyses on the prescapular lymph nodes. Moreover, 
the present work clearly demonstrated that such depletion had a strong influence on 
the anti-FMDV immune response, but this was prejudiced dependent on the antigenic 
determinants against which the humoral response was mounted. A particularly 
significant feature of the present study was the finding that CD4
+
 T-cell depletion 
resulted in ablation of antibody responses to non-structural proteins in 3 of the 4 
animals examined, while leaving intact the antibody responses to sites on the surface 
of the viral capsid. This is consistent with the notion that antibody responses to these 
antigenic components are T-D and T-I respectively. The development of a delayed 
antibody response to the non-structural proteins in one of the CD4 depleted calves 
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may be the result of low level replicating virus still being present in this animal when 
CD4
+
 T-cell function was restored.  
 
Our findings are consistent with published results using the FMDV murine 
experimental model, where the protective immune response was shown to be T-I 
(Borca et al., 1986, Lopez et al., 1990). These investigators showed that after FMDV 
challenge, the curves of viraemia and neutralising antibody responses in the athymic 
mice were not significantly different to those of the normal control mice  (Borca et 
al., 1986). In addition, the athymic mice were protected from re-challenge 240 days  
post-infection, indicating that FMDV induces a prolonged, T-I immune memory 
response in mice (Lopez et al., 1990). Early T-I protection and production of 
antibody has been described for a number of other cytopathic viruses, including VSV 
and influenza virus infection in mice (Fehr et al., 1996, Lee et al., 2005). A number 
of other picornaviruses have also been shown to act as T-I antigens (Bachmann and 
Zinkernagel, 1996). The T-I nature of these viral antigens is thought to be a result of 
their rigid, highly repetitive and highly organised structure (Bachmann and 
Zinkernagel, 1997). Also, the magnitude of the T-I immune response and 
augmentation of antibody isotype class switching has been shown to correlate with 
the degree of antigen organisation and the dose of antigen reaching the secondary 
lymphoid organs (Bachmann and Zinkernagel, 1996, Maloy et al., 1998, Ochsenbein 
et al., 2000a, Zinkernagel, 2000). One of the key protective mechanisms to prevent 
the dissemination in the host of acute cytopathic viruses is the rapid induction of 
neutralising antibodies (Bachmann and Zinkernagel, 1997). It has also been proposed 
that the surface antigenic structure of acute cytopathic viruses has evolved to 
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stimulate early T-I antibody responses, in order to limit the extent of viral infection 
and avoid rapid death of the host. Conversely, B-cell responses may have evolved to 
deal with such threats. The dynamics of infection with FMDV in cattle is consistent 
with the model described above, with infection being rapidly controlled and animals 
usually showing clinical signs only for a few days. Clearly, T-D antibody responses 
are also stimulated by these acute cytopathic viruses, and are likely to be responsible 
for the production of affinity maturated IgG-isotype antibodies and long term 
memory (Hangartner et al., 2006).  
 
Although FMDV shares structural features with other picornaviruses, there is one 
unique feature that distinguishes aphthoviruses including FMDV from other 
picornaviruses; the absence of a canyon or pit which places the integrin cell 
attachment site in the protruding, fully exposed, highly disordered and mobile 
immunogenic G-H loop of VP1 (Acharya et al., 1989). Studies with virus-specific 
MAbs, coupled with structural analyses of FMDV particles, have identified 5 
antigenic sites on the FMDV capsid, including the G-H loop, which are involved in 
virus neutralisation (Crowther et al., 1993). The G-H loop is considered highly 
immunogenic, and immunisation of cattle with synthetic peptides representing the 
loop has been shown to induce neutralising antibody and in some cases protection 
against viral challenge (Taboga et al., 1997). However, recent data describing VP1 
G-H loop-substituted chimeric vaccines indicates that the G-H loop may not be 
required for producing a strong neutralising antibody response or a protective 
immune response following vaccination in cattle (Fowler et al., 2008). In the present 
study, although CD4
+
 T-cell depletion had no discernible effect on the overall 
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neutralising antibody response, it substantially inhibited the IgG antibody response 
against the G-H loop peptide. The neutralising antibody in these animals was 
presumably directed against the other sites on the viral capsid. Our data suggest that 
the high degree of mobility of the G-H loop may result in it being less effective as a 
T-I type II antigen in comparison with the other antigenic sites, which have a more 
stable conformational structure. Antibodies directed against the G-H loop were 
detected in all CD4
+
 T-cell-depleted cattle after the phase of depletion, albeit at lower 
levels than the infected control animals. Although circulating virus was no longer 
detectable at this time, the detection of FMDV capsid antigen in mandibular lymph 
node germinal centres at post-mortem indicates that there remained a source of 
antigen for induction of G-H loop-specific antibody when CD4
+
 T cell function was 
restored. 
 
The induction of IgG after FMDV immunisation has been shown to be T-D in a 
murine experimental model (Collen et al., 1989). These results have been confirmed 
in vitro in a mouse model, in which FMDV-infected DCs could directly stimulate B 
lymphocytes to secrete FMDV-specific IgM, but T-cell help was required to induce 
class switching towards IgG (Ostrowski et al., 2007). Comparison of the kinetics of 
the FMDV-specific antibody response of experiment 1 and 2 animals over time did 
not reveal any statistically significant differences between the depleted groups and 
the control MAb-treated groups. Specific serum IgM was detected in these animals 
from 4 days post-infection and specific IgG1 and IgG2 from 5 days post-infection, 
consistent with reports by other investigators (Collen, 1994, Doel, 2005, Salt et al., 
1996a). Our results show that in vivo, in a natural ruminant host, FMDV infection 
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can not only induce a specific and rapid IgM response but also efficient and rapid 
isotype class switching in the absence of CD4
+
 T cells. The ability of T-I viral 
antigens to induce efficient class switching in the absence of T cell help is thought to 
be related to the repetitiveness of the viral antigens (Bachmann and Zinkernagel, 
1997) and the formation of antigen-specific germinal centres by a T-I process in the 
absence of T cell-derived CD40-ligand (Gaspal et al., 2006). T-I B cell proliferation 
and isotype class switching in mice following exposure to Type II T-I antigens has 
been shown to be dependent on an intact follicular dendritic cell network and 
signalling through CD40 on the surface of B cells and FDCs. The signalling through 
CD40 is dependent on complement, specifically through C4b binding protein in the 
absence of the T-cell derived CD40-ligand (CD154) (Brodeur et al., 2003, Gaspal et 
al., 2006, Ochsenbein et al., 1999b, Schriever et al., 1989, Szomolanyi-Tsuda et al., 
2001). We have shown previously in cattle that FMDV localises to germinal centres 
as early as 3 to 4 days post-challenge (Juleff et al., 2008), a process that may provide 
the signals required for T-I isotype class switching and an early FMDV-specific IgG 
response (Gaspal et al., 2006, Ochsenbein et al., 2000a, Tew et al., 2001). The TNF 
family ligands BAFF and APRIL have also been shown to contribute to CD154-
independent antibody isotype switching, germinal centre maintenance and T-I 
antibody responses (Schneider, 2005). In addition to these potential mechanisms in 
the CD4
+
 T-cell-depleted cattle exposed to FMDV, IFNγ produced by γδ T cells 
(Maloy et al., 1998), NK cells (Koh and Yuan, 1997, Szomolanyi-Tsuda et al., 2001) 
or activated B cells (Pang et al., 1992, Yoshimoto et al., 1997) may also provide 
alternative but less efficient support for CD154/CD4
+
 T-I isotype switching by acting 
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directly on B cells potentially in the absence of specific germinal centre formation 
(Snapper et al., 1992).      
 
In conclusion, the results of this study indicate that functional CD4
+
 T cells are not 
required, either to provide help for antibody production or as antiviral effector cells, 
for effective control of primary infection with FMDV in cattle. Isotype switching of 
the antibody response was also found to be independent of CD4
+
 T cells. The current 
studies do not identify whether CD4
+
 T cells play a role in the development or 
duration of a memory response or contribute to the efficacy of immunity to 
subsequent viral challenge. Further studies are required to address these questions, 
possibly using similar depletion protocols in vaccinated animals.  
 
A number of molecular approaches to FMD vaccine development have been 
followed since the mid-1970s, including the use of viral subunit proteins, protein 
fragments and peptides, isolated from viral particles or produced in bacteria, 
baculovirus and transgenic plants or as synthetic peptides (Brown, 1999, Grubman 
and Mason, 2002, Taboga et al., 1997). A general problem with most subunit 
vaccines is that they do not elicit a protective immune response comparable with that 
induced by live virus or killed whole virus vaccines (Taboga et al., 1997). Peptide 
vaccines based on the G-H loop of VP1 (Wang et al., 2002) do not appear to fully 
mimic the conformation of the native B-cell epitopes and stimulate limited antibody 
of rather narrow specificity which can be enhanced by the addition of T-cell epitopes 
or multiple antigenic sites, but still do not afford adequate protection (Cubillos et al., 
2008, Francis et al., 1987, McCullough et al., 1992, Taboga et al., 1997). In contrast, 
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studies of responses to traditional FMDV vaccines, which utilise intact inactivated 
virus, have shown that they stimulate rapid antibody responses that can provide 
protection against disease within 4 to 5 days. The results of the current study, 
together with other findings, indicate that preservation of the complex three-
dimensional structure of the FMDV capsid is critical for inducing rapid and effective 
antibody responses. This is consistent with current thinking on the development of 
safer and more effective vaccines based on the use of empty viral capsids produced 


















4. Conclusion and future work 
FMDV infection in cattle provides an opportunity to study the interactions of a 
highly cytopathic virus which has evolved and adapted to its natural host. During the 
studies reported in this thesis, FMDV structural and non-structural proteins were 
detected in cells in sections of bovine lymph node at early time-points post-infection, 
indicating that viral replication does occur within lymph node cells in vivo. However, 
only small clusters of infected cells were detected. In addition, in the sections of 
tissue studied, the clusters were restricted to the mandibular lymph node which 
receives afferent lymph from the tongue, a site associated with vesicles and a high 
degree of viral replication. Although the significance of this observation is not 
entirely clear, these data do support a model of natural FMDV infection in cattle 
during which viable virus is transported to and able to interact with cells in organised 
lymphoid tissue, which has important immunological consequences. The presence of 
intact virus within the organised lymphoid tissue, and hence the highly repetitive and 
ordered capsid antigen, promotes a rapid and effective immune response leading to 
early induction of antibody, an essential component of the protective immune 
response against acute cytopathic virus like FMDV (Bachmann and Zinkernagel, 
1997, Zinkernagel, 2000).  
  
Notably, intact FMDV capsid was detected in the light zone of mandibular lymph 
node germinal centres as early as 3 days post-infection. The complement receptors 
CD21 and CD35 are expressed in both primary and secondary follicles (Imal and 
Yamakawa, 1996) and may play an important role to trap complement-containing 
FMDV-immune-complexes formed rapidly after exposure to the pathogen, as is the 
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case for HIV (Carroll, 1998, Ho et al., 2007). Human FDCs also express the Fcα/µR 
for IgM (Kikuno et al., 2007). IgM is typically the first antibody to be produced 
during a humoral immune response to viral infections and natural antibodies, 
although not yet described for FMDV in cattle, are mainly IgM (Ochsenbein et al., 
1999a). If Fcα/µR is expressed on bovine FDCs, this receptor may play an important 
role in membrane-bound antigen presentation to B cells during the initial stages of 
FMD (Ochsenbein and Zinkernagel, 2000). Although the mechanisms underlying the 
rapid localisation of FMDV within the germinal centre light zone at this time point 
are not clear, the rapid formation of antigen-specific germinal centres, and 
consequent membrane-bound antigen presentation, is likely to be an important 
component of the immune response against FMDV, able to induce B-cell 
proliferation and rapid class switching without the need for CD4
+
 T cell help (Gaspal 
et al., 2006). Clearly, these early events which are capable of efficiently activating 
the immune system are reliant on transport of viable virus or whole, unprocessed 
antigen to organised lymphoid tissue by infected cells or by other antigen delivery 
processes. Marginal zone B cells in the spleen are able to take up blood-borne 
antigens, these cells constantly shuttle between the marginal zone and the follicle, 
carrying antigen to the FDCs (Cinamon et al., 2008, Kraal, 2008). However, lymph 
nodes lack an equivalent B cell subset. Recent studies using two-photon intravital 
microscopy to visualise living cells deep within tissue of mice, have revealed a 
number of mechanisms of intact antigen delivery in lymph nodes. Soluble antigen 
from the periphery enters the subcapsular sinus of the draining lymph node via 
afferent lymphatic vessels. Studies in mice have shown that soluble antigen can 
diffuse across small gaps in the floor of the subcapsular sinus directly to nearby  
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B-cell follicles (Pape et al., 2007). Following subcutaneous injection of antigen in 
mice, B cells in the follicle have been shown to take up antigen within 10 minutes, 
highlighting the rapid acquisition of soluble antigen by follicular B cells. These 
investigators also showed that by 4 hours post-inoculation, the antigen had already 
been processed and presented by B cells (Pape et al., 2007) and that DCs do not play 
a major role in the acquisition of soluble antigen by follicular B cells (Cahalan and 
Parker, 2008). Recently, it has also been shown that soluble antigen can diffuse along 
a system of follicular conduits that connect the subcapsular sinus with the FDC areas, 
providing an alternative route for small lymph-borne antigens to the B-cell follicle 
(Roozendaal et al., 2009). Subcapsular sinus macrophages are also able to transport 
antigen into the lymph node follicles (Martinez-Pomares et al., 1996). B cells pick up 
the antigen displayed on the surface of these macrophages and transport the antigen 
to the follicle where the antigen is off-loaded onto FDCs (Phan et al., 2007). These 
macrophages have been shown to clear lymph-borne VSV particles in mice and 
present the intact virion to B cells (Junt et al., 2007). These investigators showed that 
splenic marginal-zone macrophages require complement and natural antibodies to 
capture live VSV, by contrast, the lymph-node resident macrophages retain VSV by 
means of complement and antibody independent mechanisms. It has been proposed 
that the virus is recognised by a scavenger receptor expressed by murine subcapsular 
sinus macrophages, for example, carbohydrate-binding scavenger receptors, but the 
specific receptor has not been identified (Taylor et al., 2005). In addition, unlike 
other macrophages, the subcapsular sinus macrophages of mice are not highly 
phagocytic and do not rapidly degrade but retain surface-bound antigen (Cahalan and 
Parker, 2008, Phan et al., 2007). DCs can also display unprocessed antigen on their 
 256 
surface to B cells (Qi et al., 2006). However, it has been shown in the mouse that 
DCs do not display whole antigen to follicular B cells and the B cells that recognise 
the surface antigen remain extrafollicular where they interact with T cells and do not 
enter the germinal centre reaction, although this process may be altered in the 
presence of live virus (Qi et al., 2006). It is not implausible that different antigen 
delivery and antigen acquisition mechanisms in the different lymphoid tissues 
sampled during the current study are responsible for the observed distribution of 
FMDV capsid protein in the tissue sections. Intact capsid was detected in the palatine 
tonsils, lateral retropharyngeal lymph nodes and mandibular lymph nodes but not in 
dorsal soft palate and pharyngeal tonsil samples. In contrast to the lymph nodes, the 
organised lymphoid tissue within the mucosa of the dorsal soft palate and the 
pharyngeal tonsils are largely dependent on M cells for uptake of antigen from the 
lumen and the palatine tonsils are dependent on the crypt epithelium for antigen 
uptake (Kraehenbuhl and Neutra, 2000). In addition, the differences in antigen 
acquisition could also account for the low quantity of FMDV genome detected in 
splenic germinal centres, which was unexpected as FMDV infection in cattle 
generally results in a pronounced viraemia, and presumably widespread distribution 
of viral genome.  
 
FMDV infection is characterised by a rapid and efficient isotype-class-switched 
neutralising-antibody response directed against viral B-cell epitopes. The viraemia is 
controlled rapidly and the animals soon recover from clinical FMD. However, low 
titres of live virus can still be recovered from oropharyngeal scrapings for months 
after infection despite the high titres of virus neutralising antibody and the prolonged 
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duration of immunity after natural infection. During the studies reported in this 
thesis, FMDV particles were detected up to 38 days post-infection in the light zone 
of germinal centres. Retention of intact FMDV particles on the FDC network 
provides an ideal mechanism for maintaining a highly cytopathic and lytic virus like 
FMDV extracellularly in a non-replicating, native, stable non-degraded state and 
may represent the reservoir of virus detected in „carrier‟ animals. FDCs are able to 
maintain intact antigen beyond the contraction phase of the germinal centre response, 
a function that may be particularly relevant for infectious virus (Tew et al., 1979). In 
addition, immune complexed FMDV can bind and infect Fc receptor expressing cells 
in vitro, potentially supporting an intermittent virus replication cycle in cattle in the 
presence of high titres of neutralising antibodies (Mason et al., 1993, Rigden et al., 
2002, Robinson, 2008). We propose that viable virus detected in probang samples is 
due to direct harvesting of FDC-bound FMDV or as a consequence of virus 
originating from the FDC network and undergoing cycles of replication in 
susceptible cells, for example, macrophages, DCs or B cells, which will ensure 
efficient perpetuation of the virus within the host. Progeny virus produced by these 
cells could also infect other susceptible cells, for example, αvβ6 expressing crypt 
epithelium cells. B cells could be particularly relevant for this model of FMD in 
cattle and their interactions with FMDV at different stages of development should be 
investigated. FDC-derived iccosomes are dispersed to B cells within the germinal 
centre, which endocytose and process the immune-complexed antigen (Tew et al., 
2001). In addition, naïve B cells constantly recirculate through the spleen, different 
lymph nodes and multiple germinal centres, scanning the antigen trapped on FDCs  
(Schwickert et al., 2007). Recently, two-photon immunoimaging studies in mice 
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have shown that naïve B cells which enter the lymph node follow the scaffold of 
fibroblastic reticular cells until they reach the follicle, once within the follicle the B 
cells migrate along the scaffold formed by FDCs (Cahalan and Parker, 2008). This 
active process of scanning ensures that a large portion of the B-cell repertoire is 
exposed to antigen trapped in germinal centres, and any antigen-specific B cells will 
interact with the antigen (Schwickert et al., 2007). Recently, human peripheral 
memory B cells that are latently infected with Epstein-Barr virus, have been shown 
to originate from germinal centres, for example tonsillar germinal centres, where the 
latent infection is established and rare persistently infected cells can be detected 
(Roughan and Thorley-Lawson, 2009). Therefore, pathogens residing in germinal 
centres can be actively transported to peripheral mucosal sites (Pegtel et al., 2004).     
 
Retention of non-degraded FMDV capsid in the light zone of germinal centres may 
also contribute to the generation of long-lasting neutralising-antibody responses 
either as a direct result of persisting viral antigen or the production of memory cell 
populations and long lived plasma cells. FMDV is highly immunogenic and FMDV 
infection is able to induce a rapid and specific T-I virus neutralising antibody 
response in cattle. Therefore, the rapid evolution of antigenic sites and the diverse 
genetic and antigenic heterogeneity of FMDV are likely to be biologically relevant 
for virus survival at a population level in order to circumvent detection and 
destruction in the face of an effective host immune response (Domingo et al., 2003). 
Consequently, it would seem that a balance has been reached between the bovine 
immune system and the virus to guarantee survival of both the virus and the host 
(Zinkernagel, 1996).  
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The proposed model of host-pathogen interaction may be particularly relevant to 
understand how FMDV persists and spreads in the major wildlife reservoir of FMDV 
in Sub-Saharan Africa, the African buffalo (Syncerus caffer). Free-living African 
buffalo act as maintenance host for the three SAT serotypes of FMDV in southern 
Africa and have been shown to be a source of infection for other susceptible species 
with transmission from „carrier‟ buffalo to cattle reported under experimental 
conditions (Vosloo et al., 2002). This is in contrast to the unknown epidemiological 
significance of „carrier‟ cattle. Transmission from „carrier‟ cattle has not been 
demonstrated under experimental conditions, even during dexamethasone treatment 
and under conditions of co-infection with other viruses, for example, rinderpest and 
bovine herpes 1 viruses (Ilott et al., 1997, McVicar, 1977). Epidemiological data 
indicates that in areas where SAT serotypes are prevalent, for example, the Kruger 
National Park in South Africa, buffalo are infected with all three SAT types by 2 
years of age (Thomson et al., 1992). The SAT viruses produce cyclical epidemics of 
infection in young buffalo within breeding herds when susceptible calves, whose 
maternal antibody has waned, are recruited into the population. The virus is 
subsequently transmitted to other susceptible species (usually cattle or impala) with 
which these breeding herds come into contact (Thomson et al., 1992). FMDV has 
been successfully isolated from captive buffalo held in isolation for 5 years and from 
a small, free-living isolated population for 24 years (Condy et al., 1985). Within 
breeding herds, the virus only needs to persist in immune animals between calving 
seasons for transmission to the next generation of susceptible calves by a method that 
remains to be elucidated.  
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Although these data support a novel reservoir of FMDV, viable virus was not 
isolated from lymphoid tissue. In addition, these data provide no evidence to support 
Fc receptor mediated virus replication in vivo and the sites of replicating virus in 
cattle after recovery from FMDV have not been determined. Buffalo harbour 
persistent virus in greater amounts and for longer periods than cattle, therefore they 
provide a better opportunity to define the sites of virus localisation, to progress 
studies to isolate live virus from these sites and to elucidate the mechanism whereby 
virus is transmitted from „carrier‟ to susceptible buffalo. The inability to detect live 
FMDV in bovine lymphoid tissue samples is likely due to technical difficulties 
extracting virus from bovine tissue. FDCs remain a challenging cell type to study, 
especially in cattle. Therefore, in addition to studying the virus in buffalo, the murine 
model system could be used to attempt to detect FMDV protein and genome in 
germinal centres. In addition, established protocols for detecting viable HIV on 
mouse FDCs could be followed in an attempt to detect viable FMDV (Smith et al., 
2001).  
 
Despite the uncertainty of the requirement of persisting antigen to maintain humoral 
immunity, it is clear that serum antibodies have a short half-life and require 
replenishment either by long-lived plasma cells, activation of memory B cells to 
differentiate into plasma cells or by the ongoing recruitment and differentiation of 
naïve B cells into antibody producing cells. It is anticipated that FMDV maintained 
on FDCs in the light zone of germinal centres plays a crucial role in maintaining 
humoral immunity. In addition, in FMD convalescent cattle it has been shown that 
resistance to re-infection and local virus replication in the oropharynx shows a strong 
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correlation with a history of persistent infection (McVicar and Sutmoller, 1974, Salt, 
1993). The elimination of sequestered antigen on FDCs by injection of LTβR-Ig 
fusion proteins during the early stages of the germinal centre reaction has been 
shown to have a detrimental effect on antibody titres in mice, highlighting the 
importance of persisting antigen during the early phase of the B-cell response when 
germinal centres are producing large numbers of plasma and memory B-cell 
precursors (Gatto et al., 2007). Although it is not feasible to replicate these studies in 
cattle at this stage, replicating these studies using the FMDV murine model system 
will provide data on the importance of FMDV retention, in early and late germinal 
centres, for maintaining SNTs.  
 
It is interesting to note that pigs are reported to clear FMDV within 3 to 4 weeks 
post-infection. In addition, FMDV infection in pigs induces neutralising titres of 
antibody that are only detectable for a few months post-infection, with a reported 
half-life of 1 week (Alexandersen et al., 2003b). This is an unusual host response to a 
highly immunogenic and cytopathic virus like FMDV (Hangartner et al., 2006, Manz 
et al., 2005), sanctioning further investigation in order to understand the germinal 
centre reaction and localisation of virus in pigs following FMDV infection.      
    
The results reported in this thesis support the hypothesis that the rapid induction of 
protective neutralising antibody following natural FMDV infection in cattle is 
dependent on the highly repetitive and ordered structure of the FMDV capsid. In 
addition, the long-term maintenance of protective SNTs following infection is likely 
to be dependent on non-degraded FMDV persisting in germinal centres. The 
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induction of rapid and long-lasting protective immunity is the primary aim for 
successful vaccination against infectious diseases. Clearly, FMDV infection in cattle 
induces robust, long lasting immunity and vaccine-induced immunity which mimics 
natural infection should induce a similar degree of protection. Immunisation with a 
single dose of commercial, inactivated FMDV vaccine can induce rapid SNTs in 
ruminants, protection from clinical disease and prevent virus dissemination (Cox et 
al., 1999, Cox et al., 2005). However, vaccination and even in some cases previous 
infection, does not always confer protection against local virus replication or 
superinfection and the potential for transmission. In FMD convalescent cattle, 
resistance to local virus replication in the oropharynx correlates with a history of 
persistent infection (McVicar and Sutmoller, 1974, Salt, 1993, Salt et al., 1996a). 
Antibody in the upper respiratory tract and oral secretions are reported to persist for 
longer and at a higher titre in „carrier‟ compared to „non-carrier‟ animals (Garland, 
1974, Matsumoto et al., 1978). In addition, IgA titres persist in serum and in probang 
samples of „carrier‟ animals (Salt et al., 1996a) and it has been proposed that 
neutralising IgA in secretory fluids of these animals is primarily responsible for 
preventing local FMDV replication in the mucosa (Garland, 1974, Matsumoto et al., 
1978). The role of IgA versus IgG in the control on FMDV in the upper respiratory 
tract is not clear. The predominant antibody isotypes detected in probang samples 
following inoculation of vaccine intramuscularly, and even when administered into 
the muzzle of cattle, are IgG1 and IgG2 and low titres of IgA only become detectable 
after multiple re-vaccinations (Archetti et al., 1995, Barnett et al., 1998). Studies in 
ruminants have shown that increasing the antigen payload in single dose emergency 
vaccines administered intramuscularly can prevent or decrease local virus replication 
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and prevent persistence and shedding, suggesting that a robust systemic antibody 
response induced by the inactivated virus capsid is adequate for protection at the 
mucosal surface in the absence of local IgA, as determined by probang sampling 
(Barnett et al., 2004, Cox et al., 2006). Mucosal plasma cells produce IgG, however, 
the majority of IgG at the mucosal surfaces is derived from the plasma by a process 
of passive transudation along a concentration gradient (Lamm, 1997). In addition, 
any local inflammation or damage during FMDV infection will allow the IgG to 
diffuse across the epithelium but only after the virus has initiated infection. 
Therefore, it is likely that the majority of IgG detected in probang samples following 
intramuscular vaccination is not locally produced but serum derived and that high 
SNTs are required if local virus replication and shedding at the mucosal surface is to 
be prevented (Barnett et al., 1998, Wagner et al., 1987). Passive immunisation 
studies in mice have shown that IgA, but not IgG, can prevent influenza virus 
induced pathology in the upper respiratory tract (Renegar et al., 2004). In addition, 
titres of circulating IgG 2.5 times the normal convalescent serum anti-influenza virus 
titre was required for antibody transudation into nasal secretions and 7 times normal 
was required to lower nasal virus shedding by 98%. These authors concluded that 
IgG did not prevent the initiation of viral infection at the mucosa but neutralised 
locally produced virus (Renegar et al., 2004).  
 
The intact virus particle, which is the major immunogenic component of current 
FMD vaccines, is adversely affected by aziridine compounds during inactivation. 
The subsequent thermal instability and spontaneous dissociation of the capsid means 
that the highly repetitive and ordered conformational epitopes are not well preserved, 
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altering the immunogenic properties of the virus particle (Anderson et al., 1983, 
Bahnemann, 1975, Doel and Baccarini, 1981, Patil et al., 2002). In addition to the 
highly repetitive and ordered structure, live virus also induces innate immunity for 
appropriate conditioning of adaptive immune responses and the ability to replicate 
leads to virus distribution promoting efficient B and T-cell responses for robust and 
long-lived immunity (Jennings and Bachmann, 2008). Increasing the antigen payload 
of inactivated vaccines can overcome some of their limitation and it should be noted 
that to date, there have been no published experiments in either cattle or sheep 
immunised with a single dose of higher potency vaccine and then challenged at a 
time point beyond 28 post-vaccination to assess long-term protection. Current efforts 
focussed on the production of stable virus capsids in order to preserve 
conformational epitopes are promising for providing the next-generation of FMDV 
vaccines with the goal of being safer to produce and to trigger rapid and sustained 
antibody responses. Once synthesised, the empty capsids can form a platform for 
vaccine technology based on virus-like particles (VLPs) (Jennings and Bachmann, 
2008). During the past 20 years, VLP-based vaccines have been the subject of 
extensive research and currently VLPs derived from human papillomavirus and 
hepatitis B virus are marketed for human use (Barr and Tamms, 2007, Jennings and 
Bachmann, 2008).VLPs mimic natural virus infection to trigger an effective immune 
response, their particulate nature and size means they are effectively transported to 
lymph nodes to display ordered and repetitive antigen to follicular B cells (Jennings 
and Bachmann, 2007). In addition, VLPs which spontaneously assemble, for 
example, the L1 major capsid protein of papillomaviruses, can be packaged with 
TLR ligands and other activators of innate immunity in order to direct the subsequent 
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adaptive immune response (Jennings and Bachmann, 2008).  Although VLPs have 
been shown to induce adequate B-cell responses in mice in the absence of adjuvant 
(Gatto et al., 2004), incorporating depot forming adjuvants may extend the duration 
of immunity by replicating persisting antigen on FDCs after natural infection. The 
quadrivalent human papillomavirus VLP vaccine which incorporates an alum-based 
adjuvant has been shown to induce antibody titres in humans that peak at 7 months 
then decrease to a plateau titre that is maintained for 5 years after a single dose 
(Olsson et al., 2007). However, diffusion of soluble antigen away from adjuvant 
depots is limited and it has been reported that antigen delivery from adjuvant depots 
to lymph nodes in mice is primarily by DCs, which may ultimately reduce the 
amount of intact antigen reaching the lymph node and the amount of antigen entering 
the germinal centre reaction (Cahalan and Parker, 2008). Therefore, depots of FMDV 
capsid at peripheral vaccination sites in cattle may not functionally replicate the 
depots of intact virus after natural infection which is maintained on FDCs in direct 
contact with follicular B cells.  
 
In conclusion, the data presented here provides fresh insight into the induction and 
maintenance of the protective immune response against FMDV in the natural bovine 
host. Many issues which are pertinent to understanding the protective immune 
response and the „carrier state‟ remain to be elucidated. However, extrapolating the 
data reported here with the data provided by two-photon microscopy of host-
pathogen interactions in vivo can inform FMDV vaccine strategies which attempt to 
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Appendix 1: medium, buffers and solutions 
Acetylation solution 
The solution was prepared immediately before use. 
49ml nuclease free water (Ambion, UK) 
660μl triethanolamine solution (Ambion, UK) 
250μl HCl 37% (Sigma-Aldrich, UIK) 
60μl acetic anhydride ≥ 98% pure (Ambion, UK) 
 
Agarose gel (1%) 
1 × TBE electrophoresis buffer 
 89mM Trizma-base (Sigma-Aldrich, UK) 
 89mM boric acid (Sigma-Aldrich, UK) 
 2mM ethylenediaminetetraacetic acid disodium salt dehydrate 
(Sigma-Aldrich, UK ) 
 distilled water (CSU, IAH) 
1% (w/v) agarose (Promega, UK) 
0.002% of 10mg/mL ethidium bromide (Sigma-Aldrich, UK) 
 
Cell culture medium  
Baby hamster kidney (BHK-21) cells  
 Dulbecco‟s Modified Eagle‟s Medium (DMEM, Sigma-Aldrich, UK) 
 10% v/v fetal calf serum (Autogen Bioclear, UK) 
 20mM glutamine (CSU, IAH) 
 100µg/mL streptomycin (CSU, IAH) 
 100 SI units/mL penicillin (CSU, IAH) 
 Incubated at 37oC, 5% CO2 
 
Primary bovine thyroid (BTY) cells 
 Glasgows Modified Eagle‟s Medium (GMEM, CSU, IAH) 
 10% v/v fetal calf serum (Autogen Bioclear, UK) 
 100µg/mL streptomycin (CSU, IAH) 
 100 SI units/mL penicillin (CSU, IAH) 
 Incubated at 37oC, 5% CO2 
 
Mouse fibroblast 3T3 cells 
 DMEM (Sigma-Aldrich, UK) 
 10% v/v fetal calf serum (Autogen Bioclear, UK) 
 100µg/mL streptomycin (CSU, IAH) 
 100 SI units/mL penicillin (CSU, IAH) 







Colour substrate solution 
5ml detection buffer 
25μl of 100mg/ml nitroblue tetrazolium chloride (Roche, UK) 
18.75μl of 50mg/ml 5-bromo-4-chloro-3-indolyl-phosphate, 4-toluidine salt (Roche, 
UK) 
1mM levamisol (Sigma-Aldrich, UK) 
 
Detection buffer 
0.1M Trizma-base (Sigma-Aldrich, UK) 
0.1M sodium chloride (Sigma-Aldrich, UK) 
pH 9.5 hydrochloric acid (Sigma-Aldrich, UK) 
 
FACS wash buffer 
PBS (CSU, IAH) 
1% (w/v) bovine serum albumin (Sigma-Aldrich, UK) 




40% (v/v) deionised formamide (Sigma-Aldrich, UK) 
10% (v/v) dextran sulfate (Sigma-Aldrich, UK) 
1× Denhardt‟s solution (Sigma-Aldrich, UK) 
4×SSC buffer (Sigma-Aldrich, UK) 
10mM dithiothreitol (Sigma-Aldrich, UK) 
1mg/ml yeast t-RNA (Roche, UK) 
1mg/ml denatured and sheared salmon sperm DNA (Roche, UK).  
 
The prepared buffer was replaced with the hybridization buffer supplied in the 
mRNA Locator in situ Hybridization Kits (Ambion, UK). The buffers in this kit are 
optimised for use with radiolabelled RNA probes. DIG labelled probes and 33P 
labelled probes behave with similar kinetics and may be used under similar 
hybridization conditions (Sambrook and Russel, 2001).  
 
Luria-Bertani agar (CSU, IAH) 
Luria-Bertani broth with 1.5% (w/v) agar 
 
Luria-Bertani broth (CSU, IAH) 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
0.5% (w/v) sodium chloride 
Distilled water 
pH 7.6 Trizma-base 
 
M25-phosphate buffer, pH 7.6 (CSU, IAH) 
35 mM disodium hydrogen orthophosphate dihydrate  





Initially a solution of prepared hybridization buffer without dextran sulfate was used 
for pre-hybridization. This was replaced by the pre-hybridization buffer supplied in 
the mRNA Locator in situ Hybridization Kits (Ambion, UK). 
 
Red blood cell lyses buffer 
0.115M ammonium chloride (Sigma-Aldrich, UK) 
1mM potassium hydrogen carbonate (Sigma-Aldrich, UK) 
0.01mM ethylenediaminetetraacetic acid disodium salt dehydrate (Sigma-Aldrich, 
UK ) 
pH 7.2 (1M sodium hydroxide [Sigma-Aldrich, UK]) 
0.22µm filter sterilise (Sartorius, UK) 
 
RNA digestion solution 
0.001 µg/mL RNase A (Ambion, UK) 
1 × RNase digestion buffer (Ambion, UK) 
Distilled water 
 
SOC media (CSU, IAH) 
2% (w/v) tryptone 
0.5% (w/v) yeast extract 
10mM sodium chloride 
2.5mM potassium chloride 
20mM magnesium chloride 
20mM D(+) glucose 
Autoclaved to sterilise 
 
 
TaqMan Reverse Transcription Reagent reaction mix (Applied Biosystems, UK) 
1 × TaqMan RT buffer 
5.5mM magnesium chloride 
500µM deoxyNTPs mixture 
2.5µM random hexamers 
0.4U/µL RNase inhibitor 
1.25U/µL Multiscribe reverse transcriptase 
RNase-free water 
 
TBS washing buffer 
0.1M Trizma-base (Sigma-Aldrich, UK) 
0.15M sodium chloride (Sigma-Aldrich, UK) 









TBST blocking buffer  
0.1M Trizma-base (Sigma-Aldrich, UK) 
0.15M sodium chloride (Sigma-Aldrich, UK) 
0.1% (v/v) Tween 20 (Sigma-Aldrich, UK) 
2% (v/v) normal sheep serum (Sigma-Aldrich, UK) for blocking, 1% (v/v) for 
incubation with antibody  
pH 7.5 hydrochloric acid (Sigma-Aldrich, UK) 
 
TNB buffer 
0.1M Trizma-base (Sigma-Aldrich, UK) 
0.15M sodium chloride (Sigma-Aldrich, UK) 
0.5% (w/v) PerkinElmer TSA blocking reagent (PerkinElmer, UK) 
pH 7.5 hydrochloric acid (Sigma-Aldrich, UK) 
 
TNT buffer 
0.1M Trizma-base (Sigma-Aldrich, UK) 
0.15M sodium chloride (Sigma-Aldrich, UK) 
0.3% (v/v) Triton X-100 (Sigma-Aldrich, UK) 































Appendix 2: Primers and probes 




Probe and primer sequence (5’ to 3’)  
28sF AY639443 20-(GCG GAA TTC)-CGG TCC TGA CGT GCA AAT-37 
28sR AY639443 280-(GCG GGA TCC)-CTA GGC ACT CGC ATT CCA C-
262 
SA-UK-IRES-308R AJ539141 983-CCG AGT GTC GCG TGT TAC CT-964 
SA-UK-IRES-248F AJ539141 923-AAC CAC TGG TGA CAG GCT AAG G-944 
UK-IRES-271T AJ539141 946-TGC CCT TTA GGT ACC C-961 
SA-IR-219-246F AJ539141 893-CAC YTY AAG RTG ACA YTG RTA CTG GTA C-920 
SA-IR-315-293R AJ539141 989-CAG ATY CCR AGT GWC ICI TGT TA-967 
SAmulti2-P-IR-292-
269R 
AJ539141 949-CCT CGG GGT ACC TGA AGG GCA TCC-972 
Callahan 3DF AJ539141 7863-ACT GGG TTT TAC AAA CCT GTG A-7884 
Callahan 3DR AJ539141 7969-GCG AGT CCT GCC ACG GA-7953 
Callahan 3DP AJ539141 7914-TCC TTT GCA CGC CGT GGG AC-7933 
P15 Poly A AJ539141 GGC GGC CGC TTT TTT TTT TTT TTT 
FMDV 1F  AJ539141 6678-(GCGGAA TTC)-GGA TTG ATA GTT GAC ACC 
AGA GAT G-6702 
FMDV 1R AJ539141 7177-(GCG GGC TCC)-ATC TCG TCC TTC AGG AAG 
GTC-7157 
IgG1F S82409 305-(GTT GCG GCC GCA A)-GC AAA ACA ACC TGT 
GAC TGT TG-326 
IgG1R S82409 990-(ACG TGG AAT)-TCA TTT ACC CGC AGA CTT 
AGA GG-968 
CD321F BC113215 10-AAG AAG CCA GTG CCT GTC GT-30 
CD321R BC113215 1058-CTG CAG TAT CCT CTT CTA CCC AA-1035 
CD32Fmutant BC113215 798-CCT GGT TCC GCC TCA GGT GAT AGT CAC TCT 
CAG CCG GTC TCA C-840 
CD32Rmutant BC113215 840-GTG AGA CCG GCT GAG AGT GAC TAT CAC CTG 
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